Protocol Version 10.0 – February 5, 2021  1
  
 Oregon Health & Science University  
OHSU Knight Cancer Institute  
IRB Protocol #: 16140 
 Title: A Phase I/II study of Syk inhibitor entospletinib (GS- 9973) in combination with obinutuzumab in 
patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 
and B-cell malignancies  
 Coordinating Center:      OHSU Knight Cancer Institute  
 Principal Investigator:  Craig Okada , MD, PhD  
 
 3181 SW Sam Jackson Park Road Portland OR 97239 503-494-8397  
 okadac@ohsu.edu 
 
Co-Investigators:    Stephen Spurgeon, MD  
                                                                      
Statistician:     Byung Park, PhD  
Oregon Health and Science University Knight Cancer Research Building 2720 SW Moody Ave. #4142 
Portland OR 97239 
503-418-1555  
parkb@ohsu.edu
 
 Sponsor:    Oregon Health and Science University 
 
Supplied Agents :  Entospletinib; Obinutuzumab  
 
Original Protocol Date:   November 8, 2016 
  June 27, 2017 
  November 10, 2017 
Protocol Revision Dates:   January 8, 2018 
  April 10, 2018 
                                                                 May 24,2018 
  July 30, 2018 
  December 11, 2018 
  October 3, 2019 
      February 5, 2021 
 
  
IND Number:                                          132713 
IND Sponsor:   Alexey V. Danilov, MD, PhD  
 
[STUDY_ID_REMOVED]  
Protocol Version 10.0 – February 5, 2021  2
  
 STUDY SCHEMA 
Dose Level  Entospletinib (Cycles 1 -12) Obinutuzumab  (Cycles 1 -6) 
IV 
-1* 200 mg daily  C1D1 – 100 mg; C1D2 – 900 mg 
C1D8 & 15 – 1000 mg 
C2-6 – 1000 mg on day 1 1 200 mg BID  
2 400 mg BID  
*Dose Level -1 will be studied only if more than one patient develops a DLT in Dose Level 1 
 
Decision tree based on DLT’s with cycle 1  
(follow the Storer D 3+3 Phase I design; enroll between 3 and 6 subjects per dose  level) 
 
 
   
 
   
 
  
 
   
* The study will go back to the Phase I stage if 2 or more out of the first six subjects (including those 
treated in the Phase I) receiving the currently identified MTD experience DLT . 
  
 
  
 
  
DLT in 0/3 or 
≤1/6 subjects  
Dose level 1  
ENTO 
200 mg bid  
(enroll 3 -6 
subjects) 
DLT in ≥2/3-6 
subjects 
STOP  
Dose level 2  
ENTO 
400 mg bid  
DL T i n ≥2 /3 -6 
subjects 
DLT in 0/3 or 
≤1/6 subjects  
Dose level 2 is 
RP2D*. Proceed to 
Phase 2 (N=17)  
 
Dose level 1 is 
RP2D*. Proceed to 
Phase 2 (N=17)  Dose level -1 
ENTO 
200 mg daily D L T  i n  ≥ 2 / 3 -6 
subjects 
DLT in 0/3 or 
≤1/6 subjects  Dose level -1 is 
RP2D*. Proceed to 
Phase 2 (N=17)  
Protocol Version 10.0 – February 5, 2021  3
  
 Table of Contents   
1.0  STUDY OBJECTIVES  ................................................................................................. 7  
1.1  Primary Objective ...................................................................................................... 7  
1.1.1 Phase 1 (dose escalation): .................................................................................... 7 
1.1.2 Phase 2:............................................................................................................ 7 
1.2  Secondary objec tives ................................................................................................. 7  
1.3  Exploratory objectives  ............................................................................................... 7  
2.0  BACKGROUND .......................................................................................................... 7  
2.1  Study Disease – Non-Hodgkin lymphoma (NHL) and CLL  ......................................... 7  
2.2. Study Agent (entospletinib, GS -9973) ........................................................................ 9  
2.2.1. Nonclinical Pharmacology - entospletinib ................................................................. 9 
2.2.2. Nonclinical Absorption, Distribution, Metabolism and Elimination .............................. 9 
2.2.3. Nonclinical Toxicology  ........................................................................................10 
2.2.4. Clinical Trials  .....................................................................................................11 
2.3.  Obinutuzumab (GA101, Gazyva ™)...........................................................................11  
2.3.1. Structure and Mechanism of Action of Obinutuzumab  ...............................................11 
2.3.2. Clinical Experience with Obinutuzumab ..................................................................12 
2.3.3. Overview of Safety of Obinutuzumab  .....................................................................17 
2.3.4. Summary of Pharmacokinetic and Pharmacodynamic Data for Obinutuzumab  ..............18 
2.4 Study and Dose Rationale  .........................................................................................18  
2.4.1  Rationale for Syk inhibition in CLL  .....................................................................19 
2.4.2 Rationale for dose selection (entospletinib)  ...........................................................20 
2.5  Correlative studies background ..................................................................................20  
2.5.1. Assessment of B -cell depletion  ..............................................................................20 
2.5.2. Pharmacodynamic endpoints  .................................................................................20 
3.0  STUDY POPULATION  ...............................................................................................21  
3.1 Inclusion Criteria  ......................................................................................................21  
3.2. Exclusion criteria  .........................................................................................................22  
4.0 REGIST RATION PROCEDURES  ....................................................................................24  
4.1  Subject Registration  ..................................................................................................24  
4.1.1  Local registration.  .............................................................................................24 
5.0  TREATMENT PLAN  ..................................................................................................24  
5.1 Administration of study agents.  .................................................................................24  
5.1.1  Phase I (Dose Escalation)  ..................................................................................25 
5.1.2 Phase II ...........................................................................................................26 
5.2  Definition of Dose -Limiting Toxicities (DLT)  ..........................................................27  
5.3 General Concomitant Medication and Supportive Care Guidelines  .............................27  
Protocol Version 10.0 – February 5, 2021  4
  
 5.3.1     Prophylaxis of Tumor Lysis Syndrome (TLS) ........................................................27 
5.3.2. Risks Associated with obinutuzumab ther apy ...........................................................28 
5.3.3. CYP Inhibitors and Inducers ..................................................................................33 
5.3.4. Proton Pump Inhibitors  .........................................................................................34 
5.3.5. QT Prolonging Agents ..........................................................................................34 
5.3.6. Growth Factors ....................................................................................................34 
5.3.7. Anti -Emetic Therapy ............................................................................................34 
5.4  Duration of Treatment ...............................................................................................34  
5.5  Duration of Follow -up ..............................................................................................35  
5.6  Criteria for Removal from Study  ...............................................................................35  
5.7  Trial Discontinuation.  ..............................................................................................35  
6.0 DOSING DELAYS/DOSE MODIFICATIONS  ................................................................. 36 
6.1  Dose Modifications/Delays for Toxicities Encountered During Therapy.  ...................36  
6.3  Special Considerations  ..............................................................................................37  
7.0 ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................37  
7.1  Adverse Events and Potential Risks Lists ...................................................................37  
7.1.1  Entospletinib ....................................................................................................37 
7.1.2  Obinutuzumab .................................................................................................37 
7.2  Adverse Event Characteristics  ..................................................................................38  
7.2.1 Serious adverse event (SAE) ...............................................................................38 
7.2.2. Obinutuzumab adverse events of special interest .......................................................39 
7.2.3. Selected Adverse Events  .......................................................................................39 
7.2.4. Methods and Timing for Assessing and Recording Safety Variables  ............................40 
7.2.5. Procedures for Eliciting, Recording, and Reporting Adverse Events  ............................41 
7.2.6  Definitions  of Expectedness  ...............................................................................42 
7.2.7 Attribution .......................................................................................................43 
7.3 OHSU IRB Reporting of Unanticipated Problems and Adverse Events  .......................43  
7.5 MedWatch Reporting  ................................................................................................43  
7.6 Sponsor or additional reporting requirements.  ............................................................44  
7.6.1. Reporting to Gilead Sciences  .................................................................................44 
7.6.2. Reporting to Genentech  ........................................................................................45 
8.0 PHARMACEUTICAL AGENT INFORMATION .............................................................46  
8.1  Agent Accountability  ................................................................................................46  
8.2 Entospletinib.  ...........................................................................................................47  
8.2.2. Packaging and Labeling  ........................................................................................48 
8.2.3. Storage and Handling ...........................................................................................48 
8.3  Obinutuzumab.  ........................................................................................................48  
Protocol Version 10.0 – February 5, 2021  5
  
 8.3.1. Obinutuzumab Formulation ...................................................................................48 
8.3.2. Obinutuzumab Storage  .........................................................................................48 
8.3.3. Obinutuzumab Dosage  .........................................................................................48 
8.3.4 Obinutuzumab Preparation  .....................................................................................49 
8.3.5. Obinutuzumab distribution ....................................................................................49 
8.4. Dosage and Administration of Study Drugs ...................................................................50  
9.0 BIOMARKER, CORRELATIVE AND SPECIAL STUDIES .............................................50  
9.1. Biomarker /lab correlative studies  ..................................................................................50  
9.1.1.  Rationale and Hypothesis  ...............................................................................50 
9.1.2.  Intended Use of Data  .........................................................................................50 
9.1.3.   Preclinical Data and Sample Data Supporting the Biomarker Analysis  .....................50 
9.1.4. Assay Method and Validity  ...................................................................................50 
9.1.5.   Investigator Experience .....................................................................................51 
9.1.6 Number of Subjects ...........................................................................................51 
9.1.7 Risk to the Subject  ............................................................................................51 
9.1.8. Collection of Specimen(s)  .....................................................................................51 
9.1.9. Handling of Specimens(s)  .....................................................................................51 
10.0 STUDY PROCEDURES AND SCHEDULE OF EVENTS  ..............................................52  
10.1  Screening/Baseline Visit  ...........................................................................................52  
10.2  Treatment Period  ......................................................................................................52  
10.2.1 Pre-Treatment Criteria - Day -7 .......................................................................53 
10.2.2  Pre-Treatment Criteria – from C2 until end of treatment  ......................................53 
10.3   Follow-up ................................................................................................................53  
10.4  Study Assessments and Procedures ...........................................................................54  
10.5  Schedule of Events  ...................................................................................................56  
11.0 MEASU REMENT OF EFFECT  ......................................................................................60  
11.1  Disease Evaluations  ..................................................................................................60  
11.2  Criteria for Response  ................................................................................................60  
12.0 DATA REPORTING/REGULATORY REQUIREMENTS  ..............................................63  
12.1  Data Collection and Storage  ......................................................................................63  
12.2  Privacy, Confidentiality, and Data Security ................................................................63  
12.3  Protocol Review  .......................................................................................................64  
12.4  Informed Consent  .....................................................................................................64  
12.5  Changes to Protocol  ..................................................................................................64  
12.6  Maintenance of Records ............................................................................................65  
12.7  OHSU IRB Reporting of Unanticipated Problems and Adverse Events  .......................65  
Protocol Version 10.0 – February 5, 2021  6
  
 12.8  OHSU Knight Cancer Institute Data and Safety Monitoring Plan ................................65  
12.9  Inclusion of Women, Minorities and Children ............................................................66  
12.9.1 Inclusion of Women and Minorities  .................................................................66 
12.9.2 Inclusion of Children ...........................................................................................67 
12.10  Publication Plan ........................................................................................................67  
12.11  ClinicalTrials.Gov Requirements ...............................................................................67  
13. STATISTICAL CONSIDERATIONS  ...............................................................................67  
13.1  Study Design  ............................................................................................................68  
13.2.2 Secondary Endpoints  ...........................................................................................69 
13.2.3 Exploratory Endpoints  .........................................................................................69 
13.3 Analysis Population .....................................................................................................69  
13.4 Statistical Analysis Plan  ..............................................................................................69  
13.4.1 Analysis of Primary Endpoints ..............................................................................70 
13.4.2 Analysis of Secondary Endpoints  ..........................................................................70 
13.4.3 Analysis of Exploratory Endpoints  ........................................................................70 
13.4.4 Interim Analyses and Stopping Rules  .....................................................................70 
13.5 Sample Size and Power  ..........................................................................................70 
13.6 Randomization Method  ...............................................................................................71  
13.7 Handling of Missing Data  ............................................................................................71  
Data Monitoring Committee  ..........................................................................................71 
REFERENCES .......................................................................................................................71  
APPENDIX A Obinutuzumab Prescribing Information  ............................................................76  
APPENDIX B Creatinine Clearance Formula ..........................................................................77  
APPENDIX C Strong and Moderate Inhibitors and Inducers of CYP Enzymes  .........................78  
APPENDIX D ECOG Performance Status* .............................................................................80  
APPENDIX E LPL Assessment  ..............................................................................................81  
APPENDIX F Pre -clinical data  ...............................................................................................82  
APPEND IX G Response Criteria for FL, MZL and MCL  ........................................................83  
APPENDIX  H Safety Reporting Fax Cover Sheet  ...............................................................86  
Appendix I Response criteria for Hairy cell leukemia (determined by the Consensus Resolution 
response criteria [47])  .............................................................................................................87  
LIST OF ABBREVIATIONS  ................................................................................................. 88 
 
Protocol Version 10.0 – February 5, 2021  7
  
 1.0  STUDY OBJECTIVES  
1.1  Primary Objective  
 
1.1.1 Phase 1 (dose escalation):  
To evaluate the safety and tolerability of entospletinib administered in combination with 
obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), and identify the dose for 
phase 2 expansion 
1.1.2 Phase 2:  
To evaluate the efficacy of entospletinib in combination with obinutuzumab in patients with 
relapsed or refractory CLL/SLL, as measured by CR rate  
1.2  Secondary objectives  
Secondary endpoints of phase 2 portion of study are the following:  
• Objective  response rate (ORR, defined as complete remission, complete response with 
incomplete marrow recovery, partial remission and nodular partial response ) 
• Event free survival defined a s the interval between the date of first study treatment and the date 
of objective signs of disease recurrence, subsequent anti -leukemic therapy, or death, whichever 
is first reported  
• Safety and tolerability of entospletinib in combination with obinutuzumab by AEs  
1.3  Exploratory objectives  
• Peripheral blood B -cell depletion and recovery 
• Pharmacodynamics effects of in vivo administration of entospletinib on NFκB activation and 
expression of anti -apoptotic proteins in CLL cells.  
• Association of established biomarkers (chromosomal abnormalities, immunoglobulin heavy 
chain [IGHV] mutational status, p53 mutational status) with response (ORR and EFS) to ENTO 
in combination with obinutuzumab in patients with relapsed/refractory CLL  
 
2.0  BACKGROUND 
2.1  Study Dise ase – Non-Hodgkin lymphoma (NHL) and CLL  
 
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies arising from lymphoid tissue, 
with varied clinical and biological features. In 2008, there were an estimated 356,000 new cases of NHL and 192,000 deaths from NHL worldwide. NHL is the 8
th most commonly diagnosed cancer in men and the 
11th in women. Over 90% of NHL are B -cell type. B -cell NHL arise from the accumulation of monoclonal 
B lymphocytes in lymph nodes and often in organs such as blood, bone marrow, spleen, and liver. This 
group includes histopathologic varieties such as FL (follicular lymphoma), MZL (marginal zone lymphoma), MCL (mantle cell lymphoma), CLL/SLL, LPL (lymphoplasmacytic lymphoma), and DLBCL 
(diffuse large B -cell lymphoma). These disorders are characterized by lymphadenopathy, cytopenias, and 
sometimes induce life -threatening organ dysfunction. Patients may also have constitutional symptoms 
(fevers, night sweats, and/or weight loss) and fatigue. DLBCL is the most common type of NHL accounting 
for 30-40% all new diagnoses, whereas FL and MCL account for approximately 20- 25% and 6- 10% of new 
lymphomas, respectively.  
 Few patients with B -cell malignancies are cured with available therapies. The 3 -year PFS is only 40% with 
activated B -cell (ABC) DLBCL compared to 74% with germinal center type (GC) -DLBCL. For patients 
refractory to primary therapy or who relapse and are not transplant candidates, few therapeutic options exist. For patients with the indolent NHL (FL, MZL, CLL/SLL, and LPL) the goal of first and subsequent 
Protocol Version 10.0 – February 5, 2021  8
  
 line therapies is to induce tumor regression and delay tumor progression in order to control disease -related 
complications and potentially extend life. Patients who require treatment are commonly given chemotherapeutic and/or immunotherapeutic agents. Although patients with indolent NHL and CLL can achieve durable remissions with front -line combination therapies, most patients will eventually experience 
disease relapse.  
 
While considered a B -cell NHL,  CLL is the most common leukemia in the Western Hemisphere. It is 
estimated that 15,720 men and women will be diagnosed with and 4,600 patients will die from  CLL and its 
complications in 2016 [1]. The median age of a patient with CLL at diagnosis is 72 years, and 2/3 of cases 
are diagnosed among those aged 65 and older. Age adjusted incidence of CLL is estimated at 3.9/100,000 people, increasing to 22.3/100,000 among greater than 65 year olds and an estimated under -reporting of 10 
to 30% of cases [2, 3]. Therapy of CLL has undergone significant evolution in the past two decades resulting 
in an improved survival of patients with this disease [4]. Alkylating agents and glucocorticoids were first 
used in treatment of CLL in the 1950's [5, 6]. Purine analogues (cladribine, fludarabine and pentastatin) 
were introduced in the 1980's. Development of rituximab and its subsequent FDA approval for treatment of NHL in 1997 introduced highly efficacious chemo- immunotherapy regimens which to this day remain 
the standard approach to initial therapy of younger fit patients with CLL [7]. FCR (fludarabine, 
cyclophosphamide, rituximab) leads to an overall response rate (ORR) of ~90% and a complete response rate (CR) of 30 -72% when administered to previously untreated patients with CLL [7, 8]. Unfortunately, 
despite these improvements, the disease ultimately becomes resistant to standard chemo -immunotherapy 
approaches and therefore development of agents with novel mechanisms of action is imperative.  
 It has recently been recognized the survival of CLL cells is strongly dependent on the soluble mediators 
present in the lymph node and bone marrow microenvironment. Targeted therapies which disrupt signaling 
through the B -cell receptor (BCR) -associated k inases (BCRi) have been introduced in the clinic. Those 
therapies, in addition to direct cytotoxic effects, lead to partial disruption of the support niche, inducing cell egress into circulation, where they apoptose. Ibrutinib, a small molecule inhibitor of Bruton tyrosine kinase (BTK), and idelalisib, an inhibitor of phosphoinotiside -3 kinase δ (PI-3Kδ), have received FDA approval 
and are now a standard of care for both previously untreated (ibrutinib) and relapsed/refractory (ibrutinib, 
idelalisib) CLL [9]. Ibrutinib exhibited a remarkable single drug activity inducing responses in 71% of 
patients with relapsed/refractory CLL in a pivotal Phase Ib/II study [9]. However, complete responses were 
rare, and disease persisted in the lymph nodes and bone marrow despite daily administration of the drug. Most worrisomely, patients who progress on ibrutinib (~20% after 2 years of therapy) rapidly succumb to 
disease, with an estimated survival between 1 and 3 months [10-12]. Acquired resistance to ibrutinib due 
to mutations in BTK and phospholipase -Cγ (PLCγ) has now been documented in CLL as wel l as other B -
cell malignancies [10, 13]. Still, such mutations do not account for all patterns of resistance and functional 
studies have already begun identifying additional mechanisms of resistance to BCRi’s. Finally, FDA 
approved BCRi’s are less efficacious, especially as single agents, in other lymphomas (FL, DLBCL, MCL), where responses are less common and ar e short-lived.  
 The only curative approach in CLL and indolent lymphomas currently involves allogeneic stem cell transplantation. This approach is associated with substantial morbidity and mortality in this older group of patients. As such, most patients are not eligible for transplant. Stem cell transplant recipients with CLL who experience a relapse have limited therapeutic options and an overall survival of 35 months; outcomes are 
worse in patients who do not have evidence of graft -versus-host disease [14]. Thus, novel combination 
therapy approaches are needed to induce deep and durable responses.  
 
  
 
 
Protocol Version 10.0 – February 5, 2021  9
  
 2.2. Study Agent (entospletinib, GS -9973) 
 
Entospletinib (ENTO) is a potent and highly selective inhibitor of spleen tyrosine kinase (SYK) that is being developed by Gilea d Sciences for oral administration in the treatment of hematologic malignancies 
and chronic graft versus host disease.  
 Studies have suggested a role for the dysregulation of SYK in B -cell malignancies. SYK is expressed in B -
cells and is essentially involv ed in multiple signal transduction pathways downstream of the BCR. SYK 
trans-autophosphorylates and activates effector molecules such as PLCγ, PI- 3K, and mitogen- activated 
protein kinase (MAPK), and their associated signaling pathways, to induce B -cell proliferation, survival, 
differentiation, and apoptosis. In B -cell malignancies, including CLL, the BCR can deliver antigen-
independent signals that have also been postulated to require SYK activity. Therefore, inhibition of BCR -
mediated SYK activity is an at tractive therapeutic target, which could inhibit the proliferation and survival 
of malignant B cells. Preclinical evidence suggests that SYK inhibition may have independent benefit from 
BTK inhibition in B -cell malignancies.  
 
2.2.1. Nonclinical Pharmacology - entospletinib 
 
Entospletinib is an adenosine triphosphate (ATP) competitive inhibitor of SYK with an EC 50 of 8.5±3.6 
nM. Entospletinib binds in the ATP pocket of the SYK active site and disrupts the kinase activity of the enzyme. Kinase selectivity profiling showed a >14- fold selectivity of entospletinib for SYK versus 359 
non-mutant kinases and no significant binding (< 50%) to 67 ion channels, transporters, and receptors 
screened at 1 μM entospletinib. No significant off- target or adverse p harmacological effects of clinical 
relevance were noted in preclinical evaluations.  
 Entospletinib was evaluated in a battery of safety pharmacology studies. The IC
50 for the inhibitory effect 
of entospletinib on human ether -à-go-go- related gene (hERG) potassium current in vitro was estimated to 
be >1 μM. In dogs, entospletinib caused small increases in heart rates at doses ≥ 15 mg/kg, but had no effects on electrocard iograms (ECGs) or blood pressure at up to 150 mg/kg, the highest dose evaluated. 
Because entospletinib is 97.3% protein bound in human plasma and the total plasma concentration of 
entospletinib is in the 1 to 3 μM range, with a corresponding range of free entospletinib of 27 to 81 nM, it 
is unlikely that a clinically relevant effect on QT interval would occur.  
 
No entospletinib- related effects were noted on neurological or respiratory function in rats at doses up to 
1000 mg/kg
. 
 
2.2.2. Nonclinical Absorption, Distribution, Metabolism and Elimination  
 High bioavailability of entospletinib was observed in nonclinical studies. Consistent with this finding, entospletinib showed high permeability across Caco- 2 monolayers and low potential for efflux. Despite 
high plasma protein binding, entospletinib had a moderate volume of distribution, close to that of total body 
water. The systemic clearance was low in rats, moderate in dogs, and moderate to high in monkeys.  
Single-day dose escalation of entospletinib administ ered orally to rats, dogs, and monkeys showed a less 
than dose proportional increase in entospletinib systemic exposure in all species over the dose ranges tested.  
 Entospletinib showed good metabolic stability with human hepatic material in vitro. Therefore, clearance through metabolism in humans is expected to be low. The primary routes of metabolism of entospletinib 
involved oxidative opening of the morpholine ring as well as further oxidation or conjugation. In vitro data 
indicates entospletinib is primarily metabolized by CYP2C9 and to a lesser extent by CYP3A and CYP1A2. Metabolism followed by biliary excretion is likely the major route of elimination of entospletinib and its metabolites, as < 5% of the radiolabeled dose administered orally to rats was  recovered in urine.  
Protocol Version 10.0 – February 5, 2021  10
  
  
Entospletinib is an inhibitor of UGT1A1 and may transiently inhibit UGT1A1 activity in vivo at the 
expected clinical concentrations. Entospletinib is also an inhibitor of the uptake transporters OATP1B1 and OATP1B3 as well as the effl ux transporters P -gp and BCRP with an IC
50 value of approximately 2 μM for 
each of these transporters. Entospletinib may affect the activity of these transporters in vivo at the expected clinical concentrations and could transiently affect the disposition of other drugs, although high plasma 
protein binding (> 97%) may mitigate some of the potential drug- drug interactions at clinically relevant 
doses.  
2.2.3. Nonclinical Toxicology 
 
Entospletinib was well tolerated in single -dose studies at doses of 1000 mg/kg in dogs, and cynomolgus 
monkeys. In repeat -dose studies in rats, entospletinib was well tolerated for 14 days at doses of 1000 
mg/kg/day and for 4 weeks at 50 mg/kg/day. In dogs, entospletinib was well tolerated for 7 days at 50 
mg/kg/day and for 4 weeks at 10 mg/kg/day. In cynomolgus monkeys, entospletinib was well tolerated for 
13 weeks at 100 mg/kg/day, which was the highest dose tested as dosing higher than that did not increase exposure. In rabbits, it was tolerated for 7 days at 300 mg/kg/day.  
 The target organ(s) of toxicity identified in rats was the duodenum (enteropathy), and in rabbits and dogs 
were predominantly the gastrointestinal tract (hemorrhage and/or inflammation) and lymphoid organs. No 
target organs were identified in the cynomolgus monkeys. Additional organs potentially affected in 
individual dogs at higher doses included gallbladder, pancreas (rabbits and dogs), urinary bladder, and 
epididymis. Gastrointestinal tract toxicity in rats, rabbits, and dogs was associated with decreased food 
consumption and/or decreased body weight or body weight gain. However, decreased food consumption and body weight changes, in rabbits and dogs also occurred at doses lower than those which showed 
histological evidence of gastrointestinal toxicity.  
 
Increases in total and/or indirect bilirubin in rats, rabbits, and dogs were observed at ≥ 30 mg/kg/day and 
may have been due to the inhibition of the enzyme UGT1A1. As no histological evidence of hepatobiliary toxicity was noted concurrently with bilirubin increases in entospletinib- treated rats or dogs, and 
entospletinib levels above the IC50 for UGT1A1 were achieved in serum, this seems a plausible mechanism for the noted increases in bilirubin.  
 Hemorrhage and/or sinus erythrocytosis in lymph nodes with decreases in red cell mass in individual animals was noted in rabbits and dogs, but not in rats or cynomolgus monkeys. Although the mechanism for these changes is not clear, rodents with SYK deficiency or SYK -deficient bone marrow have been 
associated with hemorrhage, the latter in the presence of normal bleeding times, suggesting normal platelet 
function [ 15]. No evidence of altered coagulation parameters were noted at any dose level in the 
entospletinib nonclinical studies and no biologically relevant effects were noted in an in vitro study of platelet aggregation. Other inhibitors of SYK have been found to have no effect on platelet function at efficacious dose levels in patients with rheumatoid arthritis (RA) as determined by ex vivo assays, and 
similarly, SYK inhibition has not been found to affect bleeding time in rodents [16]. 
 
Adverse effects on lymphoid tissues including spleen, lymph nodes, and/or the thymus were noted in rabbits and dogs, but not in rats or cynomolgus monkeys despite higher exposures achieved. Recently, published data demonstrated that species -specific lymphoid changes can occur in dogs, but not in rats, cynomolgus 
monkeys, or humans treated with small molecule kinase inhibitors that inhibit pathways that overlap with SYK signaling pathways [17]. Lymphoid toxicity also occurs in dogs treated with p38α MAPK inhibitors, 
but not in rats or cynomolgus monkeys despite higher exposure levels achieved in these species. Ther e has 
been no evidence of significant immune -toxicity in clinical trials with p38α MAPK inhibitors. The 
relevance of the findings in rabbits and dogs to humans is unknown.  
 
Protocol Version 10.0 – February 5, 2021  11
  
 Entospletinib was negative in bacterial mutation, in vitro chromosomal aberration, and rat micronucleus 
assays and is considered non- genotoxic. Dose -range finding embryo- fetal developmental toxicity studies 
have been completed in rats and rabbits. Maternal toxicity was demonstrated by dose -dependent decreases 
in the body weight gains of the dams. Dose -dependent developmental findings included increased incidence 
of early and late fetal resorptions at 500 mg/kg/day (rat only) and reduced fetal weights (500 and ≥ 15 mg/kg/day; rats and rabbits, respectively) which correlated with the maternal toxicity.  
 
2.2.4. Clinical Trials  
 
Entospletinib has been administered to 540 subjects (328 healthy subjects, 7 subjects with rheumatoid 
arthritis, 76 subjects with CLL, and 155 subjects with NHL) in 11 Phase 1 and Phase 2 clinical studies.  
Single agent  efficacy has been demonstrated with entospletinib in subjects with relapsed or refractory 
hematologic malignancies (CLL/SLL, MCL, DLBCL, FL, LPL, or MZL). PFS rates are 70.1% (95% CI: 51.3%, 82.7%) at 24 weeks for subjects with CLL (n=41) and 50.2% (95% CI: 29.3%, 67.9%) at 24 weeks 
in subjects with FL (n=41). The most common AEs (observed in ≥ 15% of subjects) in hematology patients 
receiving entospletinib alone (n = 186) include fatigue (52.5%), nausea (43.3%), diarrhea (40.8%), decreased appetite (27.1% ), constipation (23.8%); cough (22.5.0%), dizziness (19.6%), pyrexia  
(18.8%), vomiting (18.3%), headache (17.9%), dyspnea (16.7%), insomnia (15.8%), dehydration (15.0%), and upper respiratory infection (15.0%). Thirty four subjects (14.2%) reported an AE of rash.  
 
Entospletinib is expected to produce asymptomatic and transient elevations of indirect bilirubin due to 
inhibition of UGT1A1. In studies of subjects with hematologic malignancies, 9 of 252 subjects had 
elevations of direct bilirubin with the onset of elevation ranging from Day 8 to 85, except for 1 subject at Day 169. Bilirubin elevations were generally self -limited and did not result in discontinuation of 
entospletinib.  
 
In a phase 2, open label study evaluating the efficacy, safety, tolerabilit y, and pharmacodynamics of the 
combination of entospletinib and idelalisib administered twice daily over multiple 28 day cycles to subjects with relapsed or refractory lymphoid malignancies, pneumonitis was reported in 12 of 66 subjects (18.2%), leading to the discontinuation of further evaluation of this combination [18]. All subjects were to receive 
treatment with entospletinib and idelalisib twice daily under fasted conditions and the study allowed intra -
subject dose escalations every 2 weeks. Of the 12 pneumonitis AEs, 11 (91.7%) were SAEs, 7 were Grade 3, 2 were Grade 4, and 2 were Grade 5. The protocol was amended to allow a subset of subjects to receive monotherapy with entospletinib after a 14 to 28 day washout period with no subsequent cases of pneumonitis reported. Pneumonitis has not been identified as a risk with entospletinib monotherapy.  
2.3.  Obinutuzumab ( GA101, Gazyva™) 
 
Obinutuzumab (GA101, RO5072759, Gazyva
, Gazyvaro) is a humanized glycoengineered type  II 
anti-CD20 monoclonal antibody (mAb) being developed by Genentech for the treatment of various 
hematologic malignancies.  Obinutuzumab (Gazyva) was approved in the U.S. on 1 November 2013 for 
use in combination with chlorambucil for the treatment of patients with previously untreated CLL.   In 
Europe, obinutuzumab (Gazyvaro) was approved on 25 July 2014 for use in combination with 
chlorambucil for the treatment of adult patients with previously untreated CLL and comorbidities making them unsuitable for full -dose fludarabine -based therapy.   
 Obinutuzumab is also undergoing Phase  III evaluation in NHL in combination with chemotherapy.  
 
2.3.1. Structure and Mechanism of Action of Obinutuzumab  
Obinutuzumab is characterized by high- affinity binding to a CD20 epitope that is different from the epitope 
targeted by rituximab, which is currently the widely used anti -CD20 monoclonal antibody [19, 20]. 
Obinutuzumab was derived by humanization of the parental B -Ly1 mouse antibody and subsequent 
Protocol Version 10.0 – February 5, 2021  12
  
 glycoengineering leading to the following characteristics:  high affinity binding to the CD20 antigen, high 
antibody- dependent cellular cytotoxicity (ADCC), and antibody- dependent cellular phagocytosis (ADCP); 
low complement -dependent cytotoxicity (CDC) activity; and high direct cell death induction. Nonclinical 
studies with obinutuzumab in comparison with rituximab show significantly greater ADCC and ADCP, 
increased direct cell –death induction, and low CDC.  Superior efficacy to rituximab has been demonstrated 
in various human lymphoma xenograft models [19, 21].  
 
2.3.2. Clinical Experience with Obinutuzumab  
 
Obinutuzumab is approved for use in com bination with chlorambucil in previously untreated CLL on the 
basis of data from the Phase III study BO21004/CLL11 [22].  Obinutuzumab is also undergoing Phase III 
evaluation in NHL in combination with chemotherapy.  
For the most up-to-date information on obinutuzumab, please refer to the current version of the 
Investigator’s Brochure.  
 
2.3.2.1. Clinical Pharmacology  The clinical pharmacology properties of obinutuzumab have been characterized in a number of clinical studies in patients with CLL or NHL. These studies include two Phase  I/II monotherapy studies (BO20999 
and BO21003); two Phase I monotherapy studies in Japanese patients with NHL (JO21900) and Chinese 
patients with FL, DLBCL, or CLL (YP25623); two Phase Ib combination studies (BO21000 and 
GAO4779g); two Phase II studies (a combination Study GAO4915g and a monotherapy Study GAO4768g at 1000 mg and 2000 mg); and two Phase III combination studies (BO21004/CLL11 and GAO4753g). A 
serum sampling scheme for the quantitation of obinutuzumab was undertaken in these studies to enable 
population PK analysis, which demonstrated that a two- compartment PK model comprising both a linear 
clearance pathway and a non -linear time -varying clearance pathway adequately described serum 
obinutuzumab concentration data. The initial clearance of obinutuzumab was
 > 2 × higher than the steady -
state clearance, which is consistent with a decrease in the time- varying clearance component, which is high 
at the start of treatment and declines with repeated  cycles of obinutuzumab treatment. The time -varying 
clearance pathway is consistent with target -mediated drug disposition such that, at the start of treatment 
when there is a large quantity of CD20- positive cells, it binds obinutuzumab. With repeated dosing of 
obinutuzumab, the pool of CD20- positive cells is saturated, thereby reducing this component in clearance.  
The linear clearance pathway is consistent with catabolism of IgG antibodies and is therefore independent of CD20- positive cells. Analysis furth er supports the need to minimize the time -varying clearance 
component quickly and has led to the proposed dose and regimen of 1000 mg in both induction and 
extended treatment.   
 Consistent with the mechanism of action of obinutuzumab, extensive B -cell depletion was observed both 
in patients with NHL and CLL.  In most patients receiving obinutuzumab monotherapy, there was no notable increase in complement levels during or following an infusion.  Changes in the levels of interleukin (IL)-6 and IL-8 were observed, i.e., increases during the course of the first infusion followed by a decrease 
to pre-infusion levels 7 days later.  
  2.3.2.2. Clinical Experience of Obinutuzumab in Chronic Lymphocytic Leukemia 
 
Study BO20999 (GAUGUIN; [STUDY_ID_REMOVED]) (Phase I)  
BO20999 was an open -label, multicenter, Phase I/II study to explore obinutuzumab safety and activity in 
relapsed/refractory NHL and CLL. Thirteen CLL patients have received obinutuzumab at doses with a 
range of 400− 2000 mg (given as a flat dose) across four cohor ts.  There were no dose -limiting toxicities 
(DLTs) and no requirement for dose reductions.  Infusion- related reactions (IRRs) occurred in all CLL 
patients and were characterized predominantly by National Cancer Institute Common Terminology Criteria 
Protocol Version 10.0 – February 5, 2021  13
  
 (NCI-CTC) Grade 1 −2 toxicities:  chills,  nausea, vomiting,  fever, pyrexia, hypertension, hypotension, 
dyspnea, and dizziness.  Two patients experienced four NCI -CTC Grade 3 toxicities:  sweats, flushing, 
asthenia, and hepatic  cytolysis .  
 Although the safety prof ile appears otherwise similar between NHL and CLL, there was an increase in NCI -
CTC v3.0 Grade 3− 4 neutropenia noted in CLL patients, which were observed in 9 patients across the four 
dose levels administered.  Five patients experienced NCI -CTC Grade 4 neu tropenia and 4 patients 
experienced NCI -CTC Grade 3 neutropenia as the maximum severity.  Of the 9 patients, 7 had 
one NCI-CTC Grade 3 −4 event and 2 patients experienced more than one event.  Granulocyte colony -
stimulating factor (G -CSF) support was admini stered to 6  of the 9 patients, and these patients responded 
quickly to G -CSF support.  For  the 3 patients who did not receive G-CSF, neutrophil counts normalized 
spontaneously.  Furthermore, it is important to note that these neutropenia events did not appear to be accompanied by a higher incidence of infections.  No deaths were reported in Phase I of this study for CLL . 
As assessed by the International Workshop on CLL (IWCLL) criteria, the end-of- treatment response rate 
with obinutuzumab monotherapy was 62% (8  of 13 patients with partial response [PR]) . 
 Study BO20999 (GAUGUIN; [STUDY_ID_REMOVED]) (Phase II)  
Twenty patients with relapsed/refractory CLL have received 1000 mg of obinutuzumab.  The most 
commonly reported adverse  event (AE) during the treatment period was IRR, reported in 19 (95%) of 20 
patients.  Fifteen patients experienced Grade 3 −4 AEs of whom 14 patients had treatment -related Grade 
3−4 AEs (investigator assessment).  Treatment -related Grade 3 −4 AEs were IRR (6  patients), neutropenia 
(4 patients), lymphopenia (2 patients), thrombocytopenia (2 patients), and anemia, pure red cell aplasia, 
pancytopenia, febrile neutropenia, herpes zoster, and interstitial lung disease (1 patient each).  Eleven 
serious adverse events (SAEs) in 9 patients were reported during treatment, 9 of which were assessed by 
the investigator as related to obinutuzumab:  IRR (4 patients) and febrile  neutropenia, pancytopenia, pure 
red cell aplasia, interstitial lung disease and pyrexia (1  patient each).  Three patients withdrew from  further 
study treatment after the first infusion due to IRR.  One death has been reported during follow -up from 
colon cancer.  The most common AE in follow -up was nasopharyngitis, reported in 2 patients.  End-of-
treatment response assessment showed that t hree patients (15%) achieved a clinical response.  
 Study BO21003 (GAUSS; [STUDY_ID_REMOVED]) (Phase I)  
BO21003 is an open- label, dose -escalating, multicenter Phase I/randomized Phase II study in patients with 
relapsed/refractory CD20+ malignant disease.  In Study BO21003, 5 CLL patients have been administered 
obinutuzumab.  The fifth patient withdrew at Cycle  1, Day 1 because of a Grade 4 IRR, which occurred 
minutes after the start of infusion in the setting of high tumor burden.  Efficacy assessments are availabl e 
for only the 4 patients who completed treatment (received 4 cycles of infusion).  The end-of-treatment 
response in patients with CLL receiving obinutuzumab monotherapy in this study included 3 stable disease and 1 progressive disease.  
 
Study GAO4768g / GAGE / [STUDY_ID_REMOVED] (Phase II)  
GAO4768g is an open- label, randomized, multicenter, Phase II study evaluating the efficacy and safety of 
obinutuzumab administered at 1000 mg versus 2000 mg doses in patient with previously untreated CLL.  
The results of the GAGE study were recently presented at the 2014 annual meeting of the American Society of Clinical Oncology.  
 
Eighty patients were randomized and stratified based on Rai stage and tumor mass.  
  
For patients who received the 1000- mg doses, obinutuzumab was administered with three 1000- mg doses 
in the first 21- day cycle (the first 1000- mg dose was administered over 2 days:  100 mg administered on 
Day 1, 900 mg administered on Day 2; 1000 mg was administered on both Days 8 and 15).  In the subsequent cycles (2− 8), 1000 mg of obinutuzumab was administered on the first day of each cycle.  
 
Protocol Version 10.0 – February 5, 2021  14
  
 For patients who received the 2000- mg doses, obinutuzumab was administered as follows:  100 mg on 
Cycle 1, Day 1; 900 mg on Day 2; and 1000 mg on Day 3.  On Days  8 and 15 of Cycle 1, 2000 mg was 
administered on each day.  For Cycles 2− 8, 2000 mg of obinutuzumab was administered on Day 1 of each 
cycle. 
 ORR was assessed at 2 months post -therapy according to the IWCLL criteria.  The ORR for the 1000- mg 
and 2000- mg obinutuzumab treatment arms were 49% compared with 67%, respectively; 2-sided p
 = 0.0779.  
Complete response/complete remission with incomplete blood count recovery (CR/CRi) were achieved by 5% of patients (2/41) in the 1000- mg arm compared with 21% of patients (8/39) in the 2000- mg arm. 
 The most common Grade 3/4 AEs were neutropenia (11/40 patients [27.5%] in the 1000 mg arm and 12/38 
patients 31.6% in the 2000 mg arm) and thrombocytopenia (6/40 patients [15%] in the 1000 mg arm and 
5/38 patients [13.2%] in the 2000 mg arm).  Grade 3/4 anemia was experienced by 6/38 patients (15%) in 
the 1000 mg arm and 2/38 patients 5.3% in the 2000 mg arm. 
 Study GAO4779g (GALTON; [STUDY_ID_REMOVED]) (Phase II)  
GAO4779g is an open- label, non- randomized, multicenter, Phase II study. In the GALTON study, 41 
patients with untreated CLL were treated with obinutuzumab 1000 mg (100 mg IV on Day 1, 900 mg on 
Day 2, and 1000 mg on Days 8 and 15 of Cycle 1; 1000 mg on Day 1 in Cycles 2− 8) and either 
fludarabine
 + cyclophosphamide (G-FC; 25/250 mg/m2 IV on Days 2− 4 of Cycle 1, then on Days 1− 3 of 
Cycles 2−6) or bendamustine G -B; 70 mg/m2 IV on Days 2− 3 of Cycle 1, then on Days 1− 2 of Cycles  2−6).  
Each cycle was 28 days long.    
 In the G-FC arm, 6/21 patients (29%) experienced an SAE, most frequently febrile neutropenia (14%); all 
other events were isolated events and were mostly infectious in nature (3 patients each had one serious infection; pneumonia, cellulitis and appendicitis). The incidence of AEs which lead to withdrawal of any treatment was 3 3% with 7/21 experiencing mostly hematological events (neutropenia [2 patients], 
pancytopenia [1 patient] and thrombocytopenia [1 patient]).  
 
Seventeen of the 21 patients (81%) treated with G -FC experienced 39 related Grade 3 -4 AEs, most 
frequently neutropenia (5 patients [23.8%]), followed by alanine transaminase increase (4 patients [19.0%]), 
IRRs (3 patients [14.3%]), febrile neutropenia (3 patients [14.3%]), thrombocytopenia (3 patients [14.3%]) and anemia (3 patients [14.3%]).  
 
All patients experience d at least one AE, most frequently IRR (76.2%), nausea (76.2%), fatigue (57.1%), 
and constipation (47.6%).  
 
Overall, obinutuzumab can be administered with FC, the combination is manageable. Hematologic events were the most frequent cause of treatment withd rawals of obinutuzumab or FC. IRR (all grade) occurred in 
76% of patients. These events were managed with dose interruption and only one patient withdrew from obinutuzumab treatment for this reason.  
 In the G-benda arm, 11 patients (55.0%) experienced an SAE, most frequently IRRs (15%), febrile 
neutropenia (10%) and pyrexia (10%); all other events were isolated events. The incidence of AEs which led to withdrawal of treatment was 10%  with 2/20 patients experiencing neutropenia.  
 Grade 3-4 AEs were experien ced by 85% (17/20) of patients, most frequently neutropenia (50%), 
thrombocytopenia (15%), febrile neutropenia (10%) and erythema (10%).  
 All patients experienced at least one AE, most frequently IRR (70.0%), nausea (65.0%), diarrhea (50.0%), 
neutropenia (50.0%), and pyrexia (45.0%).  
 
Protocol Version 10.0 – February 5, 2021  15
  
 Overall, obinutuzumab can be administered with bendamustine, the combination is manageable.  IRRs (all 
grade) occurred in 90% of patients. These events were managed with dose interruption and no patient 
withdrew from any treatment for this reason.  
 The ORR was 62% (CR, 2; CRi, 3; PR, 8) in patients who received G -FC and 90% (CR,  4; CRi, 5; PR, 9) 
in patients who received G -B, including 6 patients (G -FC, n
 = 4; G-B, n = 2) not evaluable due to inadequate 
response evaluation.  Four patients in the G -FC arm (0 in G -B) had stable disease during and after therapy.  
No patient progressed during the study.  
 Study BO21004 (CLL11; [STUDY_ID_REMOVED]) (Phase III)  
This is an open- label, multicenter, three- arm randomized, Phase III study to compare the efficacy and safety 
of obinutuzumab
 + chlorambucil (GClb), rituximab  + Clb (RClb), or Clb alone in previously untreated CLL 
patients with comorbidities.  BO21004 enrolled 781 patients and an additional 6 patients during a safety run-in period before randomization.   
 This study included a safety run- in period before randomization. During the run- in period, 6 patients 
received obinutuzumab in combination with Clb for up to 6 cycles. All 6 patients have completed treatment 
and are in follow -up; the safety data for these patients are not reported but are consistent with the safety 
data of the randomized patients in this study. In Stage 1, patients were randomized in a 2:2:1 rat io to GClb 
(238 patients), RClb (233 patients) or to Clb alone (118 patients). In Stage 2, the randomization continued in a 1:1 ratio to GClb and RClb for an additional 190 patients; 663 patients (330 patients randomized to the RClb arm and 333 patients randomized to the GClb arm) were included in this Stage 2 analysis. The safety data from Stage 2 is presented in this section since all randomized patients who received obinutuzumab are 
included. 
 The incidence of death was 22.9% in the GClb arm and 28.0% in the RClb arm.  
 Fatal AEs occurred in 5.7% and 7.5% of patients in the GClb and RClb arms, respectively. The type and 
number of fatal AEs was balanced between the treatment arms with the exception of cardiac disorders 
which occurred in 6/321 patients (1.9%) RClb arm compared with 2/336 patients (0.6%) in the GClb arm. The incidence of SAEs in the GClb and RClb arms was 42.0% and 36.8% respectively, the incidence of Grade 3-4 AEs was 70.5% and 56.7% respectively, and the incidence of AEs leading to withdraw al of any 
study medication was 20.2% and 15.3%, respectively.  
 
Imbalances between the treatment arms in AEs, SAEs and Grade 3 -5 AEs was mainly due to IRRs, which 
occurred primarily during the first infusion of obinutuzumab. IRRs were experienced by 238/336 patients 
(70.8%) who received GClb and led to the treatment withdrawal of 27/336 patients (11.3%). To a lesser 
extent, differences between the treatment arms are also attributable to differences in the incidence of Grade 3-5 AEs within the body system “Blood and Lymphatic System”.  
 Study BO21004 includes two separate stages evaluating efficacy and the primary endpoint is progression -
free survival (PFS). Stage 1 evaluated obinutuzumab
 + chlorambucil compared with chlorambucil alone.   
In the Stage 1 analysis, median PFS of chlorambucil vs. obinutuzumab  + chlorambucil was 11.2 vs. 27.2 
months, respectively, (median observation time, 22.8 months; hazard ratio [HR], 0.19 [0.14− 0.27]; 
p < 0.0001; stratified log- rank test) as assessed by independent review and is  consistent with investigator -
assessed PFS.   
 In the Stage 2 analysis of this study, the median PFS was 26.7 months vs. 14.9 months for 
obinutuzumab
 + chlorambucil vs. rituximab  + chlorambucil , respectively with a median observation time of 
18.7 months (HR: 0.42, 95% CI: 0.33- 0.54, p-value < 0.0001).  The ORR was 80% vs. 66%, and CR was 
26% vs. 9%, respectively.  
 
Protocol Version 10.0 – February 5, 2021  16
  
 In the comparison of obinutuzumab  + chlorambucil vs. chlorambuil alone, the most common AEs (all 
grades, Grades 3 −4), respectively, were IRRs (69% vs. 0, 21% vs. 0), neutropenia (40% vs. 18%, 34% vs. 
16%), thrombocytopenia (15% vs. 7%, 11% vs. 3%), anemia (12% vs. 10%, 4% vs. 5%), leukopenia (7% 
vs. 0, 5% vs. 0), pyrexia (10%  vs. 7%, < 1% vs. 0), and cough (10% vs. 7%, 0 vs. < 1%).  Hematologic 
laboratory abnormalities (all grades, Grades 3 −4) with obinutuzumab  + chlorambucil vs. chlorambucil 
alone, respectively, were neutropenia (77% vs. 53%, 46% vs. 27%), lymphopenia (80% vs. 9%, 40% vs. 2%), leukopenia (84% vs. 12%, 36% vs. <
 1%), and thrombocytopenia (47% vs. 50%, 14% vs. 11%).  
 
Non-hematologic laboratory abnormalities (all grades, Grades 3− 4) with obinutuzumab  + chlorambucil vs. 
chlorambucil alone, respectively, were hypocalcemia (32% vs. 29%, 3% vs. < 1%), hyperkalemia (31% vs. 
17%, 5% vs. 2%), hyponatremia (29% vs. 11%, 8% vs. 22%), AST (SGOT increased; 28% vs. 12%, < 1% 
vs. 0), creatinine increased (28% vs. 18%, < 1% vs. < 1%), ALT (SGPT increased; 25% vs. 14%, < 1% vs. 
0), hypoalbuminemia (22% vs. 14%, < 1% vs. < 1%), alkaline phosphatase increased (16% vs. 11%, 0 vs. 
0), and hypokalemia (13% vs. 4%, 1% vs. < 1%) ([22]; Obinutuzumab USPI).  
 For more i nformation related to safety and efficacy in the CLL indication, please  refer to the Obinutuzumab 
Investigator’s Brochure or the Obinutuzumab USPI.  
 2.3.2.4. Clinical Experience of Obinutuzumab in NHL  
 As of 2 July 2015, obinutuzumab has been administered to 2105 patients with NHL in 4 monotherapy studies and 6 combination therapy studies.  The combination therapy studies include the following:  
 Study BO21000 (GAUDI):  A Phase Ib, open- label study of obinutuzumab in combination with CHOP, 
fludarabine/cyclophosphamide (FC), or bendamustine in patients with CD20+  B-cell FL.  A total of 137 
patients were enrolled, including 56 with R/R disease ( obinutuzumab
 + FC:  n = 28; obinutuzumab  + CHOP:  
n = 28) and 80 first -line patients (obinutuzumab  + bendamustine:  n  = 41; obinutuzumab  + CHOP:  n  = 40). 
 
Study GAO4915g (GATHER):  A Phase II, open- label study of obinutuzumab  + CHOP in previously 
untreated advanced DLBCL.  A total of 100 patients were enrolled.  
 
Study GAO4753g (GADOLIN):  A Phase III study of obinutuzumab  + bendamustine (G -benda) vs. 
bendamustine alone in patients with rituximab- refractory CD20 + indolent NHL (iNHL).  A total of 194 
patients were randomized to the G -benda arm and 202 to bendamustine arm.  
 Study BO21223 (GALLIUM):  A Phase  III study of G -chemo vs. R -chemo in patients with advanced iNHL.  
Enrollment to the study has completed with 1401 enrolled patients; the study is ongoing.  
 Study BO21005 (GOYA):  A Phase III study of G -CHOP vs. R -CHOP in patients with previously untreated 
CD20+ DLBCL.  Enrollment to the study has completed with 1418 enrolled patients; the study is ongoing.  
 Study JO29737 (GATS):  A Phase II, open- label study of obinutuzumab (shorter duration of infusion) in 
patients with CD20+  NHL. Enrollment is ongoing, w ith 14 patients enrolled (planned enrollment of 36).  
 In the monotherapy setting (studies BO20999, BO21003, YP25623, and JO21900), the proportion of patients who had a response (CR or PR) at the end of treatment ranged from 28% (11/40 patients) to 58% (7/12 patients).  Although patients had treatment -refractory (including rituximab- refractory) or relapsed 
disease, some patients in studies BO20999, BO21003 (Phase II), and JO21900 achieved a CR by the end of treatment assessment.  
 
Protocol Version 10.0 – February 5, 2021  17
  
 In the chemotherapy combination studies BO21000 and GAO4915g, the proportion of patients achieving a 
response exceeded 90% among FL patients and was 82% among DLBCL patients.  The CR rate was also 
higher (35% −50% of patients with FL and 55% of patients with DLBCL) than in the monotherapy studies.  
Data from the pivotal chemotherapy combination Phase III study (GAO4753g) in patients with FL showed 
that treatment with G -benda for 6 cycles (28 days per cycle) followed by 2- year monotherapy with 
obinutuzumab resulted in a clinically meaningful and statistically significant increase in PFS compared with bendamustine alone.  The primary objective of the study was to evaluate PFS as determined by an 
Independent Review Committee (IRC).  Median observation time was 21.1 months.  The median 
IRC-assessed PFS in the bendamustine arm was 13.8 months.  Median IRC -assessed PFS was not reached 
in the G-benda arm (PFS hazard ratio [HR]
 = 0.48, 95% CI:  0.34− 0.68; stratified log- rank test p -value 
< 0.0001).  The investigator -assessed PFS result was consistent with the IRC -assessed PFS.  The median 
investigator- assessed PFS in the bendamustine arm was 13.7 months, and the median in the G -benda arm 
was 29.2 months (PFS HR  = 0.48, 95% CI:  0.35− 0.67; stratified log- rank test p -value < 0.0001).  
IRC-assessed best ORR within 12 months from the start of treatment was 78.7% in the G -benda arm (15.5% 
CR and 63.2% PR) and 74.7% (18.7% CR and 56.0% PR) in the bendamustine arm.  An analysis conducted with 24.1 months of median observation time revealed that the median OS was not yet reached in either 
arm. 
 
2.3.3. Overview of Safety of Obinutuzumab  
As of 2 July 2015 (the safety data cutoff date for all studies except MO28543), obinutuzumab has been 
administered to a total of 3386 patients, including 1281 patients with CLL and 2105 patients with NHL, 
from doses of 50 mg to 2000 mg in monotherapy or in combination with CHOP, FC, bendamustine, or 
chlorambucil (Clb).  Overall, the safety of monotherapy obinutuzumab, or obinutuzumab combination therapy with CHOP, FC, bendamustine, or Clb, was manageable.  
 The most frequent causes of death were disease progression and adverse events of infectious diseases.  This 
is consistent with the study population and the disease being treated.  
 
Of particular interest, IRRs were obser ved consistently in all obinutuzumab trials.  In patients with CLL 
(study BO21004), the highest incidence of IRR was at the first infusion with the incidence decreasing rapidly with subsequent infusions.  The incidence of IRR observed with combination ther apy (FC, CHOP, 
or bendamustine) appears similar to that observed with monotherapy.  Furthermore, the incidence of IRR appears to be higher with CLL compared with NHL, and higher in patients who received obinutuzumab compared with patients who received rituximab based on evidence from studies BO21003 and BO21999.  There is no clear relationship between obinutuzumab dose and the incidence of IRR based on data from Study GAO4768g.  In Stage 2 of the pivotal Phase III study, BO21004, investigating G -Clb vs. R-Clb in 
patients with CLL, the incidence of IRR, Grade 3−4 IRR, and IRR leading to discontinuation was higher in 
G-Clb arm compared with the R-Clb arm.  This study implemented several measures to minimize the risk 
of IRRs, including:  use of corticosteroids,  withdrawal of antihypertensive treatments, slow infusion, and 
split dosing.  The evidence suggests that these risk- minimization measures decreased the risk of IRRs (all 
grades); however, the impact on the incidence of Grade 3− 4 events and treatment discontinuations due to 
IRRs was limited.  In the pivotal study GAO4753g in patients with R/R iNHL, the majority of IRRs were 
Grade 1 or 2 and there were no fatal (Grade 5) IRRs.  The overall incidence of IRRs was higher in the G -
benda arm compared with the bendamustine arm (69% vs. 63%), as was the incidence of Grade 3− 4 IRRs 
(11% vs. 6%), serious IRRs, IRRs leading to withdrawal from treatment, dose reductions, or dose 
interruptions.   
In Study GAO4753g, the most common adverse reactions (incidence ≥
 10%) obser ved in patients with 
iNHL in the G -benda arm were IRRs, neutropenia, nausea, fatigue, cough, diarrhea, constipation, pyrexia, 
thrombocytopenia, vomiting, upper respiratory tract infection, decreased appetite, arthralgia, sinusitis, 
Protocol Version 10.0 – February 5, 2021  18
  
 anemia, asthenia, and ur inary tract infection.  The most common Grade 3− 4 adverse reactions (incidence 
≥ 10%) observed in patients with iNHL in the G -benda arm were neutropenia, thrombocytopenia, and IRRs.  
Due to the pharmacological class of obinutuzumab, as well as the evidence from monotherapy Phase I trials and chemotherapy combination trials GAO4779g (Phase I) and BO21004 (Phase III), the Sponsor considers acute thrombocytopenia and thrombocytopenia to be related to obinutuzumab.  The main risk associated with thrombocytopenia  is hemorrhage.  In study BO21004, the overall incidence of hemorrhagic adverse 
events was comparable between the treatment arms (8.0% G-Clb; 7.2% R-Clb), with the majority of events 
being of Grade 1 or 2 severity.  However, and importantly, all fatal hemorrhagic events in the G-Clb arm 
occurred in Cycle 1 in contrast to such events in the R-Clb arm, which occurred later (beyond 1 year after 
first administration of study drug).  In the pivotal study GAO4753g in patients with R/R iNHL, the overall incidence of hemorrhagic events was 11% in the G -bendamustine arm and 10% in the bendamustine arm.  
No fatal hemorrhagic events occurred in the study.  Grade 3− 4 hemorrhagic events were similar in both 
treatment arms (5% in the G -bendamustine arm and 3% in the benda mustine arm).   
 adverse events of special interest include IRRs, TLS, thrombocytopenia (including acute 
thrombocytopenia), neutropenia (including late -onset and prolonged neutropenia), prolonged B -cell 
depletion, infections including progressive multifoca l leukoencephalopathy (PML) and hepatitis B virus 
(HBV) reactivation, worsening of pre -existing cardiac conditions, gastrointestinal (GI) perforation, and 
second malignancies.  Details on the safety concerns and mitigation plan for obinutuzumab are provided in Section 5.3.2.  
 
2.3.4. Summary of Pharmacokinetic and Pharmacodynamic Data for Obinutuzumab  
A two-compartment model comprising a time -varying clearance pathway and a linear clearance pathway 
provides an adequate description of the pharmacokinetics of obinutuzumab following intravenous (IV) 
administration in Studies  BO20999 and BO21003. Following the infusion of obinutuzumab, the elimination 
appears to be characterized by a clearance pathway that is dependent on time (i.e., starting at a typical value 
of 630 mL/day and then gradually decreasing to an asymptote of 60 mL/day at steady state) and a li near 
clearance pathway. Tumor burden may potentially contribute significantly to the clearance of obinutuzumab, 
especially at the beginning of treatment when CD20- positive tumor cells are most abundant.  As  tumor 
burden decreases, the clearance reaches an asymptote, which is believed to be primarily a function of the 
proteolytic metabolic clearance.  Consequently, some  patients with a high tumor burden may appear to clear 
the drug from the plasma faster than do patients with a low tumor burden because obinutuzumab binds to 
the CD20- positive tumor cells and is effectively removed from the plasma. Therefore, the clearance of the 
drug will vary with time, since repeated treatments with obinutuzumab will reduce the quantity of CD20-
positive tumor cells.  Consequently, the number of obinutuzumab administrations during the first cycle of treatment may be expected to reduce the number of CD20- positive tumor cells, thus minimizing the impact 
of the time varying clearance pathway on obinutuzumab exposure.  
 Treatment w ith obinutuzumab resulted in extensive B -cell depletion, with all patients showing a reduction 
in cell count to absolute zero at some stage of their treatment cycle. Overall, there has been no notable increase in complement levels before and after infusion, but changes have been observed in the levels of 
interleukin (IL) -6 and IL-8 before and after infusion.  
2.4 Study and Dose Rationale  
 
Targeting kinases within the BCR signaling pathways in CLL and B -cell malignancies has become standard 
of care in the cli nic. Ibrutinib and idelalisib, targeting BTK and PI3K, respectively, have received FDA 
approvals in CLL (both drugs), MCL, LPL (ibrutinib) and FL (idelalisib). However, kinase inhibitors rarely induce complete responses, and daily lifelong administration i s required to maintain drug activity [9]. 
Reports of ibrutinib resistance due to mutations in the drug- binding cysteine in BTK  have now emerged 
[10, 23]. Moreover, alternate mechanisms of resistance may account for reduced efficacy of the BCR -
targeting agents. For example, in vitro data suggest that upregulation of the PI3K α isoform might rescue 
Protocol Version 10.0 – February 5, 2021  19
  
 lymphoma cells fr om idelalisib, a PI3K δ-specific inhibitor [24]. Entospletinib is a novel BCRi which targets 
Syk, a kinase located upstream of both BTK and PI3K in the BCR signaling cascade. Thus, entospletinib 
may not only serve a therapeutic alternative for patients with CLL and NHL, but also may be a potential therapy for patients who progress on currently available BCRi’s.  
 Taking into account emerging r esistance to BCRi, persistence of residual disease and ability of CLL cells 
to re-populate their niche, we recently proposed that targeting multiple compartments within the niche as 
well as targeting CLL cells outside of the lymph node through a rationally designed multidrug regimen may 
be the optimal approach required to achieve deep and long- lasting therapeutic effects in CLL [25]. This 
protocol addresses this need, combining a novel BCRi with a second- generation highly effective therapeutic 
antibody which targets CD20 (obinutuzumab).  
 
2.4.1  Rationale for Syk inhibition in CLL  
 
BCR is a transmembrane receptor complex which incorporates a surface immunoglobulin associated with 
a signal transduction moiety (CD79A/B). BCR signaling results in distinct outcomes in B -cell fate 
depending on its developmental stage. Signaling through BCR modulates clonal expansion in pre -B-cells, 
induces apoptosis of immature B -cells and, by contrast, growth and proliferation of mature B -cells. Other 
cell surface receptors (e.g., CD19, CD40) are able to modulate BCR signaling, providing both inhibitory and activating co- stimuli [26]. 
 
In a normal B -cell, BCR crosslinking mediates approximation of Src family protein kinases, i.e. Lyn, Fyn 
and Blk, to the intracellular tyrosine activation motifs (ITAMs) on CD79A/B, leading to recr uitment and 
phosphorylation of SYK, a SH2- domain containing kinase. SYK phosphorylation is the key act in BCR 
signaling, without which further signal transmission cannot occur. SYK recruits a plasma membrane -
associated signaling complex with involvement of  several tyrosine kinases (including BTK) and adaptor 
molecules (such as B cell linker protein [BLNK]). The complex signals to activate PLC γ and Ras. Ras binds 
to and activates Raf kinase which then propagates the signal down to extracellular regulated kinase (ERK). 
Meanwhile, PLC γ leads to activation of mitogen- activated protein kinase (MAPK) kinases (e.g., ERK, c -
Jun NH
2-terminal kinase (JNK ) and p38 MAPK) and transcription factors (e.g., Myc and NF κB). In parallel, 
association of CD19 with Lyn and PI -3K leads to activation of Akt.  
 
Fostamatinib disodium (R788, Rigel Pharmaceuticals ) is an ATP -competitive non- selective SYK inhibitor 
[16]. Fostamatinib has been investigated in a Phase I/II study in patients with relapsed NHL, leading to an 
ORR of 55% in CLL and 11% in MCL [27]. While the development of fostamatinib was halted, alternat ive 
SYK inhibitors demonstrate promising pre -clinical activity in CLL [28]. 
 
Entospletinib (GS -9973) is a novel selective SYK inhibitor (Gilead Sciences). Entospletinib inhibited  
phosphorylation of multiple kinases involved in B -cell activation and BCR signaling, from membrane 
proximal sites (pBLNK, pPLCγ2, pPYK2) to distal sites (pAKT, pMEK, pERK, pS6RP) with EC50s ≤ 200 
nM, in multiple cell lines in vitro and inhibited  chemokine release. Detailed description of pre -clinical 
studies may be found in Investigator’s Brochure.  
 There is now a strong clinical rationale to pursue development of entospletinib in CLL. In a Phase II study of entospletinib in patients with relapsed/refractory CLL/SLL, responses were achieved in 61% of patients, with a progression- free survival (PFS) of 70% at 24 weeks [29]. Entospletinib is well tolerated and common 
grade ¾ laboratory abnormalities included neutropenia (14.5%) and reversible elevations of transaminases 
(13.4%), while colitis and pneumonitis have not been described. Importantly, entospletinib has shown 
activity in high risk CLL with responses observed independent of adverse prognostic features, including IGHV mutations and chromosomal abnormalities (del11q, del17p). Importantly, entospletinib has now 
Protocol Version 10.0 – February 5, 2021  20
  
 demonstrated efficacy in patients with CLL who received prior therapy with BCRi (Sharman JP et al., ASH 
2015). 
 
Finally, research performed in Dr. Danilov’s laboratory demonstrates that SYK inhibition disrupts the cross-talk between the BCR and other pro- survival signals emanating from the tumor microenvironment.  
In our laboratory we mimicked the CLL lymph node niche by establishing a unique co- culture model of 
primary patient -derived CLL cells with BAFF (“B -cell activation factor”) -expressing CH O cells. Soluble 
BAFF and APRIL ("a proliferation inducing ligand") are indispensable in survival of both normal and 
neoplastic B cells and BAFF receptor is highly expressed in CLL [30]. We found that when co-cultured 
with BAFF -expressing stromal cells, but not with control stroma, CLL cell s were resistant to spontaneous 
apoptosis and chemotherapy (fludarabine, bendamustine). BAFF -stimulated CLL cells upregulated NFκB 
(Appendix F, Fig. 1) and the anti -apoptotic proteins Mcl -1 and Bcl -X. However, entospletinib induced 
apoptosis of BAFF -stimulated CLL cells in this model (Appendix F, Fig. 2). Importantly, entospletinib 
blocked BAFF signaling-induced activation of NFκB (Fig. 3) and abrogated BAFF- BCR crosstalk. 
Inhibition of SYK, but not BTK or PI -3K, downregulated the pro- survival Mcl -1 in BAFF -stimulated CLL 
cells (Appendix F, Fig. 4).  
 
2.4.2 Rationale for dose selection (entospletinib)  
 
The initial dose level tested is proposed to be 200 mg of entospletinib administered twice daily combined 
with the FDA -approved dosing of obinutuzumab.  
 
Entospletinib has been well tolerated at doses of up to 800 mg twice daily in patients with CLL using first 
formulation (Mono- MSA ENTO) [29]. The dose and schedule used in the monotherapy setting resulted in 
consistent inhibition of a biomarker of SYK activity over the dosing interval. The dose of 400 mg twice 
daily using a second formulation (Bis -MSA SD ENTO) yields a PK distribution biologically equivalent to 
800 mg twice daily the first entospletinib formulation (see Investigator’s Brochure for details). A 200 mg 
once daily dose of entospletinib is expected to provide plasma concentrations above EC50 for 
approximately 12 hours a day and it is anticipated that target inhibition by entospletinib will be approximately 24% at trough drug levels. A starting dose of 200 mg of entospletinib twice daily is 1/4th of 
the total daily dose that has been shown to be well -tolerated in patients. If tolerated, the dose of entospl etinib 
will subsequently be escalated to 400 mg twice daily. 
 
2.5  Correlative studies background  
 
2.5.1. Assessment of B -cell depletion  
 
Entospletinib and obinutuzumab target B -cell survival via distinct mechanisms, as discussed above. 
Therefore, CD19+ B-cell counts will be assessed over time in this study.  
 
2.5.2. Pharmacodynamic endpoints  
 
Lymph nodes and bone marrow are the sites of CLL cell proliferation, with expression of gene signatures 
indicating activation of the BCR and nuclear factor -κB (NFκB) pathways [32, 33]. Interactions between 
the malignant B cells and mesenchymal stromal cells, monocyte -derived nurse -like cells, and T cells in 
those niches enhance CLL cell survival and confer chemoresistance [34]. Such interactions occur through 
engagement of the BCR, chemokine receptors and tumor necrosis factor family member receptors (e.g., 
CD40, "B -cell activation factor receptor" BAFF -R among others). Both BCR and CD40 signaling 
upregulates activity of transcription factor NF κB and the anti-apoptotic proteins Bcl -2, Mcl-1, Bcl-X and 
others, thus perpetuating CLL cell survival [35, 36].  
 
Protocol Version 10.0 – February 5, 2021  21
  
 In our laboratory we have modeled the CLL lymph node niche by establishing a co- culture of primary 
patient-derived CLL cells with CD40L -expressing fibroblasts. Using this model, we demonstrated 
feasibility of pharmacologic targeting NFκB in CD40- activated CLL cells [37, 38]. Others have shown  that 
treatment with ibrutinib abrogates BCR signaling-mediated NFκB pathway activation in vitro and in vivo 
[39].  
 
Recognizing that  BAFF/APRIL ("a proliferation inducing ligand") signaling is an important pro-survival 
mechanism in normal and neoplastic B cells and BAFF -R is highly expressed in CLL [30], we establish ed 
a unique co- culture model with BAFF -expressing CHO cells. In this model CLL cells a) are resistant to 
spontaneous apoptosis and chemotherapy (fludarabine, bendamustine); b) upregulate NFκB (Appendix F, Fig. 1); and c) induce the anti -apoptotic proteins Mcl-1 and Bcl-X. Using this mew model, we have shown 
that entospletinib induces apoptosis of BAFF -stimulated CLL cells, more potently than ibrutinib (Appendix 
F, Fig. 2). Like ibrutinib, entospletinib abrogated canonical NFκB activation in BAFF- stimulated CLL cells 
(Appendix F, Fig. 3). Pharmacologic inhibition of Syk (R -406) also downregulated Mcl -1 in BAFF -
stimulated cells (Appendix F, Fig. 4).  
  In this study, we will assess the effects of in vivo SYK inhibition on the activity of the canonical and non-
canonical NFκB as well as expression of the pro- survival Bcl -2 family members.  
 
3.0  STUDY POPULATION 
3.1 Inclusion Criteria  
 
3.1.1 Patients who are ≥ 18 years of age, who have the following diagnosis:  
 
Phase I portion of the study:  
- histologically or flow cytometry confirmed diagnosis of B -CLL/SLL according to NCI -WG 
1996 guidelines [40].  
- the following types of NHL as documented by medical records and with histology based on 
criteria established by the WHO:  
  --  Mantle cell lymphoma (MCL),  
  -- Follicular lymphoma (FL) - grades 1-3a,  
  --  Lymphoplasmacytic lymphoma (LPL),  
  -- Marginal zone lymphoma (M ZL), 
  -- CLL in Richter’s transformation,  
-- B- cell prolymphocytic leukemia  
- patients with histologically confirmed classical Hairy cell leukemia (HCL)   
 
Phase II portion of the study  - histologically or flow cytometry confirmed diagnosis of B -CLL/SLL according to NCI -WG 1996 
guidelines. Patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma.  
  3.1.2. Patients underwent ≥ 1 pr ior chemotherapy- based or immunotherapy- based regimen or targeted 
therapy (e.g., inhibitors of BTK, PI3K etc.) administered for ≥2 cycles, , and have had either documented disease progression or no response (stable disease) to the most recent treatment reg imen.   
 Additional disease -specific criteria: 
 
Protocol Version 10.0 – February 5, 2021  22
  
 Patients with CLL/SLL must demonstrate active disease meeting at least 1 of the IWCLL 2008 
criteria for requiring treatment [41]: 
 
i) A minimum of any one of the following constitutional symptoms:  
 
 Unintentional weight loss >10% within the previous 6 months prior to screening.  
 Extreme fatigue (unable to work or perform usual activities).  
 Fevers of greater th an 100.5 F for ≥2 weeks without evidence of infection. 
 Night sweats without evidence of infection.  
ii) Evidence of progressive marrow failure as manifested by the development of, or worsening of anemia or thrombocytopenia.  
iii) Massive (i.e., >6 cm below t he left costal margin), progressive or symptomatic splenomegaly.  
iv) Massive nodes or clusters (i.e., > 10 cm in longest diameter) or progressive lymphadenopathy.  
v) Progressive lymphocytosis with an increase of >50% over a 2-month period, or an anticipat ed 
doubling time of less than 6 months.  
vi) Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids.  
 
Patients with HCL must be intolerant of or not candidates for purine analog- based therapy, or failed to 
achieve response (CR or  PR) or relapsed within 2 years of such therapy, AND meet the standard treatment 
initiation criteria (ANC ≤1000/µL, Hgb≤10 g/dL, platelet count ≤100,000/µ L). 
Patients with indolent lymphoma (FL, LPL, MZL) and patients with B -cell prolymphocytic leukemia must  
have an indication for treatment in the opinion of the investigator.  
Patients with MCL and patients with CLL in Richter’s transformation should have previously received or not be candidates for high dose chemotherapy/autologous stem cell transplant.  
 
3.1.4  For diseases other than CLL, LPL , and HCL, presence of radiographically measurable 
lymphadenopathy or extra -nodal lymphoid malignancy (defined as the presence of ≥1 lesion that 
measures ≥2.0 cm in the longest dimension [LD] and ≥1.0 cm in the longes t perpendicular 
dimension [LPD] as assessed by CT or MRI). For LPL, measureable disease will be defined as 
serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second 
International Workshop on LPL for requiring treatment (Appendix E).  
 3.1.4 Patients must have ECOG performance status ≤2 (Refer to Appendix D). 
 3.1.5 Patients must have organ function as defined below:  
i) direct bilirubin ≤2 X institutional ULN (unless due to known Gilbert’s syndrome or 
compensated hemolysis directly attributable to CLL)  
 ii) AST or ALT less than 2.5 X institutional ULN  
iii) estimated CrCL using the Cockroft -Gault equation ≥50 mL/min (see  Appendix B).   
iv) platelets ≥50,000/mm
3 independent of transfusion support, with no active bleeding, and 
absolute neutrophil count (ANC) ≥1000/mm3, unless due to disease involvement in the bone 
marrow. 
3.1.6 Ability to understand and the willingness to sign a written informed consent document.  
 
3.2. Exclusion criteria  
 
3.2.1 Prior therapeutic intervention with any of the following:  
• therapeutic anticancer antibodies within 4 weeks (rituximab), except within 6 
months for obinutuzumab or a similar investigational type II monoclonal 
Protocol Version 10.0 – February 5, 2021  23
  
 antibody;  
• radio- or toxin-immunoconjugates within 10 weeks;  
• inhibitors of BTK (ibrutinib), PI -3K (idelalisib), BH3 -mimetic venetoclax, 
lenalidomide and other “targeted” therapy  (including but not limited to investigational BTK and PI -3K inhibitors, etc.) – within 6 half -lives (i.e., 36 
hours for ibrutinib)  
• all other chemotherapy, radiation therapy within 3 weeks prior to initiation of 
therapy. 
• SYK inhibitors at any time  
3.2.2 Inadequate recovery from adverse events related to prior therapy to grade ≤1 (excluding Grade 2 
alopecia and neuropathy).  
 
3.2.3 Chronic use of corticosteroids  in excess of prednisone 30 mg/day or its equivalent.  
 
3.2.4 Stem cell transplant recipients must have no evidence of and not receive treatment for graft -versus-
host disease.  
 
3.2.5 Concomitant use or use in the prior two weeks of moderate or strong CYP3A and CYP2C9 inducers 
or strong CYP2C9 inhibitors (Appendix C), including nutraceutical preparations, e.g., grapefruit juice and St John’s Wort.  
 3.2.6 History prior malignancy except:  
• malignancy treated with curative intent and no known active disease pre sent for ≥ 
2 years prior to initiation of therapy on current study;  
• adequately treated non -melanoma skin cancer or lentigo maligna (melanoma in 
situ) without evidence of disease;  
• adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without 
evidence of disease;  
• asymptomatic prostate cancer managed with “watch and wait” strategy;  
• myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone 
marrow at screening.  
3.2.7 Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis or history of immune -mediated cytopenias are not  exclusions). 
 
3.2.8 History of Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C.  
 3.2.9 Major surgery (requiring general anesthesia) within 2 weeks prior to initiation of therapy.  
 3.2.10 Inability to swallow and retain an oral medication. Patients with clinically significant medical 
condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea, vomiting or any other condition that will interfere significantly with drug absorption are excluded. Patients must also have adequate venous access  
 3.2.11  Need for ongoing therapy with proton pump inhibitors. H2 antagonists are allowed.  
 3.2.12 Active uncontrolled infection 
Protocol Version 10.0 – February 5, 2021  24
  
  
3.2.13  Women who are pregnant or lactating 
3.2.14  F ertile men or women of childbearing potential unless 1) permanently sterile or 2) using a highly 
effective measure of contraception such as condoms in males and consistent and correct use of 
one of the following in females: intrauterine device, tubal steri lization, Essure micro -insert 
system, vasectomy in the male partner. Effective contraception is required for males during 
treatment with study drug and to continue for 3 months after the last dose of either entospletinib 
or obinutuzumab, whichever is later. For women, effective contraception is required to continue for
  18 months after the last dose of obinutuzumab or for 30 days after the last dose of 
entospletinib, whichever is later.  
 Definition of childbearing potential: for this study, a female subject is considered of childbearing potential until becoming post -menopausal unless permanently sterile or with medically 
documented ovarian failure.  Women are considered to be in a post -menopausal state when ≥ 54 
years of age with cessation of previously occ urring menses for ≥ 12 months without an alternative 
cause.  Women of any age with amenorrhea of ≥ 12 months may also be considered post-menopausal if their follicle stimulating hormone (FSH) level is in the post -menopausal range and 
they are not using hormonal contraception or hormonal replacement therapy.  Permanent sterilization in females includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy 
in a female subject of any age. Permanent sterilization in males include bilateral orchiectom y or 
medical documentation of alternative explanation.  
3.2.15 Any condition for which participation in the study is judged by the Investigator to be detrimental 
to the patient with inter -current illness or psychiatric/social situati ons that would jeopardiz e 
compliance with study requirements.  
 
4.0 REGISTRATION PROCEDURES  
Accrual to this study will take place at the Knight Cancer Institute Center for Hematological Malignancies at Oregon Health and Science University (OHSU). Coordination of accrual for other participating sites will 
be centralized at OHSU.  
4.1  Subject Registration  
 There is no randomization for treatment.  This is a phase I/II dose escalation trial with an intention- to-treat 
all patients who are enrolled in this clinical trial. Potential subjects will be seen by investigators of this 
study as a new patient or consult visit or as a follow -up visit.  Referral of potential subjects to co-
investigators of this study is made as part of standard of care, with the referring physician seeking advi ce 
on the diagnosis, evaluation, and/or treatment of CLL and NHL.  
4.1.1  Local registration.  
 
Registration from all consented subjects must be entered into the electronic Clinical Research System  
(eCRIS). Registration of OHSU patients will include the minimum of the following:  
• A completed Eligibility Checklist signed by the investigator  
• Signed  copies of the most recently IRB -approved, informed consent form and HIPAA 
authorization 
5.0  TREATMENT PLAN  
5.1 Administration of study agents.  
 
Protocol Version 10.0 – February 5, 2021  25
  
 This is an open- label, Phase I/II trial with a dose escalation phase. The primary objective of the dose 
escalation phase is to determine the recommended phase 2 dose (RP2D) of entospletinib in combination with obinutuzumab in patients with relapsed/refract ory CLL and B-cell malignancies. The Phase II portion 
will further evaluate the efficacy and safety of this novel combination.  
 Treatment will be administered on an outpatient basis but will also be permitted inpatient.   
Reported adverse events and potential risks associated with entospletinib and obinutuzumab are described 
in Section 7. Appropriate dose modifications for both drugs are described in Section 6. No investigational 
or commercial agents or therapies other than those described below may be administered with the intent to treat the participant’s malignancy.  
 The timing of study assessments and procedures is presented by study cycle and day and are abbreviated 
by the following references: Cycle (C) and Day (D) number, as in C1D1 (Cycle 1 Day 1). Cycles and days within each week are numbered sequentially thereafter.  
Entospletinib will be administered as single agent for 7 days (during the run- in phase (days -7 to -1) for the 
purpose of correlative studies, followed by a combination with obinutuzumab (beginning with C1D1). 
C1D1 will occur immediately after Day -1 of the run- on phase (i.e., there is no "day 0").  
 Table 1. Treatment description  
Agent Pre-medications; 
Precautions  Dose  Route  Schedule  Cycle Length  
Entospletinib*  None  According to dose 
level - see below  PO BID or daily on Days -7 to -1 
(run-in phase), and then 
beginning with C1D1  28 days 
(4 weeks) 
Obinutuzumab  Benadryl  
Tylenol 
Dexamethasone  3000 mg split 
dosing in cycle 1,  
1000 mg with each 
subsequent cycle  IV C1D1 – 100 mg 
C1D2 – 900 mg 
C1D8 & 15 – 1000 mg 
Day 1 of cycles 2 -6 – 1000 mg  
* The morning dose of entospletinib will be administered in the clinic on day -7 of the run -in phase, and 
subsequent doses will be self -administered  
5.1.1  Phase I (Dose Escalation)  
 
Patients with CLL/SLL as well as all other histologic categories of NHL will be enrolled, as specified in 
the eligibility criteria.  
 
Up to three dose levels will be evaluated in the Phase I portion of the study. The dose levels of entospletinib are 200 mg po twice daily (Dose Level 1), 400 mg po twice daily (Dose Level 2) and 200 mg po daily 
(Dose Level -1) beginning with day 1 of cycle 1 (Table 2) . The starting dose of entospletinib will be 200 
mg po bid on day -7 of the run- in phase, and the same dose will be administered on day 1 of cycle 1, which 
will occur immediately following day -1 of the run- on phase. The first dose of obinutuzumab will be 
administered IV on day 1. The dose of obinutuzumab will remain unchanged at each dose level, and the last dose will be administered with cycle 6. Each cycle will last for 28 days.  
 Each patient will be treated for at least 12 cycles, or until a qualifying event (Section 5.4 – Duration of 
therapy). Both drugs will be administered during cycles 1- 6, and entospletinib alone will be administered 
during cycles 7-12.  
The dose escalation phase will follow a standard 3+3 Phase I design. At a given dose level, 3 patients will 
be enrolled. If all 3 patients complete the run-in phase and the  first cycle of therapy  (28 days) without any 
dose-limiting toxicities (DLTs), the next cohort of 3 patients will be enrolled at Dose level 2.  If 1/3 patients 
develops a DLT the cohort will be expanded to 6 patients. However, if either ≥ 2/3 or ≥ 2/6 patients in dose 
Protocol Version 10.0 – February 5, 2021  26
  
 level 2 have DLTs, Dose level 1 wil l be defined as the MTD of the combination. The MTD will be 
considered RP2D and enrollment onto the Phase II part of the study will begin.  
 Table 2. Dose levels planned for dose escalation phase of the study 
Dose Level  Entospletinib  
(Cycles 1 -12 and thereafter ) 
PO starting on Day -7 of the run- in 
phase  
 Obinutuzumab  
(Cycles 1 -6) 
IV 
-1* 200 mg daily  C1D1 – 100 mg; C1D2 – 900 mg 
C1D18 & 15 – 1000 mg 
C2-6 – 1000 mg on day 1 1 200 mg BID  
2 400 mg BID  
*Dose Level -1 will be studied only if more than one patient develops a DLT in Dose Level 1 
 For all the Dose Levels , should more than one patient develop a DLT in the respective Dose Level; the dose 
of entospletinib will be reduced according to the plan shown in Table 3. Should more than one patient 
develop a DLT in the Dose Level " -1", the study will be stopped.  
 The decisions to escalate of de -escalate the dose of entospletinib will follow the schema in Table 3.  
 Table 3. Decision rules regarding dose modification for Entospletinib  
 
Dose level  
(entospletinib)  Number of Participants with 
DLT  
at a Given Dose Level with C1   
Decision Rule  
 
200 mg po daily (dose level -1) 0/3  Enroll Phase II part at this dose  
1/3 Enroll 3 additional subjects  
1/6 Enroll Phase II part at this dose  
> 2/6  STOP the study  
 
200 mg po BID  
(START dose level 1)  0/3  Escalate dose to 400 mg BID  
1/3 Enroll 3 additional subjects  
1/6 Escalate dose to 400 mg BID  
> 2/6  De-escalate dose to 200 mg daily  
 
400 mg po BID 
(dose level 2)  0/3  Enroll Phase II part at this dose  
1/3 Enroll 3 additional subjects  
1/6 Enroll Phase II part at this dose  
> 2/6  Enroll Phase II at Dose level 1.  
 If no significant toxicities are observed, the dose escalation part of the study is anticipated to enroll between 
6 and 12 patients. Any patient discontinuing study treatment prior to completion of the first cycle for reasons other than AEs related to the study drugs will be replaced.  
 
5.1.2 Phase II  
 
In the Phase II, patients will be treated at the MTD of entospletinib in combination with obinutuzumab, 
determined in the dose escalation part of the study. Patients will be assessed for efficacy and safety (CTCAE 
v.4.03) parameters. Only patients with CLL/SLL will be enrolled on Phase II part of the study . 
Protocol Version 10.0 – February 5, 2021  27
  
  
 
Each patient will be treated for at least 12 cycles, or until a qualifying event (Section 5.4 – Duration of 
therapy). Both drugs will be administered during cycles 1- 6 (starting with the run- in phase), and 
entospletinib alone will be administered during cycles 7 -12. Any patient discontinuing study treatment prior 
to completion of the first cycle for reasons other than AEs related to the study drugs will be replaced.  
  
5.2  Definition of Dose -Limiting Toxicities (DLT)  
 
Dose escalation will stop for DLT defined as any of the following occurring with cycle 1 (including run-
in) in the dose escalation phase, deemed related (possibly, probably or definitely) to the study drug:  
 
1. Non-hematologic toxicity: all ≥Grade 3 toxicities except  
a. Grade 3 nausea, vomiting or diarrhea reversible within 72 h with supportive care  
b. Grade 3 infusion- related toxicity  
c. Asymptomatic Grade 3-4 laboratory abnormalities that are reversible to ≤ Grade 2 within 72 
hours (for example, Grade 3- 4 elevation of uric acid, AST, ALT, changes in phosphorus and 
magnesium levels, changes in glucose levels)  
d. Grade 3 only: tumor lysis syndrome (TLS) or hyponatremia (equals Na 120- 130 mEq/L)  
 
2. Hematologic toxicity:  
a. Grade 4 neutropenia lasting more than 7 days in a subject with ANC>1500 µL before beginning therapy 
b. Febrile neutropenia of any duration (ANC < 500/µL, fever > 38.5 C)  
c. Grade 4 thrombocytopenia/anemia or grade 3 thrombocytopenia with bleeding or any requirement for platelet transfusion, unexplained by underlying disease  
 Grading of toxicities will be according to NCI CTCAE v.4.03. Grading of hematologic toxicity in patients 
with CLL/SLL will be conducted according to the 1996 modified NCI -WG criteria for CLL/small 
lymphocytic lymphoma (SLL), updated in 2008 [41]. A toxicity deemed to be unrelated to therapy (such 
as hip fracture due to a traumatic fall), will NOT be considered as a  DLT.  
 Patients who completed 1 cycle of study treatment will be evaluable for dose escalation decision purpose. 
Patients who receive < 50% of doses of entospletinib or < 2 doses of obinutuzumab during cycle 1 and who 
do not experience DLT, will NOT be evaluable for dose escalation decision purpose and will be replaced. Intra-patient dose escalation will be allowed to the level of MTD, once MTD has been determined.  
 
Management and dose modifications associated with the above adverse events are outlined in Section 6.  
5.3 General Concomitant Medication and Supportive Care Guidelines  
5.3.1     Prophylaxis of Tumor Lysis Syndrome (TLS)  
 
Patients who receive therapy for NHL and CLL are at risk for tumor lysis syndrome (TLS). TLS is an 
oncologic emergency that can occur spontaneously and/or after treatment in malignant conditions, 
particularly lymphomas and leukemias. These complications are caused by the breakdown products of dying malignant cells and include hyperkalemia, hyperphosphatemia, hyperuricemia and hypocalcemia, 
and, if left untreated, acute renal failure.  
 
Protocol Version 10.0 – February 5, 2021  28
  
 TLS definitions [42] 
 Grade 3 (present but not life -threatening): Occurrence of two or more of the following serum values after 
anticancer treatment:  
i.Uric acid: increase by more than 25% from baseline, or values ≥8 mg/dL;  
ii.Potassium: increase by m ore than 25% from baseline, or values ≥6.0 mmol/L;  
iii.Phosphorus: increase by more than 25% from baseline, or values ≥4.5 mg/dL;  
iv.Calcium: decrease by more than 25% from baseline, or values ≤7 mg/dL.  
 
Grade 4: a life-threatening and/or requiring immediate intervention such as but not limited to new renal 
failure requiring hemodialysis, or decrease in estimated creatinine clearance (eCrCL) of >50%; symptomatic cardiac arrhythmias incompletely controlled or controlled using a device (defibrillator); any 
seizure.  
 
Certain patients (for example, those with WBC>50,000 and/or hepatosplenomegaly and/or renal dysfunction [CrCL<70 mL/min] and/or pretreatment hyperuricemia) are at an increased risk of developing TLS.  
 All patients enrolled on this study will receive the following supportive care:  
 
IV hydration on C1D1 (prior to administration of obinutuzumab) . Patients will be encouraged to 
hydrate orally prior to C1D1 of therapy, aiming to consume >2 L of liquids per day. On day 1 of treatment, patients will receive IV hydration with 0.9% sodium chloride OR D5W with 100 mEq of sodium 
bicarbonate per 1 Liter at 250 mL/hour beginning at least 1 hour prior to the first dose of obinutuzumab. Hydration will continue for at least 2 hours. The rate of hydration may be adjusted by the Investigator depending on the clinical situation. Diuretics (such as furosemide IV or PO) may be given if deemed necessary.  
 
Allopurinol 300 mg PO daily (or renally adjusted dose, per treating physician). Patients will start taking 
allopurinol at least 3 days prior to the first dose of entospletinib (day -7) and continue for at least 14 days.  
 CBC and serum biochemistry/metabolic panel will be measured on C1D1, C1D2, C1D8 and C1D15. 
Optional serum biochemistry/metabolic panel measurements may be considered by the investigator at the 
end of C1D1 and C1D2.  
 
Patients whose  blood uric acid level exceeds 8.0 mg/dL on C1D1 or C1D2, and who are high risk in the 
investigator’s clinical judgement (i.e., have high tumor burden, high circulating lymphocyte count 
[>
 25 × 109/L] or renal impairment ), should be given IV rasburicase (3 mg for patients who weigh <100 kg; 
6 mg for patients who weight >100 kg). Uric acid lev els will be measured 2 hours after rasburicase is given 
and every 2 hours thereafter until level is lowered to ≤8.0 mg/dL and drug treatments will be delayed. Those measurements should occur in a chilled heparinized tube, delivered to the laboratory and analyzed STAT. Rasburicase treatment should be repeated if uric acid levels do not decrease by at least 50% within 6 hours and may be repeated at the discretion of the Investigator thereafter.  
 
Patients whose serum potassium exceeds 5 mmol/L will receive 30 g of Kayexalate, additional 1 liter fluid 
bolus and 20- 40 mg of IV furosemide (at the discretion of the Investigator). Potassium levels will be 
rechecked STAT 1 hour later and every 2 hours thereafter until serum levels are ≤5 mmol/L.  
 
5.3.2. Risks Associated with obinutuzumab therapy  
 
Important risks identified in clinical investigations with obinutuzumab were:  IRRs, TLS, thrombocytopenia (including acute thrombocytopenia), neutropenia (incl uding prolonged and late onset neutropenia), 
Protocol Version 10.0 – February 5, 2021  29
  
 prolonged B -cell depletion, infections (including hepatitis B reactivation and PML), worsening of pre -
existing cardiac conditions and GI perforation.  See the Obinutuzumab IB for additional details.  
 5.3.2.1. Hepatitis B Reactivation  
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with anti -CD20 antibodies such as obinutuzumab.  HBV reactivation 
has been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who 
are HBsAg negative but are hepatitis B core antibody (anti -HBc) positive.  Reactivation has also occurred 
in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, ant i-HBc positive, and 
hepatitis B surface antibody [anti -HBs] positive).  HBV reactivation is defined as an abrupt increase in 
HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a 
person who was previously HBsAg negative and anti -HBc positive.  Reactivation of HBV replication is 
often followed by hepatitis, i.e., increase in transaminase levels and, in severe cases, increase in bilirubin levels, liver failure, and death.  
 Positive serology for Hepatitis B is defined as positivity for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (anti -HBc).  Screen all patients for HBV infection by measuring HBsAg and anti -
HBc before initiating treatment with obinutuzumab.  For patients who show evidence of hepat itis B 
infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti -HBc positive), 
consult physicians with expertise in managing hepatitis B regarding monitoring, and consideration for HBV antiviral therapy.  
 Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of 
hepatitis or HBV reactivation during and for several months following treatment with obinutuzumab.  HBV 
reactivation has been reported for other CD20- directed cytolytic antibodies following completion of 
therapy.   In patients who develop reactivation of HBV while receiving obinutuzumab, immediately discontinue 
obinutuzumab and any concomitant chemotherapy, and institute appropriate treatment.  Resumption of 
obinutuzumab in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B.  Insufficient data exist regarding the safety of resuming obinutuzumab in patients who develop HBV reactivation.  
 
For the subset of patients w ho are Hepatitis B viral DNA -negative and anti -HBc positive and have 
undetectable Hepatitis B viral DNA levels at screening, Hepatitis B viral DNA levels must be followed 
approximately every 4 weeks.  Guidelines for the management of hepatitis B reactivati on are outlined in 
Table 1. 
Protocol Version 10.0 – February 5, 2021  30
  
 Table 4. Management of Hepatitis B Reactivation  
Hepatitis B Viral DNA 
Level by Real -Time 
PCR Guideline  
> 100 IU/mL  • Hold obinutuzumab  
• Begin anti -viral medication and treat for at least 1 year after the 
last dose of obinutuzumab. 
• Immediately refer the patient to a gastroenterologist or 
hepatologist for management.  
• Resume obinutuzumab once Hepatitis B viral DNA levels 
decrease to undetectable levels.  
> 100 IU/mL while on 
anti-viral medication  Discontinue obinutuzumab.  
29−100 IU/mL  Retest within 2 weeks.  
If still hepatitis B viral DNA positive: 
• Hold obinutuzumab  
• Begin anti -viral medication and treat for at least 1 year after the 
last dose of obinutuzumab. 
• Immediately refer the patient to a gastroenterologist or hepatologist for management  
• Resume obinutuzumab once Hepatitis B viral DNA levels 
decrease to undetectable levels  
 
5.3.2.2. Progressive Multifocal Leukoencephalopathy  
JC virus infection resulting in progressive multifocal leukoencephalopathy (PML), which can be fatal, was 
observed in patients treated with obinutuzumab.  Consider the diagnosis of PML in any patient presenting with new onset or changes to preexisting neur ologic manifestations.  Evaluation of PML includes, but is 
not limited to, consultation with a neurologist, brain magnetic resonance imaging (MRI), and lumbar puncture. Discontinue obinutuzumab therapy and consider discontinuation or reduction of any concomitant 
chemotherapy or immunosuppressive therapy in patients who develop PML.  
 5.3.2.3. Infusion -Related Reactions  
Obinutuzumab can cause severe and life -threatening IRRs; 65% of patients with CLL experienced a 
reaction to the first 1000 mg infusion of obinutuzumab, and 38% of iNHL patients experienced a reaction on Day 1 of obinutuzumab infusion.  IRRs within 24 hours  of receiving obinutuzumab have occurred.  IRRs 
can also occur with subsequent infusions.  Symptoms may include hypotension, tachycardia, dyspnea, and respiratory symptoms (e.g., bronchospasm, larynx and throat irritation, wheezing, and laryngeal edema).  Most frequently reported symptoms include nausea, fatigue, dizziness, vomiting, diarrhea, hypertension, flushing, headache, pyrexia, and chills.  
 
Medications (including subcutaneous epinephrine, corticosteroids, and intravenous diphenhydramine) and 
resuscitation equipment should be available for immediate use.  
 For patients with preexisting cardiac or pulmonary conditions, monitor more frequently throughout the infusion and the post -infusion period because patients may be at greater risk of experiencing more severe 
reactions.  Hypotension may occur as part of the obinutuzumab IRR. Consider withholding antihypertensive 
treatments for 12 hours prior to administration, during each obinutuzumab infusion, and for the first hour 
Protocol Version 10.0 – February 5, 2021  31
  
 after administration until blood pressure is stable.  For patients at increased risk of hypertensive crisis, 
consider the benefits versus the risks of withholding antihypertensive medication as suggested above.  
 
Certain patients are at risk and need to be closely monitored: those with pre -existing cardiac or pulmonary 
conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (>25,000/mm
3). This protocol prescribes a divided dose of obinutuzumab in 
all patients (100 mg on day 1 and 900 mg on day 2).  
 
Institutional guidelines may be used for obinutuzumab administration. We suggest this general approach: 
vital signs should be taken every 15 minutes for the first hour of infusion until stable, then every 30 minutes until the completion of infusion. Pulse oximetry on room air should be performed at baseline and as needed 
if dyspnea occurs. Epinephrine 1 mg/ml, dyphenhydramine 50 mg IV and hydrocortisone 100 mg IV should be readily available during obinutuzumab infusion. For first infusion (C1D1), obinutuzumab is 
administered at a rate of 25 mg/hour for four hours. On C1D2 obinutuzumab is started at 25 mg/hr (50 mg/hr if no IRR occurred on C1D1) and rate escalated by 50 mg/hour every 30 minutes until a maximum rate of 400 mg/hour provided no infusion reaction occurs. For subsequent infusions, infusion may be started 
at 50 mg/hour (100 mg/hour if no reactions with previous infusion) and increased by 100 mg/hour 
increments every 30 minutes until a maximum rate of 400 mg/hour.   
 
If a patient experiences an infusion reaction of any grade during infusion, adjust the infusion as follows:  
Grade 4 (life threatening) :  Stop infusion immediately and permanently discontinue obinutuzumab 
therapy. Grade 3 (severe) :  Interrupt infusion and manage symptoms.  Upon resolution of symptoms, consider 
restarting obinutuzumab infusion at no more than half the previous rate (the rate being used at the time that the infusion reaction occurred) and, if patient does not experience any further infusion reaction symptoms, infusion rate escalation may resume at the increments and intervals as appropriate for the treatment cycle dose.  Permanently discontinue obinutuzumab treatment if patients experience a Grade 3 infusion- related 
symptom at re -challenge .  
For CLL patients only, the Day 1 infusion rate may be increased back up to 25 mg/hr after 1 hour but not increased further.  
Grade 1  − 2 (mild to moderate):  Reduce infusion rate or interrupt infusion and treat symptoms.  Upon 
resolution of symptoms, continue or resume infusion and, if patient does not experience any further infusion 
reaction symptoms, infusion rate escalation may resume at the increments and intervals as appropriate for 
the treatment cycle dose.  
For CLL patients only, the Day 1 infusion rate may be increased back up to 25 mg/hr after 1 hour but not 
increased further.  
Any overdose or incorrect administration of study drug should be noted in the medical chart. Adverse events 
associated with an overdose or incorrect administration of study drug should be reported.  
 
For fevers, chills and rigors demerol 12.5 mg IV may be administered and repeated every 15 minutes up to 
a maximum dose of 50 mg. For severe dyspnea and bronchospasm, administer 100 mg hydrocortisone IV 
and/or 50 mg benadryl IV. In an emergent situation give epinephrine 0.3 mg/0.3 ml IM. For systolic blood 
pressure ≤80 mm Hg infuse 0.9% sodium chloride at 250 ml/hr, check blood pressure at least every 10 minutes until it reaches baseline±10%. After symptoms have resolved resume the  infusion at 50% the 
previous rate and increase as above, or at 10 mg/hr every 15 minutes (if severe reaction observed).  
Premedication to reduce the risk of infusion reactions is outlined in Table 5.  
 
Protocol Version 10.0 – February 5, 2021  32
  
 Table 5. Obinutuzumab Dosing Schedule for Six 28 -Day Treatment Cycles for Patients with 
CLL and NHL 
Day of 
Treatment 
Cycle Patients Requiring 
Premedication  Premedication  Administration  
Cycle 1 Days 
1 and 2 All patients  Intravenous glucocorticoid:  
20 mg dexamethasone or 80 
mg methylprednisolone Completed at least 1 hour 
prior to obinutuzumab 
infusion. 
650–1000 mg PO 
acetaminophen  At least 30 minutes before obinutuzumab infusion.  
anti-histamine (e.g., 50 mg 
diphenhydramine IV/ PO) 
All 
subsequent 
cycles All patients  650–1000 mg PO 
acetaminophen  At least 30 minutes before 
obinutuzumab infusion.  
Patients with an IRR (Grade 1-2) with the 
previous infusion 650–1000 mg PO 
acetaminophen  At least 30 minutes before obinutuzumab infusion.  
anti-histamine (e.g., 50 mg 
diphenhydramine IV/PO) 
Patients with a Grade 
3 IRR with the 
previous infusion OR 
with a lymphocyte 
count > 25 × 109/L 
prior to next treatment  Intravenous glucocorticoid:  
20 mg dexamethasone or 80 
mg methylprednisolone Completed at least 1 hour prior to obinutuzumab infusion. 
 
5.3.2.4. Infections  
Serious, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of obinutuzumab therapy.  Fatal infections have been reported.  Do not administer obinutuzumab to patients with an active infection.  Patients with a history of recurring or chronic infections 
may be at increased risk of infection.  
 
5.3.2.5. TLS with obinutuzumab  
TLS, including fatal cases, has been reported in patients receiving obinutuzumab.  Patients with high tumor 
burden, high circulating lymphocyte count ( >
 25 × 109/L) or renal impairment are at greater risk for TLS 
and should receive appropriate tumor lysis prophylaxis with anti -hyperuricemics (e.g., allopurinol or 
rasburicase) and hydration prior to the infusion of obinutuzumab. Continue prophylaxis prior to each 
subsequent obinutuzumab infusion, as needed. See section 5.3.1 for detailed recommendations on 
management of TLS.  
 During the initial days of obinutuzumab treatment, monitor the laboratory parameters of patients considered 
at risk for TLS.  For treatment of TLS, correct electrolyte abnormalities, monitor renal function and fluid 
balance, and administer supportive care,  including dialysis as indicated.  
 For patients with evidence of TLS, obinutuzumab should be discontinued and the patient treated as clinically indicated.  Following the complete resolution of TLS complications, obinutuzumab may be re 
administered at the full dose during the next infusion in conjunction with prophylactic therapy.  
 
5.3.2.6. Hematologic Toxicities  
Neutropenia  
Protocol Version 10.0 – February 5, 2021  33
  
 Severe and life threatening neutropenia, including febrile neutropenia, has been reported during treatment 
with obinutuzumab. Patients  with Grade 3 −4 neutropenia should be monitored frequently with regular 
laboratory tests until resolution. Anticipate, evaluate, and treat any symptoms or signs of developing 
infection (see Section 6.1 for management of neutropenia).  Consider administrati on of granulocyte colony-
stimulating factors (G -CSF) in patients with Grade 3 or 4 neutropenia (outside of the DLT window).    
Neutropenia can also be of late onset (occurring more than 28 days after completion of treatment) and/or prolonged (lasting longer than 28 days).  
Dose delays may be considered in the case of Grade 3 or 4 neutropenia.  Patients with severe and long 
lasting (>
 1 week) neutropenia are strongly recommended to receive antimicrobial prophylaxis until 
resolution of neutropenia to Grade 1 or 2.  Antiviral and antifungal prophylaxis should be considered.  
 
Thrombocytopenia 
Severe and life threatening thrombocytopenia has been reported during treatment with obinutuzumab in 
combination with chlorambucil or bendamustine.  Fatal hemorrhagic events during Cycle 1 have also been reported in patients with CLL treated with obinutuzumab.  
Monitor all patients frequently for thrombocytopenia and hemorrhagic events, especially during the first 
cycle.  In patients with Grade 3 or 4 thrombocytopenia, monitor platelet counts more frequently until resolution ( see Section 6.1 for management of thrombocytopenia). Transfusion of blood products (i.e., 
platelet transfusion) may be necessary.  Consider withholding concomitant medications which may increase bleeding risk (platelet inhibitors, anticoagulants), especially during the first cycle.  
 Hematological Toxicities in Patients with CLL  
The evaluation of potential treatment -induced toxicity in patients with advanced CLL may be quite difficult 
and requires careful consideration of both the manifestations of the underlying disease, as well as adverse reactions to the therapy under study.  Some of the conventional criteria for toxicity are not applicable, especially under circumstances of progressive bone marrow failure from the CLL itself.  
Dose modifications for hematologic toxicity in patients with CLL must be made with consideration of t he 
increased frequency of hematologic compromise at the initiation of therapy.  Therefore, the standard criteria 
used for solid tumors are difficult to be applied directly; many patients would be considered to have Grade 
2
 − 4 hematologic toxicity at presentation. 
As a consequence, dose modification decisions for patients with cytopenia (below the lower limit of the 
normal range) at baseline will be based on the NCI sponsored Working Group (NCI -WG) grading scale for 
hematologic toxicity in CLL studies.  
 
5.3.2.7. Immunization  
The safety and efficacy of immunization with live or attenuated viral vaccines during or following 
obinutuzumab therapy have not been studied.  Immunization with live -virus vaccines is not recommended 
during treatment and until B -cell recovery . 
 
 
 
5.3.3. CYP Inhibitors and Inducers  
 
In vitro data indicates that entospletinib is a substrate of CYP2C9 and to a lesser extent CYP3A. Co-
administration of CYP2C9 inhibitors or CYP2C9 or CYP3A inducers may increase or decrease entospletinib exposure, respectively. As such, coadministration of moderate and strong CYP3A and 
CYP2C9 inducers, and strong CYP2C9 inhibitors is prohibited in this study.  
 Caution should be exercised when coadministering drugs that are moderate inhibitors of CYP2C9 (e .g., 
fluconazole, voriconazole, and amiodarone). Administration of strong and moderate CYP3A and CYP2C9 inducers and strong CYP2C9 inhibitors is also prohibited for 2 weeks prior to study drug 
Protocol Version 10.0 – February 5, 2021  34
  
 administration. Examples of strong CYP2C9 inhibitors and strong/moderate inducers are provided in 
Appendix 3.  
 
In vitro data indicates that entospletinib has the potential to inhibit several transporters and the metabolizing enzyme UGT1A1, which may affect the plasma concentrations of substrates of these transporters and/or enzyme. Caution should be exercised when coadministering medications that are 
metabolized or transported by UGT1A1, OATP1B1, OATP1B3, MATE1, P -gp, and BCRP, such as 
rosuvastatin and atorvastatin. The investigator should review the prescribing information of the concomitant medication for guidance on co- administration with an inhibitor of these transporters, such as 
additional monitoring, dose modifications or avoiding co- administration. In a study in healthy volunteers, 
entospletinib 400 mg twice daily increased rosuvastatin exposure by approximately 3.3- fold; as such the 
following restrictions apply for subjects receiving entospletinib in this study: atorvastatin, pravastatin, 
simvastatin, lovastatin and fluvastatin dose needs to be limited to 20 mg daily; rosuvastatin – to 10 mg 
daily. 
 
5.3.4. Proton Pump Inhibitors  
 
Studies in healthy volunteers have demonstrated a significant reduction in entospletinib exposure when proton pump inhibitors are co- administered. Therefore, proton pump inhibitors (e.g., omeprazole, 
esomeprazole, pantoprazole, lansoprazole, rabeprazole) are prohibited in combination with entospletinib. 
H2 antagonists are allowed.  
 
5.3.5. QT Prolonging Agents  
 
Neither entospletinib nor obinutuzumab have been shown to prolong QT inter val. However, any 
medications known to cause QT prolongation should be used with caution; periodic monitoring with ECGs 
and electrolytes should be considered.  
 
5.3.6. Growth Factors  
 
Patients may receive filgrastim, peg -filgrastim, erythropoietin or related growth factors at the discretion of 
the treating physician. Growth factors cannot be administered within the DLT window.  
5.3.7. Anti -Emetic Therapy  
 
Nausea is not common with either entospletinib or obinutuzumab. Grade 3 nausea occurred in <4% of 
patients who received entospletinib on a recent Phase II study [29], thus considered low risk for 
emetogenesis.  
 Anti-emetic therapy may be instituted for any patient. Premedication with a single dose of Compazine 10 
mg is preferred, and pre -medication with 5- HT3 antagonists (e.g., ondansetron 4- 8 mg po) is allowed. 
Rescue therapy with 5- HT3 antagonists (ondansetron) is allowed according to standard dosing guidelines, 
not to exceed the maximum daily dose. Other antiemetics (aprepitant, benzodiazepines etc.) may be used as indicated.  
 
5.4  Duration of Treatment  
 
In the absence of treatment delays due to adverse events, treatment will continue for at least 12 cycles 
(treatment with entospletinib may continue beyond 12 cycles, as noted elsewhere;  obinutuzumab will 
be administered for 6 cycles) or until one of the criteria below applies.   
Protocol Version 10.0 – February 5, 2021  35
  
 • Disease progression 
• Unacceptable adverse event(s),  
• Intercurrent illness that prevents further administration of treatment,  
• Participant decides to withdraw from the study, or  
• Pregnancy, or  
• General or specific changes in the participant's condition render the partic ipant unacceptable 
for further treatment in the opinion of the treating physician.  
• Closure of study by sponsor investigator or discontinuation of drug availability.  
5.5  Duration of Follow -up 
 
Study participants will remain on study until disease progressi on,  until study drug- related toxicities have 
resolved or are deemed irreversible by the sponsor-investigator (in discussion with a treating physician), 
whichever is later , or until the study is closed.  If a study participant discontinues study treatment due to 
reasons other than progressive disease they will continue to be followed for disease assessments for 12 
months after the End of Treatment visit, and for EFS until the end of study or study closure . 
The expected duration of study will be 5 years, including enrollment (2 years), treatment ( at least 1 year) 
and follow -up and EFS (2 years).  
In the event of a study closure, participants currently receiving study drug will stop taking study drug and 
complete an abbreviated End of Treatment visit . Follow up and EFS will not continue after the End of 
Treatment visit.  
5.6  Criteria for Removal from Study 
 
Participants will be removed from study under the following circumstances:  
 
Disease progression  or start of new therapy of CLL/NHL  
Participant de cides to withdraw from the study 
Pregnancy 
Patient is off treatment and has been on study for at least 4 years since the date of consent  
Study closure  
 
The reason for study removal and the date the participant was removed must be documented in the study-
specific case report form.  Alternative care options will be discussed with the participant.  
 
In the event of unusual or life -threatening complications, a lead PI (Alexey Danilov, M.D.) needs to 
be immediately notified at danilov@ohsu.edu . 
5.7  Trial Discontinuation 
 
The trial will cease  when participants  
 - have started a subsequent treatment for CLL, or 
 - have been followed for 3 years since beginning of therapy, and are no longer receiving therapy , 
or 
 - have died of any cause  
 -come off study due to study closure  
 
The last scheduled follow -up will occur on a post -treatment visit as defined in study procedures.   
Protocol Version 10.0 – February 5, 2021  36
  
 6.0 DOSING DELAYS/DOSE MODIFICATIONS  
6.1  Dose Modifications/Delays for Toxicities Encountered During Therapy.  
 Table 6. Dose Modifications and Delays for Entospletinib and Obinutuzumab  
Description  Grade  Dose modification  
Non-
hematologic Initial  
or  first recurrence  3-4 and clinically 
significant* Hold treatment with both drugs and 
evaluate at least weekly as clinically 
indicated. Delay dose until toxicity 
resolves to Grade ≤2, then complete current cycle or start next cycle with 
reduction in entospletinib by one dose 
level (Table 5)  
Second 
recurrence  Discontinue  
Description  Grade  Dose modification  
Hematologic  Initial  
or  
first recurrence  As defined in DLTs:  
 Grade 4 neutropenia 
lasting > 7 days. 
Grade 4 
thrombocytopenia/ 
anemia or grade 3 
thrombocytopenia with 
bleeding or any 
requirement for platelet transfusion, 
unexplained by 
underlying disease  
Febrile neutropenia  Hold treatment with both drugs. Initiate at 
least weekly CBC checks, growth factor (G-
CSF allowed at Investigator’s 
discretion) and transfusion support as clinical
ly indicated until resolved to 
Grade 1 or >75% baseline. May continue 
this cycle or start next cycle with 
reduction in entospletinib by one dose level (Table 5).  
Second 
recurrence  Discontinue 
*Not clinically significant includes: Grade 3 nausea or vomiting occurring without optimal treatment; asymptomatic Grade 3 
laboratory abnormalities that are not life- threatening and respond to treatment; grade 3 obinutuzumab infusion reactions; grade 4 
infusion reaction, which will be an investigator dependent decision   
Note: Grading of non- hematologic toxicities will be according to NCI CTCAE v.4.03. Grading of hematologic toxicity will be 
according to the 1996 modified NCI -WG criteria for CLL/SLL, updated  in 2008.  
 Table 7. Restarting Doses of Entospletinib after Treatment Interruption for Drug -Related Toxicity  
Entospletinib dose at the time of first 
toxicity 1st reduction  2nd reduction  
200 mg daily  Discontinue  - 
200 mg BID  200 mg daily  Discontinue  
400 mg BID 200 mg BID  200 mg daily  
 
There are NO dose reductions for obinutuzumab.  
 
In cases where toxicities led to dose reduction, dose re -escalation of entospletinib may be considered in 
subsequent cycles at the discretion of the treating physician after at least two cycles of study therapy are 
well tolerated without any recurrent toxi cities at the reduced dose.   
Protocol Version 10.0 – February 5, 2021  37
  
 Treatment delays due to hematologic, non- hematologic and renal toxicities are permitted for up to 28 days 
from the end of a previous 28- day cycle. For longer delays, the study treatment will end (Section 5.5). In 
case of a treatment delay subsequent study assessment days will be adjusted accordingly. If a treatment 
delay occurs, both drugs (entospletinib and obinutuzumab) will be delayed.  
For less severe toxicities not described above, holding one or both drugs and dose reductions are discouraged, but remain at the discretion of the treating physician.  
 
Treatment with entospletinib and obinutuzumab will be discontinued if one of the following occurs 
despite dose modifications:  
 1. Second recurrence of grade 3- 4 non-hematologi c toxicities.  
 2. Second recurrence of grade 3- 4 hematologic toxicities.  
 3. Treatment delay of >28 days from the end of a previous 28- day cycle.  
6.3  Special Considerations  
 
Surgery 
  The following guidance should be applied during the perioperative period for subjects who require surgical 
intervention or an invasive procedure while receiving entospletinib:  
• For any surgery or invasive procedure requiring sutures or staples for closure, entospletinib 
should be held 48 hours prior to the intervention and at  least 48 hours after the procedure, and 
restarted at the discretion of the investigator when the surgical site is reasonably healed without the need for drainage tubes.  
• For emergency procedures, entospletinib should be held after the procedure until the surgical 
site is reasonably healed, for at least 48 hours after the urgent surgical procedure.  
 
7.0 ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial. The following list of 
AEs (Section 7.1) and the characteristics of an observed AE (Section 7.2) will determine whether the event 
requires expedited reporting.  
7.1  Adverse Events and Potential Risks Lists  
 
7.1.1  Entospletinib  
 
Based on the data available, the following is a  list of effects that could be encountered in patients 
administered entospletinib PO. 
 
• Rash 
• Transaminases Increased  
• Bilirubin, indirect, transient elevation  
7.1.2  Obinutuzumab  
 
Please refer to the prescribing information (Appendix A) for complete lists of  anticipated toxicities 
associated with obinutuzumab.  
 
 
Protocol Version 10.0 – February 5, 2021  38
  
 7.2  Adverse Event Characteristics  
 An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the 
use of an investigational medicinal product or other protocol-imposed intervention, regardless of attribution . 
An abnormal laboratory value will not be assessed as an AE unless that value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline  
  
This includes the following: - AEs not previously observed in the patient that emerge during the protocol -specified AE 
reporting period, including signs or symptoms associated with NHL/CLL that were not present 
prior to the AE reporting period.  
- Complications that occur as a result of protocol -mandated interventions (e.g., invasive procedures 
such as cardiac catheterizations).  
- If applicable, AEs that occur prior to assignment of study treatment associated with medication 
washout, no treatment run- in, or other protocol -mandated intervention.  
- Preexisting medical conditions (other than the condition being studied) judged by the investigator 
to have worsened in severity or frequency or changed in character during the protocol -specified 
AE reporting period.  
 Adverse events will be graded according to the NCI Common Toxicity Criteria Version 4.03. A copy of the CTC version 4.0 can be downloaded from http://ctep.info.nih.gov. Reporting of AEs will begin 
following the first dose of entospletinib and continue until End of Treatment visit. AEs after the End of 
Treatment visit should also be reported if considered related to study drug.  
Safety is the primary study endpoint and will be assessed continuously.  The safety profile will be assessed 
from the findings of physical examination, laboratory data, electrocardiograms (ECG), concomitant medications and treatments, and date of treatment withdrawal and cause. The safety profile will be based 
on incidence, severity, and cumulative nature of AEs. Adverse event seriousness, severity grade, and 
relationship to study medications will be assessed by the lead PI.  
 All subjects who completed 1 cycle of therapy or who did not complete 1 cycle of therapy (or the run- in 
phase) because of a DLT will be considered evaluable for toxicity. All AEs, with the exception of 
progressive disease, will be reported from the start of therapy until the End of Treatment visit or until the 
start of an alternative systemic anti -leukemic t herapy, if it occurs earlier.  
 All grade 3 or Grade 4 AEs considered related to study regimen must be followed until recovery to Grade ≤1 or baseline. The unresolved aforementioned events will be followed until, in the opinion of a lead PI (in discussion with a treating physician), resolution can no longer be expected.  
 All grade 3 and 4 hematological and non -hematological adverse events will be recorded on the case 
report forms.  
 
7.2.1 Serious adverse event (SAE)  
 
An AE should be classified as an SAE if the following criteria are met : 
- It results in death (i.e., the AE actually causes or leads to death).  
- It is life threatening (i.e., the AE, in the view of the investigator, places the patient at immediate 
risk of death. It does not include an AE that, had it occurred in a more severe form, might have 
Protocol Version 10.0 – February 5, 2021  39
  
 caused death.).  
- It requires or prolongs inpatient hospitalization.  
- It results in persistent or significant disability/incapacity (i.e., the AE results in substantial 
disruption of the patient’s ability to conduct normal life functions).  
- It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the IMP. 
- It is considered a significant medical event by the investigator based on medical judgment (e.g., may jeopardize the patient  or may require medical/surgical intervention to prevent one of the 
outcomes listed above).  
 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate 
in other situations, such as important medical events that may not be immediately life threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention (ie, specific measures 
or corrective treatment) to prevent one of the other outcomes listed in the definition above . 
7.2.2. Obinutuzumab adverse events of special interest  
 
Obinutuzumab events of special interest are : 
• Cases of potential drug- induced liver injury that include an elevated ALT or AST in combination 
with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law.  
• Suspected transmission of an infectious agent by the study drug, as defined below  
Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform 
encephalopathy), pathogenic or non- pathogenic, i s considered an infectious agent.  A transmission of an 
infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection 
in a patient exposed to a medicinal product.  This term applies only when a contamination of the study drug 
is suspected  
 
-The following events, if considered serious by the investigator:  
• Serious neutropenia  
• Serious infection 
• Serious IRR  
• Serious TLS  
 
7.2.3. Selected Adverse Events  
 Selected events (in clinical trials, these are events for which additional data collection or analyses will be 
performed; no special case handling or follow -up is required) include the following:  
 
- IRRs 
- Infections (including PML)  
- Neutropenia (including late -onset neutropenia, defined as neutrophil count
 < 1000 cells/mm3, 
occurring 28 days or more after obinutuzumab treatment has been completed or stopped; prolonged neutropenia, defined as neutrophil count 
 < 1000 cells/mm3, that does not resolve after 
28 days (without obinutuzumab treatment)  
- Thrombocytopenia (including acute thrombocytopenia occurring during and within 24 hours  post 
Protocol Version 10.0 – February 5, 2021  40
  
 obinutuzumab infusion)  
- Hepatitis B reactivation  
- Cardiac events  
- Second malignancies  
- GI perforation  
 
7.2.4. Methods and Timing for Assessing and Recording Safety Variables  
 The investigator is responsible for ensuring that all AEs and SAEs, that are observed or reported during the study, are collected and reported to the U.S. Food and Drug Administration (FDA), appropriate IRB(s), Gilead Sciences, and Genentech in accordance with instructions provided in this section, as well as in 
accordance with CFR 312.32 (IND Safety Reports).  
 7.2.4.1. Adverse Event Reporting Period  
The study period during which all AEs and SAEs must be reported begins after informed consent is obt ained 
and initiation of study treatment and ends 30 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier. After this period, investigators should only report 
SAEs that are attributed to prior study treatment.  From the time of consent to the initiation of treatment, 
any AEs and SAEs related to study procedures should be reported.  
 
7.2.4.2. Assessment of Adverse Events  
All AEs and SAEs whether volunteered by the patient, discovered by study personnel during questioning, 
or detected through physical examination, laboratory test, or other means will be reported appropriately.  
Each reported AE or SAE will be described by its duration (i.e., start and end dates), regulatory seriousness criteria if applicable, suspected relationship to entosple tinib or obinutuzumab, and actions taken.  
 To ensure consistency of AE and SAE causality assessments, investigators should apply the following general guideline:  
 Yes 
There is a plausible temporal relationsh ip between the onset of the AE and administration of the 
entospletinib or obinutuzumab, and the AE cannot be readily explained by the patient’s clinical state, intercurrent illness, or concomitant therapies; and/or the AE follows a known pattern of respons e to the 
entospletinib or obinutuzumab; and/or the AE abates or resolves upon discontinuation of the study drug or 
dose reduction and, if applicable, reappears upon re -challenge.  
 No 
Evidence exists that the AE has an etiology other than the study drug (e.g., preexisting medical condition, 
underlying disease, intercurrent illness, or concomitant medication); and/or the AE has no plausible temporal relationship to study drug administration (e.g., cancer diagnosed 2 days after first dose of study 
drug).  Expected AEs are those AEs that are listed or characterized in the USPI or current Investigator’s Brochure.  
Unexpected AEs are those not listed in the USPI or current Investigator’s Brochure or not identified.  This 
includes AEs for which the specificity or severity is not consistent with the description in the USPI or 
Investigator’s Brochure.  For example, under this definition, hepatic necrosis would be unexpected if the USPI or Investigator’s Brochure only referred to elevated hepatic enzymes or hepatitis.  
 
Protocol Version 10.0 – February 5, 2021  41
  
 7.2.5. Procedures for Eliciting, Recording, and Reporting Adverse Events  
 
7.2.5.1. Eliciting Adverse Events  
 
A consistent methodology for eliciting AEs at all patient evaluation time  points should be adopted.  
Examples of non- directive questions include:   
“How have you felt since your last clinical visit?”  
“Have you had any new or changed health problems since you were last here?”   
7.2.5.2. Specific Instructions for Recording Adverse Events  
Investigators should use correct medical terminology/concepts when reporting AEs or SAEs.  Avoid 
colloquialisms and abbreviations.  
 
Infusion- Related Reactions  
Adverse events that occur during or within 24 hours after study drug administration and are judged to be related to study drug infusion should be captured as a diagnosis (e.g., "infusion- related reaction" or
 
"anaphylactic reaction."  If possible, avoid ambiguous terms such as "systemic reaction."  Associated signs and symptoms should be recorded.  If a patient experiences both a local and systemic reaction to the  same 
dose of study drug, each reaction should be recorded separately, with signs and symptoms also recorded separately.  
 
Diagnosis versus Signs and Symptoms  
If known at the time of reporting, a diagnosis should be reported rather than individual signs and symptoms 
(e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, it is acceptable to report the information that is currently available.  If a diagnosis is subsequently established, it should be reported as follow -up information.  
 
Deaths 
All deaths that occur during the protocol -specified AE reporting period, regardless of attribution, will be 
reported to the appropriate parties.  When recording a death, the event or condition that caused or contributed to the fatal outcome should be reported as the single medical concept.  If the cause of death is unknown and cannot be ascertained at the time of reporting, report “Unexplained Death”.  
 
Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the start of the study. Such conditions should be 
reported as medical and surgical history. A preexisting medical condition should be re -assessed throughout 
the trial and reported as an AE or SAE only if the frequency, severity, or character of the condition worsens during the study. When reporting such events, it is important to convey the concept that the preexisting 
condition has changed by including applicable descriptors (e.g., “more frequent headaches”).  
 
Hospitalizations for Medical or Surgical Procedures  
Any AE that results in hospitalization or prolonged hospitalization should be  documented and reported as 
an SAE.  If a patient is hospitalized to undergo a medical or surgical procedure as a result of an AE, the 
event responsible for the procedure, not the procedure itself, should be reported as the SAE.  For example, 
if a patient is hospitalized to undergo coronary bypass surgery, record the heart condition that necessitated 
the bypass as the SAE.  
Hospitalizations for the following reasons do not require reporting:  
- Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for preexisting conditions  
- Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study or 
Protocol Version 10.0 – February 5, 2021  42
  
 - Hospitalization or prolonged hospitalization for scheduled therapy of the target disease of the 
study. 
 
Pregnancies  
- Pregnancies in Female Patients  
If a female patient becomes pregnant while receiving study drug or within 18 months after the last dose of 
entospletinib or obinutuzumab, a report should be completed and expeditiously submitted to Gilead Sciences and Genentech.  Follow -up to obtain the outcome of the pregnancy should also occur.  
 
- Pregnancies in Female Partners of Male Patients  
If the female partner of male patients become pregnant while receiving the study drug or within 6 months after the last d ose of entospletinib or obinutuzumab, a report should be completed and expeditiously 
submitted to Gilead Sciences and Genentech. The pregnant partner will need to sign an IRB approved 
Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow up on her 
pregnancy. After the authorization has been signed, the investigator will submit a Pregnancy Report when updated information on the course and outcome of the pregnancy becomes available.  
 
Congenital Anomalies/Birth Defects and A bortions 
Abortion, whether accidental, therapeutic, or spontaneous, should always be classified as serious, and expeditiously reported as an SAE.  Similarly, any congenital anomaly/birth defect in a child born to a female patient exposed to obinutuzumab or  the female partner of a male patient exposed to obinutuzumab or 
entospletinib should be classified as an SAE.  
 
Post-Study Adverse Events  
The investigator should expeditiously report any SAE occurring after a patient has completed or discontinued study par ticipation if attributed to prior entospletinib or obinutuzumab exposure. If the 
investigator should become aware of the development of cancer or a congenital anomaly in a subsequently conceived offspring of a female patient who participated in the study, this should be reported as an SAE.  
 
7.2.5.3. Reconciliation (Genentech)  
The Sponsor agrees to conduct reconciliation for the product.  Genentech and the Sponsor will agree to the 
reconciliation periodicity and format, but agree at minimum to exchange quar terly line listings of cases 
received by the other party.  
If discrepancies are identified, the Sponsor and Genentech will cooperate in resolving the discrepancies.  
The responsible individuals for each party shall handle the matter on a case -by-case basis until satisfactory 
resolution.  The Sponsor shall receive reconciliation guidance documents within the ‘Activation Package’.  
 
7.2.6  Definitions of Expectedness  
 
Adverse events can be 'Expected' or 'Unexpected.'  
7.2.6.1. Expected Adverse Event  
 
Expected adverse events are those that have been previously identified as resulting from administration of 
the agent. For the purposes of this study, an adverse event is considered expected when it appears in the 
package insert or is included in the informed consent document as a potential risk.  Refer to the prescribing 
information for a listing of expected adverse events associated with the study agents.  
 
7.2.6.2. Unexpected Adverse Event  
 
Protocol Version 10.0 – February 5, 2021  43
  
 For the purposes of this study, an adverse event is considered unexpected  when it varies in nature, intensity 
or frequency from information provided in the package insert or when it is not included in the informed 
consent document as a potential risk.  
7.2.7 Attribution  
 
Attribution is the relationship between an adverse event or serious adverse event and the study treatment. Attribution will be assigned as follows:  
 
o Definite – The AE is clearly related  to the study treatment.  
o Probable – The AE is likely related to the study treatment.  
o Possible – The AE may be related  to the study treatment.  
o Unlikely – The AE is doubtfully related to the study treatment.  
o Unrelated –The AE is clearly NOT related  to the study treatment.  
7.3 OHSU IRB Reporting of Unanticipat ed Problems and Adverse Events  
Unanticipated Problems and Adverse Events (AE) will be reported to OHSU IRB according to the policies, 
procedures and guidelines posted on the OHSU IRB web site http://www.ohsu.edu/xd/about/services/integrity/policies/all- irb-documents.cfm
.Reportable New 
Information (RNI) will be reported to the OHSU as defined in the OHSU Investigator Guidance document titled Prompt Reporting Requirements (HRP -801). Fatal and life -threatening events must be reported to 
OHSU IRB within 5 business days after the PI learns of the event. If any of these require a change (as 
determined by the  PI or the IRB) to the protocol or consent form, the PI will make those changes promptly 
and submit the revised documents to the OHSU IRB.  
All other UP reports will be submitted to OHSU IRB no later than 15 calendar days of notification of the event.  If t he event requires changes as determined by the PI or the IRB to the protocol or consent form, the 
PI will make the changes promptly and submit the revised documents to the IRB.  Unanticipated Problems 
and AE reports are submitted through OHSU e -IRB and will be reviewed by OHSU IRB.   
7.5 MedWatch Reporting  
 
For this investigator -initiated study, the investigator is the study sponsor. The investigator / sponsor is 
required to report adverse experiences to the FDA through the MedWatch reporting program, even if the 
trial involves a commercially available agent. Adverse experiences to be reported include any unexpected 
(not listed in the package label), serious adverse experiences with a suspected association to the study drug. 
 
Adverse events that occur during clinical studies are to be reported to FDA as specified in the investigational new drug/biologic regulations using Form FDA 3500, the MedWatch Voluntary Reporting form, which is available online at:  
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf
.   
 Investigators may also complete Form FDA 3500 online at: https://www.acce ssdata.fda.gov/scripts/medwatch/
.   
 Serious adverse events experienced by subjects at the participating sites require completion and submission of the OHSU Safety Reporting Form along with supporting materials to OHSU within 24 
hours of participating investigator’s knowledge of the event. The OHSU Safety Reporting Form can be 
found in the study operations manual. OHSU will report the event to the FDA via Voluntary Form 3500. 
Protocol Version 10.0 – February 5, 2021  44
  
 A copy of Form FDA 3500 and supporting materials will be kept on file in the study regulatory binder. 
All SAEs occurring on study will be disseminated to the coordinating center by OHSU.  
 
For sponsor -investigators who hold an IND, Form FDA 3500 will be submitted to the IND/IDE associate 
who will assist the study team in a formal safety report to the FDA.  
7.6 Sponsor or additional reporting requirements.  
 
Unexpected fatal or life-threatening experiences associated with the use of the study treatment will be 
reported to FDA as soon as possible but in no event later than 7 calendar days after initial receipt of the information. 
 
All other serious unexpected experiences associated with the use of the study treatment will be reported to 
FDA as soon as possible but in no event later than 15 calendar days after initial receipt of the information.  
   
Events will be reported to the FDA using Form FDA 3500, the MedWatch Voluntary Form. Forms are 
available at http://www.fda.gov/medwatch/getforms.htm
.  
 
7.6.1. Reporting to Gilead Sciences  
 
SAE reporting  
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period. 
However, if the investigator learns of any SAEs that occur after study participation has concluded and the 
event is deemed relevant to the use of IMP, he/she should promptly document and report the event to 
Gilead Drug Safety and Public Health within 24 hours. All deaths which occur during study follow -up 
will be reported to Gilead Drug Safety and Public Health within 24 hours.  
 Pregnancy reports  
The investigator should report pregnancies in female study subjects that are identified after  initiation of 
study medication and throughout the study, including the post study drug follow -up period to Gilead Drug 
Safety and Public Health within 24 hours of becoming aware of the pregnancy.  
 The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a pregnancy without medical reasons. Any premature termination of pregnancy (e.g., a spontaneous abortion, an 
induced therapeutic abortion due to complications or other medical reasons) must be reported within 24 
hours as an SAE. The underlying medical reason for this procedure should be recorded as the AE term. A spontaneous abortion is always considered to be an SAE.  Furthermore, any SAE occurring as an adverse pregnancy outcome post study must be reported to Gilead Drug Safety and Public Health. The subject 
should receive appropriate monitoring and care until the conclusion of the pregnancy. The outcome 
should be reported to Gilead Drug Safety and Public Health. If the end of the pregnancy occurs after the 
study has been completed, the outcome should be reported directly to Gilead Drug Safety and Public Health. 
 Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs must also be 
reported and relevant information should be submitted to Gilead Drug Safety and Public Health within 24 
hours. Monitoring of the subject should continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gile ad 
Drug Safety and Public Health.  
 
 
Gilead Drug Safety and Public Health contact information is as follows : 
Fax: 1-650-522-5477 
Protocol Version 10.0 – February 5, 2021  45
  
 Email: Safety_FC@Gilead.com  
  
7.6.2. Reporting to Genentech  
 
Investigators must report all SAEs to Genentech within the timelines described below.  The completed MedWatch/case report should be faxed immediately upon completion to Genentech Drug Safety at:  
 (650) 225 4682 
OR 
(650) 225 4630 
 Relevant follow -up information should be submitted to Genentech Drug Safety as soon as it becomes 
available. 
 Please see Appendix H.  
 SAEs, pregnancy reports, and AESIs, where the patient has been exposed to the study drug (Product), will be sent on a MedWatch or CIOMS I form to the Genentech contact  specified in Addendum 2 of this SDEA.  
Transmission of these reports (initial and follow -up) will be either electronically or by fax and within the 
timelines specified below.  
 Serious Adverse Drug Reactions  
Serious adverse event reports that are related to the Product shall be transmitted to Genentech within fifteen 
(15) calendar days of the awareness date.  
 Other Serious Adverse Events  
Serious adverse event reports that are unrelated to the Product shall be transmitted to Genentech 
within 
thirty (30) cal endar days of the awareness date.  
 
Pregnancy Reports  
While such reports are not serious adverse events or ADRs per se, as defined herein, any reports of 
pregnancy, where the fetus may have been exposed to the Product, shall be transmitted to Genentech  within 
thirty (30) calendar days of the awareness date. Pregnancies will be followed up until the outcome of the 
pregnancy is known, whenever possible, based upon due diligence taken to obtain the follow -up 
information. 
 
Adverse Events of Special Interest  
AESIs requiring expedited reporting shall be forwarded to Genentech within fifteen (15) calendar days of 
the awareness date.  Others shall be sent within thirty (30) calendar days.  
 
Special Situation Reports  
In addition to all adverse events, pregnancy reports  and AESIs, the following Special Situations Reports 
should be collected and transmitted to Genentech even in the absence of an AE within thirty (30) calendar 
days: - Data related to the Product usage during pregnancy or breastfeeding 
- Data related to ove rdose, abuse, off -label use, misuse, inadvertent/erroneous administration, medication 
error or occupational exposure, with or without association with an AE/SAE unless otherwise specified in the protocol  
- Data related to a suspected transmission of an infectious agent via a medicinal product (STIAMP)  
 
Protocol Version 10.0 – February 5, 2021  46
  
 In addition, reasonable attempts should be made to obtain and submit the age or age group of the patient, 
in order to be able to identify potential safety signals specific to a particular population.  
 
Aggregate Reports  
OHSU will forward a copy of the Publication to Gilead Sciences and Genentech upon completion of the 
Study.   
Reporting to Gilead Sciences and Genentech at Study Close Out  
Any study report submitted to the FDA by the Sponsor -investigator should be copied to Gilead Sciences 
and Genentech.  This includes all IND annual reports and the Clinical Study Report (final study report).  
Additionally, any literature articles that are a result of the study should be sent to Gilead Sciences and 
Genentech.  Copies of such reports should be mailed to the assigned Genentech Clinical Operations contact 
for the study (e-mail:  ga101-gsur@gene.com
; fax:  866-706-3927 ) and Gilead Sciences Clinical Operations 
contact personnel . 
 
IND Annual Reports  
Copies to Gilead Sciences and Genentech:  
All IND annual reports submitted to the FDA by the Sponsor-Investigator should be copied to Gilead 
Sciences and Genentech.  Copies of such reports should be faxed to Genentech Drug Safety [f ax (650) 225-
4682 or (650) 225-4630] and Gilead Sciences Clinical operations contact personnel.  
 
Product Complaints  
• All Product Complaints (with or without an AE) shall be forwarded to Genentech within fifteen 
(15) calendar days of the awareness date.  
 
• A Product Complaint is defined as any written or oral information received from a complainant 
that alleges deficiencies related to identity, quality, safety, strength, purity, reliability, durability, effectiveness, or performance of a product after it has been  released and distributed to the 
commercial market or clinical trial.  
  
8.0 PHARMACEUTICAL AGENT INFORMATION 
A list of the adverse events and potential risks associated with the investigational or commercial agents 
administered in this study can be found in Section 7.1.  
8.1  Agent Accountability 
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of 
the inventory and disposition of the study agent. (See the NCI Investigator’s Handbook for Procedures for Drug Accountability and Storage).  
http://ctep.cancer.gov/investigatorResources/investigators_handbook.htm
  
 Responsibility for drug accountability at the study site rests with the Investigator; however, the Investigator 
may assign some of the drug accountability duties to an appropriate pharmacist or designee. Inventory and 
accountability records must be maintained and readily available for inspection by the study monitor and are 
open to inspection at any time by any applicable regulatory authorities.  
 The Investigator or designee will be expected to collect and retain all used, unused, and partially used containers of study medication until the end of the study. The Investigator or designee must maintain 
Protocol Version 10.0 – February 5, 2021  47
  
 records that document:  
• investigational product delivery to the study site  
• the inventory at the site  
• use by each subject including pill/unit counts from each supply dispensed 
• return to the Investigator or designee  
 These records should include dates, quantities , batch/serial numbers (if available), and the unique code 
numbers (if available) assigned to the investigational product and study subjects.  
 The investigational product must be used only in accordance with the protocol. The Investigator will also maintain records adequately documenting that the subjects were provided the correct study medication 
specified.  
 Completed accountability records will be archived by the site. At the completion of the study, the Investigator or designee will oversee destruction of any remaining study drug according to institutional standard operating procedures.  
 
Please refer to the Pharmacy Manual located in the separate Study Operations Manual for details on 
drug supply, ordering and shipment process.  
8.2 Entospletinib.  
 Entospletinib will be obtained from Gilead Sciences, Inc. Up to 4, 600 tablets (200 mg dose) and up to  
26,000 tablets (200 mg dose) will be provided for the first year of entospletinib therapy. Additionally, it is 
estimated that up to 32,000 200 mg dose tablets may be provided for patients who desire to continue therapy 
with entospletinib single agent beyond 1 year.  
  8.2.1. Formulation  
 Entospletinib may be supplied as either Clinical Trade Dress or Commercial Trade Dress.  
 
Clinical Trade Dress  
Entospletinib is available as 200 mg strength capsule -shaped, plain- faced, film -coated blue tablets. 
Each tablet contains the equivalent of 200 mg entospletinib free base in the form of an entospletinib spray -
dried dispersion prepared using the entospletinib bismesylate monohydrate. In addition to the active ingredient, entospletinib tablets contain the following inactive ingredients: Methanesulfonic acid, 
hydroxypropyl methylcellulose (hypromellose), mannitol, microcrystalline cellulose, crospovidone, 
poloxamer 188, silicon dioxide, magnesium stearate, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and FD&C blue #2 aluminum lake.  
 Commercial Trade Dress  
Entospletinib is also available as 200 mg strength capsule -shaped, debossed, film -coated beige tablets. 
The tablet is debossed with “GSI” on one side and “9973” on the other side. Each tablet contains the 
equivalent of 200 mg entospletinib free base in the form of an entospletinib spray- dried dispersion prepared 
using the entospletinib bismesylate monohydrate. In addition to the active ingredient, entospletinib tablets contain the following inactive ingredients: Methanesulfonic acid, hydroxypropyl methylcellulose 
(hypromellose), mannitol, microcrystalline cellulose, crospovidone, poloxamer 188, silicon dioxide , 
magnesium stearate, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, ferrosoferric 
oxide/black iron oxide, iron oxide red, and iron oxide yellow.  
 
Protocol Version 10.0 – February 5, 2021  48
  
 8.2.2. Packaging and Labeling 
 
Entospletinib tablets are packaged in white, high- density polyethylene bottles with silica gel desiccant, 
and polyester packing material in each bottle. Each bottle contains 60 tablets and is capped with a child-
resistant polypropylene screw cap fitted with an induction- sealed, aluminum -faced liner.  
 
Study drug(s) will be distributed to centers in the US and will be labeled by at the corresponding pharmacies to meet applicable requirements of the United States Food and Drug Administration (FDA).  
 
8.2.3. Storage and Handling 
 
Entospletinib tablets should be stored at  a controlled room temperature of 25 °C (77 °F); excursions are 
permitted between 15 °C and 30 °C (59 °F and 86 °F). To ensure stability of the tablets and proper 
product identification, the drug should not be stored in a container other than the container  in which it is 
supplied. Measures that minimize drug contact with the body should always be considered during handling, preparation, and disposal procedures.  
8.3  Obinutuzumab.  
 Obinutuzumab will be provided by Genentech Inc. 8000 mg of obinutuzumab will  be provided   
per patient, up to 240,000 mg total drug for this study.  
 
8.3.1. Obinutuzumab Formulation  
 
Obinutuzumab is provided as a single -use vial. Each vial contains sterile liquid formulation in a 50- mL 
pharmaceutical -grade glass vial containing a nominal dose of 1000 mg of obinutuzumab (G3 material). 
The formulated drug product consists of 25 mg/mL drug substance formulated in histidine/histidine -HCl, 
trehalose, and poloxamer 188. The vial contains 41 mL (with 2.5% overfill).  
 
8.3.2. Obinutuzumab S torage 
 
The recommended storage conditions for the obinutuzumab drug product are between 2° C and 8°C, 
protected from light. Chemical and physical in- use stability for obinutuzumab dilutions in 0.9% sodium 
chloride (NaCl) at concentrations of 0.2 to 20 mg/mL have been demonstrated for 24 hours at 2°C− 8° C 
and an additional 24 hours at ambient temperature and ambient room lighting. The prepared diluted 
product should be used immediately. If not used immediately, in- use storage times and conditions prior to 
use are the responsibility of the user and would normally not be longer than 24 hours at 2°C− 8° C unless 
reconstitution/dilution has taken place in controlled and validated aseptic conditions. Obinutuzumab 
should not be frozen or shaken. Mix gently. All transfer procedures require strict adherence to aseptic 
techniques. Do not use an additional in- line filter because of potential adsorption.  
 
8.3.3. Obinutuzumab Dosage  
 
Obinutuzumab is administered in six treatment cycles. The first 1000 mg is administered over the first 2 
days of the first cycle of treatment. On Day 1, Cycle 1, 100 mg is administered. On the following day (Day 2), 900 mg is administered. On Days 8 and 15 of Cycle 1, 1000 mg is administered on each day for 
a total of 3000 mg in the first cycle. For Cycles 2 − 6, 1000 mg of obinutuzumab is administered on Day 
1 of each 28- day cycle.  
 
Protocol Version 10.0 – February 5, 2021  49
  
 Administration sets with polyvinyl chloride, polyurethane, or polyethylene as product contact surface and 
IV bags with polyolefine, polypropylene, polyvinyl chloride, or polyethylene as product contact surface 
are compatible and may be used. Use of a port or peripherally inserted central catheter line is acceptable.  
 Obinutuzumab must be administered in a clinical setting (inpatient or outpatient). Full emergency resuscitation facilities should be immediately available, and patients should be under close supervision by 
the investigator at all times. Obinutuzumab should be given as a slow IV infusion through a dedicated 
line. IV infusion pumps should be used to control  the infusion rate of obinutuzumab. Do not administer as 
an IV push or bolus. After the end of the first infusion, the IV line should remain in place for at least 2 
hours in order to be able to administer IV drugs if necessary. If no AEs occur after 2 hour s, the IV line 
may be removed. For subsequent infusions, the IV line should remain in place for at least 1 hour from the end of infusion; if no AEs occur after 1 hour, the IV line may be removed. Obinutuzumab will be 
provided by the Sponsor to investigational centers.  
 
8.3.4 Obinutuzumab Preparation  
 
Prepare the solution for infusion, using aseptic technique, as follows:  
• Inspect visually for any particulate matter and discoloration prior to administration. Dilute into a 0.9% 
sodium chloride PVC or non- PVC polyolefin infusion bag.  
• Do not use other diluents such as dextrose (5%).  
• Do not use obinutuzumab beyond the expiration date stamped on the carton.  
 
Preparing the First 1000 mg for Administration over Days 1 and 2 of Cycle 1:  
The administration of the first 1000 mg of obinutuzumab must occur over 2 days. On day 1 of the first treatment cycle, 100 mg should be administered. On the following day (Day 2), 900 mg should be 
administered.  
 
Obinutuzumab drug product intended for IV infusion is prepared by dilution of the drug product into an infusion bag containing 0.9% NaCl. One vial may be used to prepare the 100- mg dose (equals 4 mL) and 
900-mg dose (equals 36 mL) following the directions below. If both bags are prepared at the same time, the 
reconstitut ion/dilution has to take place in controlled and validated aseptic conditions, subsequently store 
the 900-mg bag for a maximum of 24 hours at 2°C− 8° C and administer the next day.  
•  Withdraw 40 mL of obinutuzumab solution from the vial.  
•  Dilute 4 mL (100 mg) of obinutuzumab into a 100 mL 0.9% sodium chloride infusion bag for immediate administration. 
• Dilute the remaining 36 mL (900 mg) into a 250- mL 0.9% sodium chloride infusion bag at the same 
time for use on Day 2 and store at 2° C to 8°C (36°F− 46°F) for up to 24 hours. After allowing the 
diluted bag to come to room temperature, use immediately.  
•  Clearly label each infusion bag.  
 Preparation of 1000 mg Solution for Infusion on Days 8 and 15 of Cycle 1 and Day 1 of Cycles 2 − 6: 
•  Withdraw 40 mL of obinutuzumab solution from the vial.  
• Dilute 40 mL (1000 mg) into a 250- mL 0.9% sodium chloride infusion bag.  
•  Mix diluted solution by gentle inversion. Do not shake or freeze.  
 
8.3.5. Obinutuzumab distribution  
 
Study drug(s) to be distributed to centers in the US shall be labeled to meet applicable requirements of the 
United States Food and Drug Administration (FDA).  
Protocol Version 10.0 – February 5, 2021  50
  
  
 
Please refer to the package insert for further information regarding the storage, handling and administration of obinutuzumab (Appendix A).  
8.4. Dosage and Administration of Study Drugs  
 Entospletinib tablets will be provided by Gilead Sciences, Inc. and will be taken orally. Initiation of 
treatment with the study drug will take place after enrollment and cohort assignment. Subjects will take 
entospletinib on Day -7 of the run- in phase. Starting on Day -6, subjects will continue to take entospletinib 
at approximately the same time each day. To reduce variability, subjects will be instructed to take entospletinib approximately 1 hour before or 2 hours after a meal.  
 
Obinutuzumab will be obt ained from Genentech. Obinutuzumab is administered as an infusion and requires 
pre-medications due to the risk of infusion reactions. See section 5.3.2 and the package insert for details. 
On days when obinutuzumab is administered with entospletinib, obinutuzumab will be given after 
entospletinib.  
 
If the subject misses a dose of entospletinib, he/she should be instructed to take the study drug as soon as 
he/she remembers, unless more than 12 hours has elapsed since the scheduled time of the missed dose of entospletinib if administered once daily or 6 hours has elapsed if administered twice daily. In this case, the subject should be instructed to wait and take the next dose at the regularly scheduled time.  
  
9.0 BIOMARKER, CORRELATIVE AND SPECIAL STUDIES  
9.1. Biomarker/lab correlative studies  
 
9.1.1.  Rationale and Hypothesis   
 SYK is a key kinase which ensures activation of the B -cell receptor signaling cascade. BAFF receptor co -
opts BCR signaling in CLL via a poorly described mechanism, which involves funct ional SYK. Thus, 
downstream events of BCR activation, either via antigen engagement or soluble BAFF receptor ligands, cannot occur if SYK kinase is rendered inactive. BCR is involved in activation of NF κB and thereby 
upregulation of anti -apoptotic Bcl -2 family members Bcl -2, Bcl-X and Bfl -1, and repression of pro-
apoptotic BH3- only protein Bim. SYK is also directly involved in stabilization of the pro- survival protein 
Mcl-1. Thus, we hypothesize that SYK inhibition in CLL (lymphoma) cells in vivo will abrogate NF κB 
activity and modulate the balance between pro- and anti-apoptotic Bcl -2 family members in favor of cell 
death. 
9.1.2. Intended Use of Data  
 
The biomarker studies from treated subjects will provide evidence of the drug mechanism, and findings 
will be correlated with disease response.  
9.1.3.  Preclinical Data and Sample Data Supporting the Biomarker Analysis  
  
 Supporting data is discussed in Section 2.5.3 and Appendix F, Figures 1-4. 
 
9.1.4. Assay Method and Validity 
 
Peripheral blood mononuclear cells will be isolated from each subject using standard Ficoll techniques. 
Samples will be analyzed by western blotting, NF -κB Transcription Factor As say and RT -PCR.  
Protocol Version 10.0 – February 5, 2021  51
  
   
9.1.5.  Investigator Experience  
 
The Sponsor Investigator has used these assays to measure these biomarkers in more than 50 CLL patient 
samples ex vivo. All of the above methods have been previously published by us [37, 38, 43]. 
 9.1.6 Number of Subjects  
 
The number of subjects to be accrued is driven by the study primary objectives. The biomarker analysis 
will be performed on all subjects. In patients who do not have circulating tumor cells, peripheral  blood 
mononuclear cells will be collected and studied based on the availability of biologic material.  
 
9.1.7 Risk to the Subject  
 
The risk to the subject based on the biomarker studies is only the collection of blood at two time points in 
cycle 1.  The benefit to the study will be to facilitate further development of this therapeutic rationale.  
 
9.1.8. Collection of Specimen(s)  
 
Blood (20 ml with each collection) will be obtained on Day -7 of the run- in phase (prior to entospletinib 
dosing) and on C1D1 (prior to administration of obinutuzumab or any pre -medications; patient may have 
taken entospletinib); on C7D1, at the end of study treatment and at relapse.  
Bone marrow aspirate (10 mL  in a heparinized syringe) will be obtained with each bone marrow biopsy 
performed on study, including at screening (if performed) and at the time of CR confirmation biopsy (if 
performed) or End-of- Treatment biopsy.  
 In the event of study closure, specimens mentioned above will not be collected at the end of treatment vi sit.  
 
9.1.9. Handling of Specimens(s)  
 
Venous blood samples and bone marrow aspirates  collect at OHSU  will be transported to Dr. Danilov's  
laboratory within 2 hours  after collection. Samples will be transported at room temperature. Blood samples 
collected at participating sites will be shipped ambient to Dr. Danilov’s laboratory the day of collection.  
Sample shipments from participating sites can only be accepted at Dr. Danilov’s Monday- Friday.  Please 
see the Study Operation Manual for the shipping addr ess. 
Peripheral blood mononuclear cells (including CLL B -cells, or lymphoma B -cells where present in the 
blood) will be isolated using Ficoll -Hypaque gradient and used for preparation of protein, RNA and DNA 
at Dr. Danilov laboratory or laboratories identi fied at participating sites. Protein and RNA will then be 
stored at -80C, and DNA will be stored at -20C.  
 
 The following analysis will be conducted:  
• IGHV mutational status (if not available after routine testing) will be assessed 
employing IgH Somatic Hypermutation Assay v.2.0 (InVivoScribe Technologies). This testing will be performed at Dr. Danilov's laboratory [44], unless otherwise available;  
• Expression of BCR activation markers (immunoblotting:, pSyk, pBTK, pErk, pAkt)  
• Expression of Bcl -2 family proteins (immunoblotting: Bcl -2, Mcl-1, Bim, Bcl -X) 
• Markers of apoptosis (immunoblotting: PARP)  
Protocol Version 10.0 – February 5, 2021  52
  
 • NF-κB transcription targets (RT- PCR: cFLIP, CCND1)  
• NF-κB activity – NF-κB Transcription Factor assay [ 37]; 
 
Comparison of the above biomarkers will be conducted: before/after in vivo exposure to entospletinib. 
Exploratory analysis will be performed using paired t -test statistics.   
 Remaining cells will be viably frozen (10% DMSO/FBS), and stored in liquid nitrogen, until further 
processing. Remaining cell lysates will also be stored and may be used to assess additional biomarkers that 
may be correlated with response to entospletinib.  
  
10.0 STUDY PROCEDURES AND SCHEDULE OF EVENTS  
Patients will be considered on study upon signing the informed consent. Toxicities which occur prior to administration of the first dose of entospletinib will not be subject to analysis. The study consists of a 
Screening Period with baseline tumor assessment before entospletinib administration and Treatment Period 
of at least  twelve cycles (28 days  per cycle), and a Follow-up and EFS Period, unless participants come off 
study in the event of study closure . Subjects will receive a total of six cycles of combination therapy 
(entospletinib and obinutuzumab) and an additional six cycles or more of entospletinib single agent therapy, 
unless treatment is discontinued for one of the pre -specified reasons (Section 5.4) . 
 
10.1  Screening/Baseline Visit  
 
During the Pretreatment Period, subjects are screened and consented for the study.  Informed consent must 
be obtained before initiation of any clinical screening procedure that is performed solely for the purpose of determining eligibility for this researc h study. Evaluations performed as part of routine care before informed 
consent can be utilized as screening evaluations if done within the defined time period.  Informed consent should be obtained within 30 days before the first dose of study treatment.  
 Subjects will undergo screening evaluations to determine study eligibility. All qualifying screening and eligibility assessments must be performed within 30 days before the first dose of study treatment. Tests 
used for baseline disease assessments must be performed within specified time frame of the initial dose of 
study treatment. Refer to section 10.4 and 10.5. Those assessments will be performed at OHSU or the 
participating sites. However, results provided by other institutions are acceptable as long as they satisfy the 
timing criteria.  
 
 
10.2  Treatment Period  
 
Clinic visits will be performed every cycle on Day 1. Under certain circumstances (e.g., clinic holiday, 
inclement weather) Day 1 may be delayed by not more than 3 days or occur earlier than scheduled by not 
more than 3 days during cycles 2- 12; Days 8 and 15 of Cycle 1 may be delayed by 1 day or occur 1 day 
early.  
 
Clinical laboratory assessments are to be collected on D1 of each cycle visit, or ≤ 48 hours before those 
visits, and the test results must be available and reviewed before obinutuzumab is given (C1- 6).  Screening 
assessment tests can be considered as Day -7 tests (start of treatment) if performed ≤72 hours before the 
first dose of study treatment; otherwise, the required evaluations must  be repeated within this timeframe.  
Protocol Version 10.0 – February 5, 2021  53
  
  
On Day -7 and C1D1 all patients with CLL/SLL will provide samples for biomarker analysis.  
 
After the initial 12 treatment cycles subjects in whom it is clinically safe to do so, are benefitting from 
entospletinib, and who desire to continue entospletinib monotherapy may continue entospletinib therapy 
beyond the  initial twelve cycles, with approval from the treating physician and sponsor -investigator, until 
disease progression or removal from treatment (see Section 5.4).  
 
10.2.1 Pre-Treatment Criteria - Day -7 
 
Hematologic parameters: platelets must be ≥50,000/mm3 (in absence of transfusion support), ANC ≥ 
1000/mm3 unless due to disease involvement in the bone marrow; hemoglobin > 8 g/dL (transfusion support 
permissible);  
 
Non-hematologic parameters: bilirubin (total, and if elevated – direct) ≤ 2 X institutional ULN (unless due 
to known Gilbert’s syndrome or hemolysis directly attributable to CLL/SLL); AST or ALT < 2.5 X 
institutional ULN.  
 Vital signs, all laboratory data (including pregnancy testing) must be reviewed by the treating physician prior to administering the first dose of a study agent.  
 The study treatment period ends on day 28 of the last cycle of study treatment.  Subjects will return to the study site 2 months (±7 days) after the last 28- day cycle of study treatment for an End of Treatment visit  
unless early study closure procedures  are in affect ( see section 5.4) . A bone marrow biopsy will be 
performed no later than 3 months after the End of Treatment visit  unless early study closure procedures are 
in affect (See section 5.4) . Adverse events that are related to study treatment and are ongoing at the time of 
this visit will be followed until resolution or until considered irreversible by the sponsor -investigator unless 
early study closure procedures are in affect.  
 
10.2.2  Pre-Treatment Criteria – from C2 until end of treatment  
 
Hematologic parameter s: platelets must be ≥50,000/mm
3 or >75% of baseline, whichever is lower (without 
transfusion support); hemoglobin > 8 g/dL (transfusion support permissible); ANC ≥1000/mm3 or >75% of 
baseline, whichever is lower (G -CSF support permissible at the discretion of the investigator in case of 
ANC<1000).  
 
Non-hematologic parameters: bilirubin (total, and if elevated – direct) ≤2 X institutional ULN (unless due 
to known Gilbert’s syndrome or hemolysis directly attributable to CLL); AST or ALT < 2.5 X institutional 
ULN.  
 
 
10.3  Follow- up 
 
 
Follow-up visits will occur every 3 months for the first 12 months following the End of Treatment visit.  
Disease assessments will be obtained every 3 months or earlier, if clinically indicated.  Laboratory 
assessments and physical examinations will be completed  at every vi sit. CT scans will be obtained at 6 and 
12 months after the end-of- treatment visit (±7 days) and as clinically indicated thereafter. All subjects  will 
participate in EFS analysis  upon completion of the Follow -up period. 
In the event of Study Closure, patients who are receiving study drug at the time of closure will complete an abbreviated End of Treatment visit.  No additional follow up will occur.  
Protocol Version 10.0 – February 5, 2021  54
  
 10.4  Study Assessments and Procedures  
 
• Demographics and Medical History:  Demographic data will be collected at screening and a 
complete medical history will be collected at visits prior to starting study treatment. Medical history in between visits should be documented at each study visit once study treatment has started. All transfusions including date, product  transfused, number of units, and reason for 
transfusion should also be collected as part of the interval medical history.  
 
• Concomitant Medications :  All concomitant medications and treatments must be recorded in the 
case report form (CRF).  Any prior medication received up to 30 days prior to the screening visit 
will be recorded in the CRF. Concomitant treatments that are required to manage a subject’s medical condition during the study will also be recorded in the CRF. Prior and/ or ongoing 
medications will be reviewed during screening to determine subject eligibility. The medication record will be maintained following enrolment including any changes to the dose or regimen. Prior and concomitant medication including any prescription, over the counter or 
natural/herbal/multivitamin preparations taken will be recorded.   
 
• Physical Exam :  Physical examination consists of a review of all major body systems at 
screening and on day 1 visits of each cycle only (Day -7 during the run- in phase in lieu of C1D1). 
Symptom- directed physical examination relevant to the subject’s symptoms is performed during 
the treatment period and at the post -treatment periods. Symptom -directed physical examinations 
must at a minimum document changes in lymphadenopathy, hepatomegaly, and splenomegaly.  
  If abnormal findings emerge or worsen from baseline assessment, then the AE page of the CRF should be completed for these findings. If a finding meets the criteria for an SAE, then the 
appropriate procedures for reporting such events will be followed as described in Section 7.  
 
• Performance Status :  ECOG will be determined and performed at the visits indicated in the 
schedule of events in section 10.5. Refer to Appendix D for ECOG scale.  
 • Pregnancy Test :  A serum or urine pregnancy test is required for all female subjects during 
screening for women of childbearing potential. If the urine pregnancy test is positive, serum 
pregnancy tests must be performed per institutional standards.  
 
• Vital Signs :  Vital sign measurements should include: blood pressure, heart rate, temperature, 
respiration rate, and oxygen saturation.  
 • Complete Blood Count :  5-part differential, hemoglobin, white blood cell count (WBC), platelet 
count, absolute neutrophil count (ANC), and absolute lymphocyte count (ALC) are r equired at 
each time point as described in the schedule of events. Direct antiglobulin test and % reticulocyte 
count are required at screening only.  
 
 CBC performed < 72 hours prior to D1 of each cycle can be used in lieu of repeating on D1. 
 
 
• Coagulation Panel:  activated partial thromboplastin time (aPTT) and prothrombin time or INR 
(PT/INR).   
 • Chemistry :  LDH, creatinine, urea (BUN), potassium, sodium, chloride, bicarbonate, glucose, 
Protocol Version 10.0 – February 5, 2021  55
  
 alkaline phosphatase, AST, ALT, phosphorus, total bilirubin, direct bilirubin (if total bilirubin is 
elevated only), albumin, uric acid are required.  
 
 Chemistry performed < 72 hours prior to D1 of each cycle can be used in lieu of repeating on D1.  
 
• Urinalysis : performed per institutional standards.  
 
• β2-microglobulin: performed per institutional standards  
 • Hepatitis Screening : hepatitis B surface antigen and hepatitis C antibody are required. Results 
from within 12 months prior to the first dose of study treatment are acceptable.  
 • Serum Immunoglobulins : IgG, IgM and IgA are required.  
 • Genetic and Molecular Prognostic Markers : Testing results are NOT required to proceed with 
study enrollment. Testing for IGHV mutational status (if not previously available) and GeneTrails 
analysis will be performed on a blood sample obtained on day 1 of the study (see Section 9 of the 
protocol). 
o CLL FISH panel (trisomy 12, deletion 11q, deletion 17p, deletion 13q), results 
acceptable if performed within 6 months prior to the first dose of study treatment, and 
if no intervening treatment occurred 
o ZAP-70 expression - results acceptable if performed at any time since diagnosis and 
will be documented where available, but not require d 
o IGHV mutational status, if available - results acceptable if performed at any time 
since diagnosis. If this result is not available, testing for IGHV mutational status will 
be performed in Dr. Danilov's laboratory (see Section 9: Correlative studies).  
 
• Electrocardiogram (ECG):  12-lead ECG must be performed at screening. QTc interval should 
be measured per institutional standard. ECGs will be repeated as clinically indicated.  
 • Echocardiogram (ECHO):  will be performed at screening if clinically indicated. LVEF will be 
measured per institutional standard. Echocardiograms will be repeated as clinically indicated.  
 • Computerized Tomography Scan (CT):  neck, chest, abdomen and pelvis are required with 
contrast. If contrast cannot be used for clinical reasons, a CT without contrast will be acceptable. 
Cheson criteria should be used to read each scan.   
 
 CT scans performed within 30 days of the first study treatment are acceptable for baseline 
assessment. Additional CT scans will be obtained at C4D1, C7D1, C10D1 (or ≤72 h prior), C18D1 
and C24D1, if appropriate , at the end of treatment visit, at 6 and 12 months after the end of treatment 
visit (±7 days) and as clinically indicated thereafter. CT scanning may be performed at any point 
where it is suspected that disease progression has occurred between scheduled assessments.  
 
 NOTE: In subjects with NHL (FL, MZL, MZL) – PET-CT scans may be performed in place  of CT 
scans at screening, during the study and at follow -up. However, the same modality should be used 
for each individual patient during the study.  
Protocol Version 10.0 – February 5, 2021  56
  
   
 NOTE: In subjects with LPL, CT scans on C4D1, C10D1 and during follow -up will be performed 
only if lymphadenopathy is present at screening, or if new lymphadenopathy develops during 
scheduled CT scans on C7D1 or the EOT visit.  
 
• Adverse Event Assessments:  Toxicities and adverse experiences will be assessed at each visit 
using the NCI Common Toxicity Criteria  for Adverse Events 4.0.  Adverse events will be 
reported and recorded as indicated in section 7 of this protocol . 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 • Bone Marrow Aspirate and Biopsy (optional at screening unless ANC<1,000/mm
3 or 
platelets<50,000/mm3; optional at the end of treatment) : will include cytogenetics and FISH, per 
institutional standards. Bone marrow biopsy performed within 6 months prior to the first dose of 
study treatment is acceptable.  
 
 Bone marrow biopsy should also be performed between 1 and 3 months at any time CR is suspected 
(e.g., C7D1, C10D1, C18D1, C24D1). An End-of- Treatment visit bone marrow biopsy will be 
performed between 1 and 3 months after the End of Treatment visit, unless study closure occurs . 
However, if CR is confirmed by bone marrow biopsy after C7D1,  an EOT biopsy will not be 
performed. 
  • Biomarker Blood Samples:  see protocol section 9 – Correlative studies for detailed description 
of collection  
 • Overall Response Assessment:  performed at C7D1, EOT and during the first year following 
EOT to coincide with CT scans at 6 and 12 months post EOT.  
•  
• Event-Free Survival (EFS) Assessment : performed every 3 months during the Follow -up 
period, and every 6 months after the Follow -up period unless study closure is in effect . EFS is 
defined as the date of objective signs of disease recurrence, subsequent anti -leukemic therapy, or 
death, whichever is first reported.  
 
10.5 Schedule of Events  
 
Table 8. SCREENING AND CYCLE 1  
Visit/Cycle   
Screening  Day -7 
(Run-in Phase)  Cycle 1 
Cycle Day  1 2  
8  15 
Study Windows  -30 days -3 days for 
screening tests to 
count for Day -7    
±1 
day    ±1 day 
Entospletinib    Days -7 to -1 Days 1-28 
Obinutuzumab    X X X  X 
Informed consent  X           
Protocol Version 10.0 – February 5, 2021  57
  
  
  Medical history  X X X X X  X 
Concomitant medication (s)  X X X X X  X 
Adverse events  assessment    X X X X  X 
Height, weight  X X         
Vital signs  X X  X X X  X  
ECOG performance status  X X         
Physical examination  X X         
12-lead ECG  X           
ECHO XA           
Bone marrow aspirate and biopsy  
(includes biomarker aspirate)  XB           
Hematology  X X X X X  X 
Chemistry  X X XC XC  X  X  
Hepatitis serologies  X           
aPTT, INR  X           
Serum immunoglobulins  X           
Reticulocyte count  X           
Direct antiglobulin test  X           
β2-microglobulin  X       
Genetic and molecular prognostic 
markers  XD XD       
  
Biomarker blood samples    X  X       
Serum/Urine pregnancy test  X           
Urinalysis  X           
CT neck, chest, abdomen and pelvis 
(with contrast when clinically 
acceptable)E X         
  
  KEY 
AECHO will be performed only if clinically indicated 
BBone marrow aspirate and biopsy is optional unless ANC<1,000/mm3 or platelets<50,000/mm3. Results 
acceptable if performed within 6 months prior to screening visit.  Biomarker sample (10 mL aspirate) 
should be obtained (see 9.0 Correlative studies) .  
COptional serum biochemistry/metabolic panel measurements may be considered by the investigator at 
the end of C1D1 and C1D2.  
DCLL FISH panel results acceptable if perform ed within 6 months prior to the first dose of study 
treatment, and if no intervening treatment occurred; ZAP -70 expression results acceptable if performed 
at any time since diagnosis and will be documented, but not required; IGHV mutational status - results 
acceptable if performed at any time since diagnosis. If this result is not available, testing for IGHV 
mutational status will be performed in Dr. Danilov's laboratory.  
EIn subjects with NHL (FL, MZL, MCL) – PET-CT scans may be performed in place of CT sc ans at 
screening, during the study and at follow -up. However, the same modality should be used for each 
individual patient during the study.  
 
Protocol Version 10.0 – February 5, 2021  58
  
 Table 9. CYCLE 2 - 
Visit/Cycle  Cycle 2-6 Cycles 7-12  
Cycles 13, 14, 16, 18, 20 
and then every two 
cycles until  end of 
therapy 
Cycle Day  1 1 1 
Study Windows  +/- 3 days +/- 3 days +/- 7 days 
Entospletinib E  Days 1-28 Days 1-28 Days 1-28 
Obinutuzumab  X   
Medical history  X X X 
Concomitant medication (s)  X X X 
Adverse events assessment  X X X 
, Weight  X X X 
Vital signs  X X X 
ECOG performance status  X X X 
Physical examination  X X X 
Hematology  X X X 
Chemistry  X X  
CT neck, chest, abdomen and pelvis 
(with contrast when clinically 
acceptable)A XB 
(C4D1 or ≤72 
h prior) XB 
(C7D1 and C10D1 or 
≤72 h prior)  C18D1 and C24D1 
Assessment of B -cell depletion   X (C7D1)   
Biomarker blood sample   X (C7D1)   
Bone marrow aspirate and biopsy 
(includes biomarker aspirate) C  X X 
Overall response assessmentD X X XB 
KEY:  
AIn subjects with NHL (FL, MZL, MCL) – PET-CT scans may be performed in place of CT scans at screening, 
during the study and at follow -up. However, the same modality should be used for each individual patient during 
the study.  
BIn subjects with LPL, CT scans on C4D1, C10D1 and during follow -up will be performed only if 
lymphadenopathy is present at screening, or if new lymphadenopathy develops during scheduled CT scans on 
C7D1 or the EOT visit.  
CIf radiographic and laboratory findings suggest that CR has been obtained, a bone marrow aspirate/biopsy 
should be  obtained to confirm CR between 1 and 3 months after the corresponding CT, accompanied by a 
biomarker sample (10 mL aspirate) – see 9.0, Correlative studies  
DOverall response assessment should be performed when CTs or PET -CTs are performed  
ESubjects may c ontinue entosplentinib monotherapy beyond C12.  
  
Protocol Version 10.0 – February 5, 2021  59
  
 Table 10. End of Treatment and Follow -up prior to study closure  
Visit/Cycle  EOTF Follow upF 
Cycle Day  8 weeks 
after last 
dose of 
study drug  Every 3 months 
for the first year 
following EOT  Every 6 
months for 
EFS 
thereafter  
Study Windows  +/- 7 days +/- 7 days +/-2 months  
Medical history  X     
Concomitant medication (s)  X     
Adverse events assessment  X     
Height, weight  X     
Vital signs  X X  
ECOG performance status  X X  
Physical examination  X X X 
MRD assessment, peripheral blood  X   
Bone marrow aspirate and biopsy; includes 
biomarker aspirate (all patients)  XA     
Hematology  X X X 
Chemistry  X X  
Serum immunoglobulins  X   
CT neck, chest, abdomen and pelvis (with 
contrast when clinically acceptable)B X XC, D   
Overall response assessmentE X X   
Event-free survival assessment    X X 
KEY:  
AAn optional  bone marrow aspirate/biopsy should be obtained between 1 and 3 months after End of 
Treatment visit, accompanied by MRD assessment  and a biomarker aspirate . Exception: patients who 
underwent a bone marrow biopsy to obtain CR confirmation after 6 cycles of therapy will not undergo 
EOT bone marrow biopsy 
BIn subjects with NHL (FL, MZL, MCL) – PET-CT scans may be performed in place of C T scans at 
screening, during the study and at follow -up. However, the same modality should be used for each 
individual patient during the study.  
CCT scans will be obtained at 6 and 12 months after the end of treatment visit (±7 days), and as 
clinically ind icated thereafter.  
DIn subjects with LPL, CT scans on C4D1, C10D1 and during follow -up will be performed only if 
lymphadenopathy is present at screening, or if new lymphadenopathy develops during scheduled CT 
scans on C7D1 or the EOT visit.  
EOverall respon se assessment should be performed when CTs or PET -CTs are performed.  
F Participants still participating at study closure will complete an abbreviated EOT visit and no 
additional follow up will occur.   
 
 
 Table 11. Modified End of Treatment SoE : participants on study at time of study closure  
Protocol Version 10.0 – February 5, 2021  60
  
 Visit EOT 
Timing At the time of study drug 
discontinuation  
Window +30 days 
Medical History  X 
Concomitant medications  X 
Adverse Events Assessment  X 
Height, weight  X 
Vital signs  X 
ECOG performance status  X 
Physical examination  X 
Hematology  X 
Chemistry  X 
 
 
11.0 MEASUREMENT OF EFFECT 
All subjects who received at least one dose of study drug (ITT, section 13.3) will be evaluable for efficacy.  
11.1 Disease Evaluations  
 
Physical examination, which will focus on documenting a change in the number of site s and size of 
lymphadenopathy, hepatomegaly and splenomegaly, will be done as part of the full disease evaluation 
during treatment h.  More extensive physical exams will be performed if guided by the development of new 
symptoms.  
 Complete blood count (CBC) with measurement of parameters including ALC will be obtained before start of treatment (Day -7), Days 1, 2, 8 and 15 of C1; on day 1 for the remaining twelve cycles, every 3 months 
for the first 12 months, and every 4- 6 months thereafter until disease progression or death.  
 Serum biochemistry/metabolic panel will be obtained on will be obtained on Days -7, 1, 2, 8 and 15 of C1; 
on day 1 for the remaining twelve cycles, every 3 months for the first 12 mont hs, and every 4- 6 months 
thereafter until disease progression or death.  
 Computed tomography (CT) scan of neck, chest, abdomen and pelvis with intravenous contrast where possible will be performed at screening, on C4D1, C7D1, C10D1 (or ≤72 hours prior), at C18D1 and C24D1 
should patients opt to continue Entospletinib monotherapy A unilateral bone marrow aspirate and biopsy must be obtained during screening or up to 6 months before 
the first dose of study drug. Subjects who have bone marrow aspirate and biopsy results since completion 
of their last therapy for CLL may use those results if they were obtained within 6 months prior to the first dose of study drug. If the subject's physical examination findings, laboratory and radiographic evaluations suggest that CR has been obtained during C7D1, a bone marrow aspirate/biopsy should be obtained to 
confirm the CR within the timeframe specified above . 
 
11.2 Criteria for Response 
 
11.2.1. Subjects with CLL/SLL  
 
Modified IWCLL guidelines [41] will be used to measure response in CLL/SLL subjects.  
 
Protocol Version 10.0 – February 5, 2021  61
  
 ORR for CLL/SLL subjects is defined as CR, CRi, nPR and PR, PD and SD . Subjects will be assessed for 
response at the end of treatment. If there is a clinical suspicion for progression, disease assessment may be performed at any time.  
 
Complete Remission (CR)   
 
Requires all of the following:  
• Peripheral blood lymphocytes (evaluated by blood and differential count) below 4 × 109/L 
• Absence of significant lymphadenopathy ( eg,lymph nodes  >1.5 cm in diameter) by physical 
examination and imaging, if baseline scans were abnormal  
• No hepatomegaly or splenomegaly by physical examination and imaging, if baseline scans were 
normal  
• Absence of constitutional symptoms (B symptoms)  
• Blood counts must have the following findings:  
a) Neutrophils > 1.5 × 109/L without need for exogenous growth factors  
b) Platelets > 100 × 109/L without need for exogenous growth factors  
c) Hemoglobin > 11.0 g/dL without red blood cell transfusion or need for exogenous erythropoietin 
• Bone marrow aspirate and biopsy must have the following findings:  
a) Normocellular for age  
b) Less than 30% of nucleated cells being lymphocytes  
c) No B-lymphoid nodules (confirmed by IHC)  
 
Complete Response with Incomplete Marrow Recovery (CRi ) 
 
Subjects who fulfill all the criteria for a CR but who have a hypocellular marrow and persistent anemia or 
thrombocytopenia or neutropenia unrelated to CLL but secondary to drug toxicity. If the marrow is 
hypocellular, a repeat determination should be performed after 4 weeks, or when peripheral blood counts 
have recovered.  
 
Nodular Partial Response (nPR )  
 Subjects who fulfill all the criteria for CR but who have bone marrow evidence of B -lymphoid nodules by 
IHC. 
 
Partial Remission (PR)  
 
Blood count should show at least one of the following results:  
 
• Neutrophils more than 1.5 × 109/L without need for exogenous growth factors  
• Platelet counts > 100 × 109/L or 50% improvement over baseline without need for exogenous 
growth factors  
• Hemoglobin > 11.0 g/dL or 50% improvement over baseline without requiring red blood cell 
transfusions or exogenous erythropoietin 
Protocol Version 10.0 – February 5, 2021  62
  
  
AND two of the following three criteria  should be met : 
• Decrease in number of blood lymphocytes by 50% or more from the value before therapy 
• Reduction in lymphadenopathy by physical examination or by imaging as defined by:  
• A decrease in lymph node size by 50% or more either in the sum products of up to 6 lymph 
nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy 
• No increase in any lymph node, and no new enlarge lymph  node  
• In small lymph nodes (˂ 2 cm), an increase of less than 25% is not considered significant 
A reduction in splenomegaly and hepatomegaly by 50% or more, by physical examination or 
imaging.  
 
PR with Lymphocytosis  
 
Because of the expected egress of CLL cells into the peripheral blood with BCRi \, lymphocytosis may 
be encountered with entospletinib. Therefore progressive lymphocytosis without other clinic al evidence 
of disease progression cannot be used to define disease progression. Accordingly,  lymphocyte count 
will be ignored in the evaluations of progression. Of note, this has been an accepted standard in trials using inhibitors of B -cell receptor sign aling for the treatment of CLL.  
 
Furthermore, lymphocytosis should not interfere at the time of designation of a PR. PR with 
lymphocytosis should be based on other measurable aspects of disease other than ALC [45]. 
 
 
Progressive Disease  
 
Includes at least one of the following:  
• Appearance of any new lesion, such as enlarged lymph nodes > 1.5 cm, splenomegaly, 
hepatosplenomegaly, or other organ infiltrates.  
• An increase by 50% or more in greatest determined diameter of any previous site inc luding, liver  
and/or spleen,  
• A 50% or greater increase in lymphocyte count.  
• Transformation to a more aggressive histology (eg, Richter syndrome). Whenever possible this diagnosis should be established by lymph node biopsy.   
Progressive Disease After Treatment  
 
Includes at least one of the following:  
• Any progressive disease criteria listed above  
• The progression of any cytopenia (unrelated to autoimmune cytopenia) which occurs at least 3 
months after treatment as documented by:  
− a decrease in Hb levels b y more than 20 g/L (2 g/dL) or to less than 100 g/L (10 g/dL), OR  
− a decrease of platelet counts by more than 500,  
• OR 
− a decrease of platelet counts by more than 50% or to less than 100 x 109/L (100 000/uL).  
 
Protocol Version 10.0 – February 5, 2021  63
  
 Stable Disease  
 Patient who have not achieved a CR or a PR, and who have not exhibited progressive disease, will be 
considered to have stable disease (which is equivalent to a nonresponse).  
 
11.2.2. Subjects with Follicular Lymphoma, Marginal Zone Lymphoma and Mantle Cell 
Lymphoma (enrolled on Phase I p ortion of the study) – See Appendix G  
 
The determination of MZL and MCL response and progression will be based on standardized response 
criteria for malignant lymphoma [46]. 
 
11.2.3. Subjects with Lymphoplasmacytic Lymphoma (enrolled on Phase I portion of the 
study) – See Appendix E  
 11.2.4. Subjects with Hairy cell Leukemia (enrolled on Phase I portion of the study)  – See 
Appendix I  
 
 
 
12.0 DATA REPORTING/REGULATORY REQUIREMENTS  
12.1 Data Collection and Storage  
Study outcome data will be captured in electronic case report forms (eCRFs) using an electronic data capture (EDC) system on OHSU secure servers, which facilitates information being stored in a unified format and location. To further preserve confidentiality, PHI in the  EDC system will be limited to just birth 
date and visit dates. The web -accessible EDC system is password protected and encrypted with role -based 
security, and administered by designated informatics staff within OHSU or Knight Cancer Institute. All users of the database are assigned a unique ID, username, and password and must complete training 
appropriate to their role before they are authorized to enter, access, and store data in the database.  
Basic accrual tracking information (demographic, consent, visit information) will be captured in OHSU’s electronic clinical information research system (eCRIS), hosted on OHSU secure servers and managed by OHSU’s information technology group at their data center in downtown Portland, Oregon. Any additional printed documents containing participant identifiers, such as those from the medical record to confirm 
eligibility, will be filed in binders and kept in a locked, secure location.  
Data from correlative studies will be entered into the EDC system by study personnel a t OHSU. All other 
electronic data extracts will be stored only on OHSU computers and restricted drives, limited only to study investigators and staff with authorization to access the data.  
Quality assurance will be conducted as outlined in section 12.7 under data safety and monitoring.  
12.2 Privacy, Confidentiality, and Data Security 
 
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Participants will sign an 
authorization that includes the following:  
• What protected health information (PHI) will be collected from subjects in this study 
• Who will have access to that information and why 
• Who will use or disclose that information 
Protocol Version 10.0 – February 5, 2021  64
  
 • The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains 
the ability to use all information collected prior to the revocation of subject authorization.  
Loss of patient confidentiality is a risk of participation. Study participant identities will be kept confidential except as required by law. Subjects’ samples will be identified by code only (i.e. linked, but de -identified). 
Subject samples will be de -identified at the time and site of collection.  Ele ctronic case report forms, 
participant, and study information will be kept in a password protected database. Additionally, documents containing participant identifiers, such as those from the medical record to confirm eligibility, will be filed 
in binders and kept in a locked, secure location in the Office of Clinical Research at each center.  
 
Study outcome data will be captured in electronic case report forms (eCRFs) using an electronic data capture (EDC) system stored on REDCap CLOUD secure servers, which facilitates information being 
stored in a unified format and location. REDCap Cloud is a web- hosted application hosted by nPhase 
(located in Encinitas, California), and is an approved system that has been reviewed by OHSU Security. To 
further preserve confidentiality, PHI in the EDC system will be limited to just birth date and dates associated with patient’s medical care and life events. The web -accessible EDC system is password protected and 
encrypted with role -based security, and administered by designated informatics staff within OHSU or 
Knight Cancer Institute. All users of the database are assigned a unique ID, username, and password and must complete training appropriate to their role before they are authorized to enter, access, and store data 
in the database. 
 
 Each subject who signs consent will be assigned a unique coded identifier consisting of numbers. This identifier will be associated with the subject throughout the duration of their participation in the trial. The 
coded identifier will used to identify subject specific samples that are received both at OHSU and other 
sites. Blood and tissue samples collected for the purposes of this protocol will be stored until they can be 
analyzed and will then be destroyed.  
  
12.3 Protocol Review  
 
The protocol and informed consent form for this study must be reviewed and approved in writing by the 
OHSU Knight Cancer Institute Clinical Research Review Committee and the appropriate Institutional Review Board prior to any subject being consented on this study at OHSU.   
 
Other participating sites must have IRB approvals of the protocol by the IRB of record before consenting 
any subjects . 
12.4 Informed Consent  
 
Written informed consent will be obtained from all subjects, or the legally authorized representative of the 
subject, participating in this trial, as stated in the Informed Consent  section of the case of Federal 
Regulations, Title 21, Part 50. If a subject’s signature cannot be obtained, and for all subjects under the age 
of 18, the investigator must ensure that the informed consent is signed by the subject’s legally authorized representative. Documentation of the consent process and a copy of the signed consent shall be maintained in the subject’s medical record. All participating sites must have IRB approval of ICF by the IRB of records 
before consenting any subjects.  
 
12.5 Changes to Protocol  
Protocol Version 10.0 – February 5, 2021  65
  
  
Any modification of this protocol must be documented in the f orm of a protocol revision or amendment 
signed by the principal investigator and approved by the CRRC and IRB before the revision or amendment may be implemented.  The only circumstance in which the amendment may be initiated without regulatory approval is  for a change necessary to eliminate an apparent and immediate hazard to the subject.  In that 
event, the investigator must notify the CRRC and IRB in writing within 10 working days after the implementation. Investigators holding the IND must notify FDA of  substantive changes to the protocol.  
 Other participating sites must submit any proposed changes to protocol to the OHSU Coordinating Center for review and endorsement before submitting or implementing changes.  
12.6 Maintenance of Records  
 
If the investi gator relocates or for any reason withdraws from the study, the study records must be 
transferred to an agreed upon designee, such as another institution, another investigator, or to OHSU Knight Cancer Institute Clinical Trials Office. Records must be maintained according to sponsor or FDA 
requirements.  
 
Following closure of the study, the investigator will maintain all site study records in a safe and secure 
location. The records are maintained to allow easy and timely retrieval, when needed (e.g., audit o r 
inspection) and, whenever feasible, to allow any subsequent review of data in conjunction with assessment of the facility, supporting systems, and staff. Upon completion of study analysis,  research information is 
stored in Records Management off -site storage. Documents are shredded on site after 50 years of storage.  
 
Electronic case report forms, participant, and study information will be kept in an electronic password protected database indefinitely.  
12.7 OHSU IRB Reporting of Unanticipated Problems and Adverse Events  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 (Adverse Events: List and Reporting Requirements).  
 
 
12.8 OHSU Knight Cancer Institute Data and Safety Monitoring Plan  
 
In addition to complete study and pharmacy files, complete records must be maintained on each subject 
treated on this protocol.  OHSU Knight Cancer Institute, through the auditing function of the Knight Clinical Trials Office, is responsible for ensuring t hat all member investigators and affiliate investigators 
conduct clinical research studies in compliance with local IRB standards, FDA regulations and NIH policies and in accordance with the Data and Safety Monitoring Plan policies and procedures here
. 
 
Locally initiated studies will be audited by OHSU Knight CI Auditor.  Newly approved studies may be 
audited any time after enrollment has been initiated. Each OHSU  Knight approved treatment protocol will 
be audited on an annual basis in accordance with the Knight Data and Safety Monitoring Plan.   
 It is the responsibility of each participating site’s principal investigator to ensure that the study is being 
conducted in compliance with local IRB standards, FDA regulations, and NIH policies. It is also the 
responsibility of each site’s principal investigator to ensure that quality assurance audits at their site are 
conducted according to their institution’s policies and procedures. The quality assurance audit process provides assurance that reported data accurately reflects the data in the primary subject record.  
 
Protocol Version 10.0 – February 5, 2021  66
  
 Study monitoring will be performed by OHSU and will include periodic assessment of the regulatory 
compliance, data quality, pharmacy records and study integrity. Study records will be reviewed and directly 
compared to source documents and the conduct of the study will be discussed with the Lead PI. Monitors 
may request access to all regulatory documents, source documents, CRFs, and other study documentation for on-site inspection. Direct access to these documents is guaranteed by the investigator, who must provide 
support at all times for these activities.  
 
12.9 Inclusion of Women, Minorities and Children  
 
12.9.1 Inclusion of Women and Minorities  
 
No OHSU Knight Cancer Institute study will focus on any particular gender, racial or ethnic subset. No 
subject will be excluded from the study on the basis of gender, racial or ethnic origin. Male, female and 
minority volunteers will be recruited for this study from the general population.  
 CLL occurs with higher frequency in males.  CLL is also more common among the Caucasians. It is less common among African Americans and much less common among the Hispanics, Asians and American 
Indians. We anticipate a distribution of gender in this study that is comparable to the disease incidence.  
However fewer than 25% of individuals in our catchment area are designated as racial or ethnic minorities, 
and rarely have these individuals appeared as cancer patients. Table 11 below reflects the projected ac crual 
for the study based on the abovementioned factors.  
  
Table 11: Population Demographics - Oregon (%)              
Source: Adapted from U.S. Census Bureau, 2010  *Totals may not equal 100 due to rounding  
 
Table 12: Projected Accrual for the Present Study  Ethnic Category  Sex/Gender  
Females Males Total 
Hispanic or Latino  5.9 5.8 11.7 
Not Hispanic or Latino  44.5 43.8 88.3 
Ethnic Category: Total of all subjects*  50.4 49.3 100* 
Racial Category  
American Indian or Alaskan Native  0.7 0.7 1.4 
Asian 1.9 1.8 3.7 
Black or African American  0.9 0.9 1.8 
Native Hawaiian or other Pacific Islander  0.2 0.1 0.3 
White 42.1 41.5 83.6 
More than one race  1.9 1.9 3.8 
Unknown/Other  2.7 2.6 5.3 
Racial Category: Total of all subjects*  50.4 49.5 100* 
TOTALS  50.4 49.6 100* 
Protocol Version 10.0 – February 5, 2021  67
  
 Ethnic Category  Sex/Gender  
Females Males Unknown Total 
Hispanic or Latino  0-1 1 0-1 1 
Not Hispanic or Latino  8 12 0-1 20 
Unknown  0-1 0-1 0-1 0-1 
Ethnic Category: Total of all subjects*  13 16 0-1 30* 
Racial Category  
American Indian or Alaskan Native  0-1 0-1 0-1 0-1 
Asian 0-1 2 0-1 2 
Black or African American  0-1 0-1 0-1 0-1 
Native Hawaiian or other Pacific Islander  0-1 0-1 0-1 0-1 
White 13 14 0-1 27 
More than one race  0-1 0-1 0-1 0-1 
Unknown  0-1 0-1 0-1 0-1 
Racial Category: Total of all subjects*  14 16 0-1 30* 
 
12.9.2 Inclusion of Children  
 
This protocol does not include children for the following reason: the number of children with CLL and 
NHL is limited.  The most common form in children is acute lymphoblastic leukemia which has a very 
different biology.  We plan to survey only the adult forms of these diseases and do not plan to accrue 
children (under 18 years of age).  
 
12.10  Publication Plan  
 
The results of the study will be submitted as a manuscript to a peer -reviewed scientific journal in the field 
of oncology for publication.  
12.11  ClinicalTrials.Gov Requirements  
 
As an applicable clinical trial (ACT) under FDAAA (FDA Amendments Act of 2007, US Public Law 110-
85, Section 801), this study requires mandatory registration and results reporting into a clinical trial registry.  As per Knight SOP, this trial will be registered both in NIH ClinicalTrials.gov ( http://clinicaltrials.gov
) 
under the OHS U Knight Cancer Institute’s centrally managed organizational account.  It will also be 
registered under the NCI’s Clinical Trial Reporting Program ( https://trials.nci.nih.gov ) prior to enrollment 
of the first subject. Once complete, primary outcome results will be posted to ClinicalTrials.gov within 12 months of the primary completion date.  This process is facilitated and monitored by Knight Clinical Trial Registration Administrator (
CTRP-Admin@ohsu.edu ) within the Knight Clinical Trials Office with 
consultation and assistance from the Knight Biostatistics Shared Resource.  
 
 
13. STATISTICAL CONSIDERATIONS  
The Knight Cancer Institute Biostatistics  Shared Resource at OHSU will provide statistical support for 
Protocol Version 10.0 – February 5, 2021  68
  
 this trial.  
 
13.1 Study Design  
 
Phase I Study Design  
 
This is an open- label, phase I/II, dose -finding study in which safety and tolerability of  escalating  doses 
SYK inhibitor entospletinib (GS -9973) in combination with obinutuzumab in patients with 
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and NHL 
(FL, MCL, LPL, MZL). Since best responses for both entospletinib and obinutuzumab have been 
documented in CLL/SLL, the Phase II portion of the study will be limited to those patients, however additional expansion cohorts may be considered at a later date.  
 For the dose finding part of the study, Dose escalation will proceed within each cohort according to the 
following scheme. Dose -limiting toxicity (DLT) is defined in the section 5.2. The starting dose of 
entospletinib will be 200 mg po bid daily with and one dose escalation (dose level 2) and 1 dose de -
escalation. Entospletinib will be administered as a single agent for 7 days prior t o C1D1 to allow for 
assessment of biomarkers.  
 
Table 13. Dose levels planned for dose escalation phase of the study 
Dose Level  
Entospletinib (Cycles 1 -12) 
 Obinutuzumab  (Cycles 1 -6) 
IV 
-1* 200 mg daily  C1D1 – 100 mg; C1D2 – 900 mg 
C1D8 & 15 – 1000 mg 
C2-6 – 1000 mg on day 1 1 200 mg BID  
2 400 mg BID  
*Dose Level -1 will be studied only if more than one patient develops a DLT in Dose Level 1 
 
Determination of MTD  
 The dosage will follow the 3+3 traditional escalation rules, starts with 3 cohorts at a planned dose level. If 0 out of 3 patients experiences DLT, dose will be escalated to the next higher level at which 3 cohort will be enrolled.  If 1 out of 3 patients experiences DLT, 3 more patients will be enrolled at the same 
dose level. Escalation w ill continue if 1 of 6 patients experiences a DLT. If 2 or more patients in any 
dose level except for the starting dose level experience DLTs, dosing will stop, and previous dose level 
is determined to be MTD, unless only 3 patients have been treated at that level (the tentative MTD). If 2 or more patients in the starting dose level experience DLT, dose will be de -escalated to the -1 dose 
levels. A tentative MTD becomes final when a total of 6 patients are treated with less than 2 DLT , or a 
total of 3 patie nts are treated with less than 1 DLT .  
 
Phase II Study Design  
 The phase II study will begin after determination of MTD. The Phase 2 study of the effect of treatment 
is designed as a single -stage study with a primary endpoint of efficacy (response rate: OR R, CR). The 
study will go back to the Phase I stage if 2 or more out of the first six subjects (including those treated 
in the Phase I) receiving the currently identified MTD experience DLT  
 
13.2 Primary and Secondary Endpoints:  
 
13.2.1 Primary Endpoints:  
 
Protocol Version 10.0 – February 5, 2021  69
  
 The primary endpoint of the Phase I portion of the study is to determine the  maximum tolerated 
dose (MTD) and/or a recommended Phase II dose (RP2D) of entospletinib in combination with 
obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and NHL (FL, MCL, LPL, MZL) as  measured  by the incidence of dose 
limiting toxicities (see Section 5.2) . 
 
The primary efficacy endpoint of the Phase 2 portion of the study is the CR, defined as the proportion 
of subjects who achieve CR described in the section 11.2.1 
13.2.2 Secondary Endpoints  
 
Secondary endpoints of phase 2 portion of study are the following:  
• Objective  response rate (ORR)  
• Event free survival defined as the interval between the date of first study treatment and the date of objective signs of disease recurrence, subsequent anti -leukemic therapy, or death, 
whichever is first reported  EFS will be censored if entospletinib is discontinued for other 
reasons (such as drug is no longer available)  
• Safety and tolerability of entospletinib in combination with obinutuzumab by AEs  
13.2.3 Exploratory Endpoints  
 
• Peripheral blood B -cell depletion and recovery 
• Pharmacodynamics effects of in vivo administration of entospletinib on NFκB activation and 
expression of anti -apoptotic proteins in CLL cells.  
• Association of established biomarkers (chromosomal abnormalities, immunoglobulin heavy chain [IGHV] mutational status, p53 mutational status) with response (ORR and EFS) to 
ENTO in combination with obinutuzumab in patients with relapsed/refractory CLL  
13.3 Analysis Population  
 
Safety analysis set includes all patients who consent and take at least one dose of study drug, regardless of how long they stay on study drug.   The end of treatment and early termination visit (see schedule) 
includes an evaluation of response at that visit.   Reason(s) for going off study will be collected on 
every patient.  
 
The dose-determining set (DDS) consists of a subset of patients in the safety analysis set who either 
meet the following minimum exposure criterion and have sufficient safety evaluations, during the first 1 cycle of dosing (including the run- in phase) or discontinue earlier due to DLT.  
  
 
The efficacy -evaluable population will include all intent -to-treat (ITT) subjects who received at least 
1 dose of study medication. Per protocol population will include all intent -to-treat (ITT) p atients 
who completed 1 cycle of study treatment.  The ITT subjects will include all subjects who are 
consented and enrolled in the Phase 2 Portion of the study.  
13.4 Statistical Analysis Plan  
 
Demographic and baseline data will be summarized  descriptively  by phase and dose level. For continuous 
variables,  descriptive statistics will include the mean, standard deviation (or standard error), median, 
range, and interquartile  range. For categorical  variables,  descriptive statistics will include the number and 
percent. 
 
 
Protocol Version 10.0 – February 5, 2021  70
  
 13.4.1 Analysis of Primary Endpoints  
 The MTD will be determined according to 3+3 dose escalation design using the dose determining set. Adverse events will be graded and categorized according to the CTCAE v4.03. All adverse events will be 
tabulated and summarized by major organ category, grade, anticipation, and drug attribution. SAE 
specific incidence and exact 95% confidence interval will be provided where appropriate.  
 The CR will be computed and presented together will the exact 95% confidence interval (CI), using t he 
method of Clopper and Pearson. A null hypothesis of a 20% CR will be rejected if at least 7 of 17 patients 
achieve a CR and a treatment arm will not be considered further if this threshold is not reached.  
 
13.4.2 Analysis of Secondary Endpoints  
• Overall response rate (ORR) will be summarized with 95% confidence intervals.  
• Event free survival (EFS) will be summarized descriptively using the Kaplan- Meier estimate.  
• Safety and tolerability of entospletinib in combination with obinutuzumab by AEs  
Safety data will be summarized for the safety population separately for phase 1 and phase 2 
portions by dose level. All AEs will be coded by system organ class, MedDRA preferred 
term, and severity grade using NCI CTCAE (v 4.03). 
 
13.4.3 Analysis of Exploratory Endpoi nts  
 
Pharmacokinetic parameters including peak and trough levels will be determined by non- compartmental 
method(s) using the pharmacokinetic profile of entospletinib and obinutuzumab. EFS and ORR by status 
of complete response  will be summarized using descriptive statistics.  
 
We hypothesize that subjects with tumors demonstrating unfavorable chromosomal abnormalities (i.e., del(17p) or del(11q)), unmutated immunoglobulin heavy chain [ IGHV], or mutations in TP53 will be 
associated with decreased ORR and EFS compared with subjects without these biomarkers when treated 
with entospletinib and obinutuzumab combination.  Point and interval estimates of ORR and EFS by 
biomarker outcome will be provided for each patient subgroup.  
 Similarly, we hypothesize that patients who have previously received targeted therapy with kinase inhibitors (ibrutinib, idelalisib or investigational inhibitors of BTK, PI3K) will demonstrate worse outcomes. Point and interval estimates of ORR and EFS will be  provided separately for such patients.  
 
13.4.4 Interim Analyses and Stopping Rules  
 
 A 3+3 dose -escalation algorithm will be followed to insure safety. After the completion of the 
dose-determining part and prior to enrolling on the expansion cohort (phas e II), safety and preliminary 
efficacy interim analysis will be performed.  
 
13.5 Sample Size and Power  
 
Determination of phase I sample size  
 
3+3 dose escalation scheme will be utilized, with 3 to 6 evaluated at each dose level. It is expected that 
maximum of 12 patients will be enrolled.  
 Determination of phase II sample size  
 
Protocol Version 10.0 – February 5, 2021  71
  
 Entospletinib has been associated with an ORR 61% at the end of study and obinutuzumab in combination 
with chlorambucil has led to an ORR of 77.3% and CR rate of 20.7% after completion of therapy [22]. The 
null hypothesis that the true  CR rate is  20% will be tested against a one -sided alternative. A sample size of 
17 achieves 83% power to detect a difference in complete response of 0.30 (0.2 vs. 0.5) using a one -sided 
binomial test with the target significance level of 0.05. The actual significance level achieved by this test is 
0.0984. If more than equal to 7 patients achieve complete response, then conclude the regimen is effective, and consider a larger/next phase of clinical trial (phase III).  
  A sample size of 17 subjects treated at the RP2D provides a reasonable probability to detect a rare adverse 
event, for example, 83% chance of detecting an adverse event with an incidence of 10% (Table 14).  Subjects with CLL treated at the RP2D in Phase I will be counted towards Phase II enrollment.  
Anticipating a n attrition  rate of 15%, a total of 20 patients per protocol population will need to be 
enrolled.  
Table 14.   Probability of detecting an AE with a specified incidence rate at the RP2D  
AE incidence  N=17: Probability  of detect an AE 
0.01 0.16 
0.05 0.58 
0.10 0.83 
0.15 0.94 
0.20 0.98 
 
13.6 Randomization Method  
 
Not applicable  
 
13.7 Handling of Missing Data 
 
For missing data, we will evaluate whether or not the other time points can be used to fulfill the primary 
and secondary data.  No missing data will be imputed. Whenever possible, all available data will be 
included in the analysis. A sample size for each analysis will be clearly stated along with the reason for 
exclusion, if any subject is excluded from the analysis due to missing data.  
Data Monitoring Committee  
 
The Knight Data Safety Monitoring Committee  (DSMC) at the OHSU Knight Cancer Institute will be to 
monitor safety data. 
 
REFERENCES 
1. SEER Cancer Statistics Review, 1975 -2010 [Internet]. 2013.  
2. Zent CS , Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially 
higher than estimated from tumor registry data. Cancer. 2001;92(5):1325- 30. Epub 2001/09/26. PubMed 
PMID: 11571749.  
3. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bjorkholm M, Landgren O. Improved 
survival in chronic lymphocytic leukemia in the past decade: a population- based study including 11,179 
patients diagnosed between 1973 -2003 in Sweden. Haematologica. 2009;94(9):1259- 65. Epub 
2009/09/08. doi: 10.3324/h aematol.2009.007849. PubMed PMID: 19734417; PubMed Central PMCID: 
PMC2738718.  
Protocol Version 10.0 – February 5, 2021  72
  
 4. Brenner H, Gondos A, Pulte D. Trends in long -term survival of patients with chronic lymphocytic 
leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916- 21. Epub 2008/03/01. doi: 
10.1182/blood -2007- 12-129379. PubMed PMID: 18309034.  
5. Galton DA, Israels LG, Nabarro JD, Till M. Clinical trials of p -(di-2-chloroethylamino) -phenylbutyric 
acid (CB 1348) in malignant lymphoma. Br Med J. 1955;2(4949):1172- 6. Epub 1 955/11/12. PubMed PMID: 
13269823; PubMed Central PMCID: PMC1981252.  
6. Shaw R.K. BDR, Silberman H.R., and Frei E. III. A Study of prednisone in Chronic Lymphocytic 
Leukemia. Blood. 1961;17(2):182- 95. 
7. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a 
chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for 
chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncolo gy. 2005;23(18):4079- 88. Epub 2005/03/16. doi: 10.1200/JCO.2005.12.051. PubMed PMID: 
15767648.  
8. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to 
fludarabine may prolong progression- free survival and overa ll survival in patients with previously 
untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 
and CALGB 9011. Blood. 2005;105(1):49- 53. Epub 2004/05/13. doi: 10.1182/blood -2004- 03-0796. 
PubMed PMID: 15138165.  
9. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in 
relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013;369(1):32 -42. Epub 
2013/06/21. doi: 10.1056/NEJMoa1215637. PubMed PMID: 23782158; PubMed Central PMCID: PMC3772525.  
10. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance Mechanisms 
for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. The New England journal of medicine. 2014. Epub 
2014/05/30. doi:  10.1056/NEJMoa1400029. PubMed PMID: 24869598.  
11. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic 
lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015. doi: 10.1182/blood- 2014- 09-
603670. PubMed PMID: 25573991.  
12. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three -year follow -up of 
treatment -naive and previously treated patients with CLL and SLL receiving single -agent ibrutinib. Blood. 
2015. doi: 10.1182/blood -2014- 10-606038. PubMed PMID: 25700432.  
13. Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell -cycle reprogramming 
for PI3K inhibition overrides a relapse -specific C481S BTK mutation revealed by longitudinal functional 
genomics in mantle cell lymphoma. Cancer discovery. 2014;4(9):1022- 35. doi: 10.1158/2159- 8290.CD -14-
0098. PubMed PMID: 25082755; PubMed Central PMCID: PMC4155003.  
14. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, et al. Outcomes of Patients 
With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(14):1557 -63. 
doi: 10.1200/JCO.2014.58.6750. PubMed PMID: 25847930; PubMed Central PMCID: PMC4417727.  
15. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential 
functions for immunoreceptor signalling. Immunol Today. 2000;21(3):148 -54. PubMed PMID: 10689303.  
16. Braselmann S, Tay lor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available 
spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex -mediated 
inflammation. The Journal of pharmacology and experimental therapeutics. 2006;319 (3):998- 1008. Epub 
2006/09/02. doi: 10.1124/jpet.106.109058. PubMed PMID: 16946104.  
17. Morris DL, O'Neil SP, Devraj RV, Portanova JP, Gilles RW, Gross CJ, et al. Acute lymphoid and 
gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase -activated protein 
kinase -2 (MK2) inhibitors in the dog. Toxicol Pathol. 2010;38(4):606- 18. doi: 10.1177/0192623310367807. 
PubMed PMID: 20448081.  
Protocol Version 10.0 – February 5, 2021  73
  
 18. Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, et al. Phase 2 study of 
idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. 
Blood. 2016. doi: 10.1182/blood -2015- 12-683516. PubMed PMID: 26968534.  
19. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasin g the efficacy of 
CD20 antibody therapy through the engineering of a new type II anti -CD20 antibody with enhanced direct 
and immune effector cell -mediated B -cell cytotoxicity. Blood. 2010;115(22):4393- 402. doi: 
10.1182/blood -2009- 06-225979. PubMed PMID: 20194898; PubMed Central PMCID: PMCPMC2881503.  
20. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope 
characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II 
distinction of CD20 antibodies. Blood. 2011;118(2):358- 67. doi: 10.1182/blood -2010- 09-305847. PubMed 
PMID: 21444918.  
21. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the 
type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Molecular cancer therapeutics. 2013;12(10):2031- 42. doi: 10.1158/1535- 7163.MCT -
12-1182. PubMed PMID: 23873847.  
22. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et a l. Obinutuzumab plus 
chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014;370(12):1101- 10. doi: 10.1056/NEJMoa1313984. PubMed PMID: 24401022.  
23. Stilgenbauer S, editor Tumor genomic profiling reveals mecha nisms ofresistance to BTK inhibitor 
ibrutinib in chronic lymphocytic leukemia. International Workshop on Chronic Lymphocytic Leukemia; 
2013; Cologne.  
24. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha- mediated constitutive 
PI3K signaling limits the efficacy of p110delta -selective inhibition in mantle cell lymphoma, particularly 
with multiple relapse. Blood. 2013;121(12):2274- 84. Epub 2013/01/24. doi: 10.1182/blood -2012- 10-
460832. PubMed PMID: 23341541; PubMed Central PMCID: PM C3606064.  
25. Danilov AV, Soderquist RS, Bates DJ, Eastman A. Toward a cure for chronic lymphocytic leukemia: 
an attack on multiple fronts. Expert Rev Anticancer Ther. 2013;13(9):1009- 12. Epub 2013/09/24. doi: 
10.1586/14737140.2013.825424. PubMed PMID: 24053199; PubMed Central PMCID: PMC3910377.  
26. Kurosaki T. Regulation of B -cell signal transduction by adaptor proteins. Nature reviews 
Immunology. 2002;2(5):354- 63. PubMed PMID: 12033741.  
27. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk 
with fostamatinib disodium has significant clinical activity in non -Hodgkin lymphoma and chronic 
lymphocytic leukemia. Blood. 2010;115(13):2578- 85. Epub 2009/12/08. doi: 10.1182/blood -2009- 08-
236471. PubMed PMID: 19965662; P ubMed Central PMCID: PMC2852362.  
28. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, et al. Selective, novel spleen 
tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B -cell activation and migration. 
Leukemia. 2012;26(7):1576- 83. Epub 2012/03/01. doi: 10.1038/leu.2012.24. PubMed PMID: 22362000.  
29. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, et al. An open- label phase 2 trial of 
entospletinib (GS -9973), a selective spleen tyrosine kinase inhibitor,  in chronic lymphocytic leukemia. 
Blood. 2015;125(15):2336- 43. doi: 10.1182/blood -2014- 08-595934. PubMed PMID: 25696919; PubMed 
Central PMCID: PMC4401348.  
30. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF -R, the major B cell -activating facto r 
receptor, is expressed on most mature B cells and B -cell lymphoproliferative disorders. Human pathology. 
2005;36(10):1113- 9. Epub 2005/10/18. doi: 10.1016/j.humpath.2005.08.005. PubMed PMID: 16226112.  
31. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Bus ch RM, Fingerle -Rowson G, et al. Minimal 
residual disease quantification is an independent predictor of progression- free and overall survival in 
chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. Journal of 
clinica l oncology : official journal of the American Society of Clinical Oncology. 2012;30(9):980 -8. doi: 
10.1200/JCO.2011.36.9348. PubMed PMID: 22331940.  
Protocol Version 10.0 – February 5, 2021  74
  
 32. Herishanu Y, Perez -Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node 
microenvironm ent promotes B -cell receptor signaling, NF -kappaB activation, and tumor proliferation in 
chronic lymphocytic leukemia. Blood. 2011;117(2):563- 74. Epub 2010/10/14. doi: 10.1182/blood -2010-
05-284984. PubMed PMID: 20940416; PubMed Central PMCID: PMC3031480.  
33. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R, et al. Rel a is an independent 
biomarker of clinical outcome in chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(5):763- 9. Epub 2009/01/07. doi: 
10.1200/JCO.2008.19.1114. PubMed PMID: 19124804.  
34. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. 
Hematology / the Education Program of the American Society of Hematology Am erican Society of 
Hematology Education Program. 2011;2011:96- 103. Epub 2011/12/14. doi: 10.1182/asheducation -
2011.1.96. PubMed PMID: 22160019.  
35. Burger JA. The CLL Cell Microenvironment. Advances in experimental medicine and biology. 
2013;792:25- 45. Epub 2013/09/10. doi: 10.1007/978-1- 4614- 8051- 8_2. PubMed PMID: 24014291.  
36. Ramsay AD, Rodriguez -Justo M. Chronic lymphocytic leukaemia --the role of the 
microenvironment pathogenesis and therapy. British journal of haematology. 2013;162(1):15 -24. Epub 
2013/04/27. doi: 10.1111/bjh.12344. PubMed PMID: 23617880.  
37. Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8 -
activating enzyme inhibitor MLN4924 thwarts microenvironment -driven NF -kappaB activation and 
induces apopto sis in chronic lymphocytic leukemia B cells. Clinical cancer research : an official journal of 
the American Association for Cancer Research. 2014;20(6):1576- 89. Epub 2014/03/19. doi: 10.1158/1078-
0432.CCR -13-0987. PubMed PMID: 24634471; PubMed Central PMCID: PMC3960291.  
38. Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR, Danilov AV. Targeting neddylation 
effectively antagonizes nuclear factor -kappaB in chronic lymphocytic leukemia B -cells. Leukemia & 
lymphoma. 2015;56(5):1566- 9. doi: 10.3109/10428194.2014.990901. PubMed PMID: 26086969.  
39. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and 
NF-kappaB signaling and reduces tumor proliferation in tissue -resident cells of patients with CLL. Blood. 
2014;123(21):3286- 95. Epub 2014/03/25. doi: 10.1182/blood -2014- 02-548610. PubMed PMID: 
24659631; PubMed Central PMCID: PMC4046423.  
40. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-
sponsored Working Group guidelines  for chronic lymphocytic leukemia: revised guidelines for diagnosis 
and treatment. Blood. 1996;87(12):4990- 7. Epub 1996/06/15. PubMed PMID: 8652811.  
41. Hallek M, Cheson BD, Catovsky D, Caligaris -Cappio F, Dighiero G, Dohner H, et al. Guidelines for 
the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop 
on Chronic Lymphocytic Leukemia updating the National Cancer Institute -Working Group 1996 guidelines. 
Blood. 2008;111(12):5446- 56. Epub 2008/01/25. doi: 10.1182/blood -2007- 06-093906. PubMed PMID: 
18216293; PubMed Central PMCID: PMC2972576.  
42. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the 
management of tumor lysis syndrome. Haematologica. 2008;93(12):1877- 85. Epub 2008/10/08. doi: 
10.3324/haematol.13290. PubMed PMID: 18838473.  
43. Paiva C, Godbersen JC, Berger A, Brown JR, Danilov AV. Targeting neddylation induces DNA 
damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating  a g ents.  
Cell death & disease. 2015;6:e1807. doi: 10.1038/cddis.2015.161. PubMed PMID: 26158513.  
44. Humphries LA, Godbersen JC, Danilova OV, Kaur P, Christensen BC, Danilov AV. Pro -apoptotic 
TP53 homolog TAp63 is repressed via epigenetic silencing and B -cell receptor signalling in chronic 
lymphocytic leukaemia. British journal of haematology. 2013;163(5):590- 602. Epub 2013/10/15. doi: 
10.1111/bjh.12580. PubMed PMID: 24117128.  
45. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, et al. Novel targeted agents and the 
need to refine clinical end points in chronic lymphocytic leukemia. Journal of clinical oncology : official 
Protocol Version 10.0 – February 5, 2021  75
  
 journal of the American Society of Clinical Oncology. 2012;30(23):2820- 2. Epub 2012/07/11. doi: 
10.1200/JCO.2012.43.3748. PubMed PMID: 22778323; PubMed Central PMCID: PMC3410400.  
46. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for 
initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano 
classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2014;32(27):3059- 68. doi: 10.1200/JCO.2013.54.8800. PubMed PMID: 25113753.  
47. Consensus resolution: proposed criteria for evaluation of response to tr eatment in hairy cell 
leukemia. Leukemia. 1987;1(4):405. PubMed PMID: 3669765.  
  
  
Protocol Version 10.0 – February 5, 2021  76
  
 APPENDIX A Obinutuzumab Prescribing Information 
 The most current obinutuzumab prescribing information can be found at the link below.  
 
http://www.gene.com/download/pdf/gazyva_prescribing.pdf
 
 
  
Protocol Version 10.0 – February 5, 2021  77
  
 APPENDIX B Creatinine Clearance Formula  
CrCL should be calculated using the Cockroft -Gault formula:  
CrCL= [(140 -age) x Weight (kg) x 0.85 (if female)]/[72 x serum creatinine (in mg/dL)].  
 
  
Protocol Version 10.0 – February 5, 2021  78
  
 APPENDIX C Strong and Moderate Inhibitors and Inducers of CYP Enzymes  
 
CYP Inhibitors   
Strong  Moderate  
CYP2C9 - fluvoxamine  
- ticlopidine  - fluconazole  
- esomeprazole 
- fluoxetine 
- moclobemide 
- omeprazole 
- voriconazole  
CYP3A • boceprevir  
• clarithromycin  
• conivaptan 
• grapefruit juice  
• indinavir 
• itraconazole 
• ketoconazole 
• lopinavir/ritonavir 
• mibefradil 
• nefazodone 
• nelfinavir 
• posaconazole 
• ritonavir  
• saquinavir  
• telaprevir  
• telithromycin  
• voriconazole  - amprenavir  
- aprepitant  
- atazanavir  
- ciprofloxacin 
- darunavir/ritonavir 
- diltiazem 
- erythromycin 
- fluconazole 
- fosamprenavir 
- grapefruit juice  
- imatinib 
- verapamil  
  
CYP Inducers  
 
Strong  Moderate  
CYP2C9   • carbamazepine  
• rifampin  
CYP3A - avasimibe  
- carbamazepine 
- phenobarbital • bosentan 
• efavirenz 
• etravirine 
Protocol Version 10.0 – February 5, 2021  79
  
 - phenytoin  
- rifampin 
- St. John’s wort  • modafinil 
• nafcillin  
 
  
Protocol Version 10.0 – February 5, 2021  80
  
 APPENDIX D ECOG Performance Status*  
 
Grade ECOG 
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. 
Up and about more than 50% of waking hours  
3 Capable of only l imited selfcare, confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5 Dead 
* As published in Am. J. Clin. Oncol.:  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649- 655, 1982.   
  
Protocol Version 10.0 – February 5, 2021  81
  
 APPENDIX E LPL Assessment  
 
Definitions of Response for Waldenstrom’s Macroglobulinemia 
• Complete r esponse (CR): Absence of serum monoclonal IgM protein by immunofixation; normal 
serum IgM level and complete resolution of extramedullary disease, i.e. lymphadenopathy and splenomegaly if present at baseline; morphologically normal bone marrow/aspirate and trephine 
biopsy. 
• Very good partial response: Monoclonal IgM protein is detectable; ≥ 90% reduction in serum 
IgM level from baseline; complete resolution of extramedullary disease, i.e. lymphadenopathy 
and splenomegaly if present at baseline; no new signs or symptoms of active disease.  
• Partial response (PR): Monoclonal IgM protein is detectable; ≥ 50% but < 90% reduction in 
serum IgM level from baseline; reduction of extramedullary disease, ie, lymphadenopathy and 
splenomegaly if present at baseline; no new  signs or symptoms of active disease.  
• Minor response: Monoclonal IgM protein is detectable; ≥ 25% but < 50% reduction in serum 
• IgM level from baseline; no progression in extramedullary disease, i.e. 
lymphadenopathy/splenomegaly if present at baseline; no new signs or symptoms of active 
disease. 
• Stable disease: Monoclonal IgM protein is detectable; < 25% reduction and < 25% increase in serum IgM level from baseline; no new signs or symptoms of active disease.  
• Progressive disease: ≥ 25% increase in serum IgM  level from lowest nadir (requires 
confirmation) and/or progression in clinical features attributable to the disease.  
 
 
 
 
 

Protocol Version 10.0 – February 5, 2021  82
  
  
 
APPENDIX F Pre -clinical data  
SYK Inhibition abrogates BAFF -mediated CLL survival  
 
  

Protocol Version 10.0 – February 5, 2021  83
  
 APPENDIX G Response Criteria for FL, MZL and M CL 
 Response criteria for subjects with Follicular Lymphoma, Marginal Zone Lymphoma and 
Mantle Cell Lymphoma 
 
Complete Response (CR)  
  1. Complete disappearance of all detectable clinical evidence of disease and disease- related symptoms 
if present prior to therapy. Typically FDG -avid lymphoma: in patients with no pre -treatment PET scan or 
when the PET scan was positive before therapy, a post -treatment residual mass of any size is permitted as 
long as it is PET negative. Variably FDG -avid lymphomas/FDG avidi ty unknown: in patients without a 
pretreatment PET scan, or if a pretreatment PET scan was negative, the designation of CR requires all nodal indicator lesions to regress to the size of normal lymph nodes. Lymph nodes that were > 15 mm in GTD regardless of  the short axis diameter at the screening tumor assessment must regress to ≤ 15 mm in GTD 
regardless of the short axis diameter. Lymph nodes that were 11 to 15 mm in GTD and > 10 mm in the short axis diameter at the screening tumor assessment must regress to ≤ 10 mm in the short axis diameter. 
 2. The spleen and/or liver, if considered enlarged prior to therapy on the basis of a physical examination 
or CT scan, should not be palpable on physical examination and should be considered normal size by imaging studies, and nodules related to lymphoma should disappear. However, determination of splenic 
involvement is not always reliable because a spleen considered normal in size may still contain lymphoma, whereas an enlarged spleen may reflect variations in anat omy, blood volume, the use of hematopoietic 
growth factors, or causes other than lymphoma.  
 3. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared 
on repeat bone marrow biopsy. The biopsy sample on which this de termination is made must be adequate 
(> 20 mm unilateral core). If the sample is indeterminate by morphology, it should be negative by immunohistochemistry. A sample that is negative by immunohistochemistry but demonstrating a small population of clonal lymphocytes by flow cytometry will be considered a CR until data become available demonstrating a clear difference in patient outcome.  
 
Partial Remission (PR)  
 1. ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes 
or nodal masses. These nodes or masses should be selected according to the following: (a) they should be clearly measurable in at least 2 perpendicular dimensions; (b) if possible they should be from disparate 
regions of the body; (c) they should inc lude mediastinal and retroperitoneal areas of disease whenever these 
sites are involved.  
 
2. No increase in the size of the other nodes, liver, or spleen.  
 
3. Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in the gre atest 
transverse diameter.  
 
4. With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable 
and no measurable disease should be present.  
 5. Bone marrow assessment is irrelevant for determination of a PR if the sample was positive prior to 
treatment. However, if positive, the cell type should be specified (e.g., large -cell lymphoma or small 
neoplastic B cells). Patients who achieve a complete remission by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders.  
Protocol Version 10.0 – February 5, 2021  84
  
  
6. No new sites of disease should be observed (e.g., nodes > 1.5 cm in any axis).  
 
7. Typically FDG -avid lymphoma: for patients with no pretreatment PET scan or if the PET scan was 
positive before therapy, the post -treatment PET should be positive in at least one previously involved site.  
 8. Variably FDG -avid lymphomas/FDG -avidity unknown: for patients without a pretreatment PET 
scan, or if a pretreatment PET scan was negative, CT criteria should be used. 
 9. In patients with follicular lymphoma, a PET scan is only indicated with one or at most two residual 
masses that have regressed by more than 50% on CT; those with more than two residual lesions are unlikely to be PET negative and should be considered partial responders.  
  
Stable Disease (SD)  
 1. Failing to attain the criteria needed for a CR or PR, but not fulfilling those for progressive disease 
(see below).  
 2. Typically FDG -avid lymphomas: the PET should be positive at prior sites of disease with no new 
areas of involvement on the post - treatment CT or PET.  
 3. Variably FDG -avid lymphomas/FDG -avidity unknown: for patients without a pretreatment PET scan 
or if the pretreatment PET was negative, there must be no change in the size of the previous lesions on the post-treatment CT scan.  
 Relapsed Disease (RD; after CR) or Progressive Disease (PD; for Patients with PR or SD)  
 
Progressive/Relapsed Disease 
 1. Lymph nodes should be considered abnormal if the long axis is > 1.5 cm, regardless of  the short axis. 
If a lymph node has a long axis of 1.1−1.5 cm, it should only be considered abnormal if its short axis is > 1.0. Lymph nodes ≤ 1.0 cm by ≤ 1.0 cm will not be considered as abnormal for relapse or progressive 
disease. 
 
2. Appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if 
other lesions are decreasing in size. Increased FDG uptake in a previously unaffected site should only be considered relapsed or progressive disease after confirmation with ot her modalities  
 
3. At least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single 
involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered progressive 
disease, a lymph node with a diam eter of the short axis of less than 1.0 cm must increase by ≥ 50% and to 
a size of 1.5 × 1.5 cm or more than 1.5 cm in the long axis.  
 
4. At least a 50% increase in the longest diameter of any single previously identified node more than 1 
cm in its short a xis. 
 
5. Lesions should be PET positive if observed in a typical FDG -avid lymphoma or the lesion was PET 
positive before therapy unless the lesion is too small to be detected with current PET systems (< 15 mm in 
its long axis by CT).  
 
Protocol Version 10.0 – February 5, 2021  85
  
 6. Measurable extrano dal disease should be assessed in a manner similar to that for nodal disease. For 
these recommendations, the spleen is considered nodal disease.  
 
Notes:  Bone marrow status is evaluated as follows:  
 Positive:  Unequivocal cytological or architectural evidence of malignancy.  
 Negative:  No aggregates or only a few well -circumscribed lymphoid aggregates.  
 
  
Protocol Version 10.0 – February 5, 2021  86
  
 APPENDIX  H Safety Reporting Fax Cover Sheet  
  
 
GENENTECH SUPPORTED RESEARCH 
AE/SAE FAX No:  (650) 225 -4682 
Alternate Fax No:  (650) 225- 4630 
 Page 1 of ___ 
Genentech Study Number   
Principal Investigator   
Site Name   
Reporter name  
Reporter Telephone #  
Reporter Fax #  
Initial Report Date   / /  
 dd / mmm / yyyy 
Follow -up Report Date   / /  
 dd / mmm / yyyy 
Patient Initials  
(Please enter a dash if the 
patient has no middle name)  ____ - ____ -____ 
 
SAE or Safety Reporting questions, contact Genentech Safety:  (888) 835- 2555 
PLEASE PLACE MEDWATCH REPORT or SAFETY REPORT BEHIND THIS COVER SHEET  
 

Protocol Version 10.0 – February 5, 2021  87
  
 Appendix I Response criteria for Hairy cell leukemia (determined by the Consensus 
Resolution response criteria [47]) 
Complete response (CR)  
• A morphological absence of hairy cells in the blood and bone marrow  
• A normalization of any organomegaly and cytopenias  
Partial response (PR)  
• A normalization of cytopenias  
• ≥50% reduction in organomegaly and bone marrow hairy cells.  
All other responses are considered as no response (NR)  
Relapse af ter CR 
• Reappearance of hairy cells in the blood or bone marrow  
• Development of cytopenias and/or splenomegaly on physical examination 
Relapse after PR  
• >50% increase of residual disease  
Protocol Version 10.0 – February 5, 2021  88
  
 LIST OF ABBREVIATIONS  
The following abbreviations and special terms are used in this study protocol.  
 
Term Explanation  
AE Adverse Event  
ALC Absolute lymphocyte count  
ALT Alanine aminotransaminase  
ANC Absolute neutrophil count  
aPTT Activated partial thromboplastin time  
AST Aspartate aminotransferase  
BCR B-cell receptor 
BID Twice daily  
BTK Bruton tyrosine kinase  
CBC Complete blood count  
CCRC Clinical Cancer Review Committee  
CIRS Cumulative Illness Rating Scale  
CLL Chronic lymphocytic leukemia  
CPHS Committee for the Protection of Human Subjects  
CR Complete  response 
CrCL (estimated) Creatinine clearance  
CRi Complete response with incomplete marrow recovery  
CRMS Knight Clinical Research Management System  
CT Computed tomography  
CTO Clinical Trials Office  
DLT  Dose-limiting toxicity  
DSMC  Data and Safety Monitoring Committee  
eCRF  Electronic case report form  
EFS  Event-free survival  
FISH  FISH  
FL Follicular lymphoma  
IGHV  Immunoglobulin heavy chain gene  
IHC Immunohistochemistry  
IRB  Institutional Review Board  
IRR Infusion-related reaction  
IV Intravenously  
IWCLL  International Workshop on Chronic Lymphocytic Leukemia  
KCI Knight Cancer Institute  
LPL Lymphoplasmacytic lymphoma  
LVEF  Left Ventricular Ejection Fraction  
LDH  Lactate dehydrogenase  
MCL Mantle cell lymphoma  
MTD  Maximum tolerated dose  
MZL Marginal zone lymphoma  
nPR Nodular partial response  
OHSU  Oregon Health and Science University  
ORR  Objective  response rate  
OS Overall survival  
Protocol Version 10.0 – February 5, 2021  89
  
 PD  Pharmacodynamic  
PFS Progression -free survival  
PI  Principal investigator  
PI-3K  Phosphoinositide -3 kinase 
PK  Pharmacokinetic  
PO By mouth 
PR  Partial remission  
RP2D  Recommended Phase II dose  
SAE SAE  
SLL  Small lymphocytic lymphoma  
t½ - half-life Half-life 
ULN  Upper limit of normal  
USPI United States prescribing information  
WBC  White blood cells  
ZAP-70  Zeta chain -associated T -cell receptor protein kinase 70 kDa  
 
 
 
  
 
 
 
   